

**Remarks/Arguments**

**A. Summary of the claims**

Claims 6 and 35 were pending at the time the Action was mailed. Claim 6 has been amended. Support for the amendments may be found generally throughout the specification and original claims, at least at paragraphs [0002] and [0019]. Claim 35 has been canceled. Thus, claim 6 is pending.

Reconsideration of the present case in view of the following arguments is respectfully requested.

**B. The Obviousness Rejection is Overcome**

Claims 6 and 35 are rejected under 35 U.S.C. § 103(a) as being obvious over U.S. Application No. 2003/0124184 by Mezaache in view of WO 97/48384 and Orifer F Prenatal Vitamin Supplement (September 25, 1996) ("Orifer F"). The Action asserts that it would be obvious to combine features of Orifer F with the teachings of Mezaache regarding embossed tablets that are said to comprise the presently claimed active ingredients and the teachings of WO 97/48384 regarding imprinting markings on dosage forms to arrive at the presently claimed invention. Action, page 2.

Applicant respectfully traverses. However, in an effort to advance prosecution of this case, claim 35 has been canceled. Regarding the rejection of claim 6, insofar as the rejection may continue to apply to amended claim 6, Applicant respectfully traverses. The cited references considered alone or in combination do not provide a pharmaceutical tablet containing a combination of drugs against excessive nausea and vomiting in pregnant women and having a graphical representation thereon to improve dosage regimen compliance.

Applicant further maintains that Mezaache may not be relied upon as prior art and as such, the present obviousness rejection is moot, as discussed in Applicant's Response to Office Action dated November 25, 2008 ("the November 2008 Response"), and incorporated herein by reference. Despite Applicant's showing that Mezaache is not prior art, Applicant provides arguments to establish that any combination of Mezaache, WO 97/48384 and Orifer F does not render the claimed invention obvious.

**1. A Prima Facie Case of Obviousness Has Not Been Established**

In making a determination as to whether a *prima facie* case of obviousness exists, the examiner should: (A) determine the "scope and content of the prior art;" (B) ascertain the "differences between the prior art and the claims at issue;" (C) determine "the level of ordinary skill in the pertinent art;" and (D) evaluate evidence of secondary considerations. *Graham v. John Deere*, 383 U.S. 1, 17, (1966); *KSR International Co. v. Teleflex Inc.*, 550 U.S. 398 (2007); *see also* MPEP § 2141.

However, an analysis of these factors in this case does not establish *prima facie* obviousness. For example, a combination of the references fails to teach all the elements of the current claim. Further, in attempting to provide an apparent reason why the cited art, in combination, renders the claimed invention obvious, the Action relies on impermissible hindsight bias. Moreover, there is no reasonable expectation of success regarding any alleged combination of the cited art.

**a. The present claims and the cited art**

The present invention is directed to solving a problem of poor compliance with physician prescribed dosage regimen. The rejected claim is drawn to subject matter regarding a pharmaceutical tablet that comprises therapeutically effective amounts of two different active

ingredients: doxylamine succinate and pyridoxine hydrochloride. The claim also recites that the tablet comprises a graphical representation of a pregnant woman applied to the tablet surface, where the graphical representation is visible to the naked eye. The claim further recites that the tablet is destined for administration to pregnant women for use against excessive nausea and vomiting and improves patient dosage regimen compliance.

The scope and content of Mezaache is explained in the November 2008 Response, which is incorporated herein by reference. The scope and content of WO 97/48384, and Orifer F are explained in Applicant's Response to Office Action dated March 5, 2008 ("the March 2008 Response"), which is incorporated herein by reference. In summary, Mezaache relates to a quick dissolve composition, where doxylamine succinate and vitamin B6 are mentioned as two possible substances in a composition. Orifer F relates to a prenatal vitamin supplement. WO 97/48384 discloses the general principle of marking the surface of pharmaceutical oral dosage forms.

**b. Differences between the rejected claims and the cited art**

Differences between the subject matter of the rejected claims and Orifer F and WO 97/48384 are described in the March 2008 Response, which are incorporated herein by reference. Differences between the subject matter of the rejected claims and Mezaache are described in the November 2008 Response, which are incorporated herein by reference. Additional differences are discussed below.

Mezaache further differs from the subject matter of the current claim in the fact, for example, Mezaache relates to a composition where doxylamine succinate and vitamin B6 are mentioned separately at opposite ends of a laundry list including a myriad of possible active ingredients. No example is provided of a composition containing both of the two ingredients.

Similarly, no example is provided that discloses a composition addressing the illness of excessive nausea and vomiting during pregnancy.

Similarly, Orifer F further differs from the subject matter of the current claim in the fact that Orifer F does not relate to a therapeutic drug against pregnancy related illnesses such as excessive nausea and vomiting. Orifer F shows no indication of poor patient dosage regimen compliance and no indication that the packaging graphics have any particular purpose. Further, the graphical representation on the packaging is not intended to and does not necessarily improve poor patient dosage regimen compliance.

Finally, WO 97/48384 further differs from the subject matter of the current claim in that, for example, the reference fails to mention applying any sort of patient dosage regimen compliance improvement in the context of a pharmaceutical treatment of excessive nausea and vomiting during pregnancy.

In view of these differences and those previously identified, there is no disclosure or suggestion in the cited references, individually or in combination, of a pregnancy-friendly indicia directly on a prescription drug pharmaceutical tablet comprising doxylamine succinate and pyridoxine hydrochloride and as such the cited references fail to disclose each element of the current claim. The failure of an asserted combination to teach or suggest each and every feature of a claim remains fatal to an obviousness rejection under 35 U.S.C. § 103.

**c. The differences between the rejected claims and the cited art are not obvious differences**

The Supreme Court in *KSR* stated that regarding an analysis supporting a rejection under 35 U.S.C. § 103(a), it is “important [for an examiner] to identify a reason that would have prompted a person of ordinary skill in the relevant field to combine the [prior art] elements” in the manner claimed. *KSR Int’l Co. v. Teleflex, Inc.*, 550 U.S. 398 (2007). Indeed, the Court

indicated that there should be an “explicit” analysis regarding “whether there was an *apparent reason* to combine the known elements *in the fashion claimed* by the patent at issue.” *Id.* (emphasis added).

The Examiner has not provided a reasonable articulated line of reasoning as to why a person of skill in the art would, at the filing date of the present application, have 1) considered Mezaache since it addressed a problem completely unrelated to that of the present invention, and 2) considered it in combination with both WO 97/48384 and Orifer F which also fail to address any problem related to that of the present invention. Rather, the Action simply continues to assert that “it would have been obvious to a person of ordinary skill in the art at the time the invention was made desiring to utilize a graphic design on a drug tablet to indicate prenatal (sic) consumption, to use one of Mezaache modified with a figure of Orifer, in order to enhance acceptability & consumption by pregnant women.” Action at page 2.

It appears that the Examiner is relying on hindsight to find a motivation to combine these references. The use of hindsight, however, is not appropriate to establish a motivation to combine. See *W.L. Gore Assoc., Inc. v. Garlock, Inc.*, 721 F.2d 1540 (Fed. Cir. 1983); MPEP § 2143.01 (“The mere fact that references can be combined or modified does not render the resultant combination obvious unless the prior art also **suggests the desirability** of the combination.”) (emphasis added). The problem of poor patient compliance with dosage regimen has traditionally been addressed by more patient counseling and warnings that discontinuation of prescribed dosage regimen could have tragic results for mother and child to be. Prior to the present invention, no one had ever associated a pregnancy friendly indicia on a tablet as possibly leading to improved patient compliance. The industry knew about poor patient compliance being associated with drug side-effects, bad tasting tablets, complicated dosage regimen or overly large

oral dosage forms. However, any form of association between improved patient compliance and a graphical indicia of a pregnant women being imprinted directly on the dosage form was heretofore unknown. Thus, there was no reasonable expectation of success of such a pregnancy-friendly marking to improve patient dosage regimen compliance, as other strategies for improving patient compliance were available and common. It was surprising and completely against expectation that particular markings on the dosage form itself could lead to a marked advance in patient compliance.

The previously filed 1.132 Declaration of Dr. Gideon Koren indicates that the results achieved by the currently claimed invention were entirely unexpected, as discussed in Applicant's Response to the Office Action dated October 16, 2006 ("the October 2006 Response"), which is incorporated herein by reference, as well as in the March 2008 Response. A copy of the Declaration is attached at Appendix 1. Indeed, in the Declaration of Dr. Koren, submitted with the October 2006 Response, Dr. Koren stated, "*The results reported in the '803 application are unexpected.* One having practical knowledge of paediatrics and obstetrics would have expected little or no clinical effect stemming from graphical representations placed on dosage forms." Koren Declaration, para. 11.2 (emphasis added).

Prior to the present invention, no one had thought to place a pregnancy-friendly indicia directly on a prescription drug pharmaceutical tablet in order to improve poor patient compliance with dosage regimen. The data provided in the patent application clearly shows statistically significant and reproducible improvement in patient perception and concomitant improvement in compliance with dosage regimen. This valuable invention is simply nowhere to be found in the cited references.

**d. Secondary considerations**

Even if the Office had established a *prima facie* case, which Applicant disputes, sufficient evidence exists to rebut that *prima facie* case. When an applicant submits evidence to rebut the Office's *prima facie* case, the Office must reconsider the initial obvious determination in view of such evidence and the entire record. *In re Piasecki*, 745 F.2d 1468, 1472 (Fed. Cir. 1984). In this case, the Office has not addressed the numerous objective evidence of nonobviousness previously submitted by the Applicant.


In particular, the Examiner is reminded of the objective evidence of commercial success in this case, which is solely supported by improved patient compliance with dosage regimen. This is discussed in the October 2006 Response. Additionally, the previously filed Declaration by Eric Gervais, filed with the October 2006 Response, is further evidence of commercial success and non-obviousness of the presently claimed invention. A copy of the Declaration is attached at Appendix 2. In brief, the increased sales of the commercialized Diclectin<sup>TM</sup> tablets having the application of the pregnant woman indicia observed was directly attributed to the claimed application of the pregnant woman indicia on the pharmaceutical tablets, since nothing else was modified in the medicament itself, or in the sales and marketing of the drug. Gervais Declaration at ¶¶ 11-12. This unexpected commercial success, commensurate with and derived from the claimed indicia, constitutes further evidence of the non-obviousness of the present claims. MPEP 716.03.

For the reasons set forth above and set forth in responses to previous Office Actions, including Declaration evidence, claim 6 is not obvious. Reconsideration and withdrawal of the obviousness rejection is respectfully requested.

**C. Conclusion**

The Examiner is invited to contact the undersigned Attorney at (512) 536-3030 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Tamsen L. Barrett  
Reg. No. 57,318  
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 536-3123  
(512) 536-4598 (facsimile)

Date: April 16, 2009



**APPENDIX 1**  
**(Koren Declaration)**

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
Date of Signature 2012/06 [Signature]  
and Deposit: 2012/06

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ducheonay Inc.  
Serial No.: 10/611,803  
Filed: July 1, 2003  
Title: PHARMACEUTICAL DOSAGE FORM BEARING PREGNANCY-FRIENDLY INDICIA  
Examiner: Hawes, Pili Asabi

## DECLARATION UNDER 37 CFR 1.132

Dear Sir:

I, Gideon Koren, of the City of Toronto, Canada, being duly sworn, MAKE OATH AND SAY AS FOLLOWS:

1. This Declaration sets forth my opinion relating to this matter and the basis for my opinion.
1. EXPERIENCE AND QUALIFICATIONS
2. I am a paediatrician. I was educated and trained at the Sackler School of Medicine, Tel Aviv, Israel and a resident at the Tel Hashomer Hospital, Tel Aviv University, Israel. Since 1988, I am Fellow of the Royal College of Physicians and Surgeons of Canada.
3. I am Acting Ward Chief, The Department of Paediatrics, The Hospital for Sick Children, Toronto. I have held this position since 1988. Between 1992 and 2000 I was the Director, Division of Clinical Pharmacology/Toxicology at the same hospital. Between 1987 and 2000, I was Head, Population Health Sciences at the same hospital. I have also held and/or continue to hold various research roles within The Hospital for Sick Children.

4. I have a particular clinical interest in *Perinatal Toxicology*. Adverse effects of drugs and chemicals in the perinatal period and more specifically on the teratogenic and developmental effects of drugs and chemicals. I planned and currently direct the "Motherisk" program for antenatal counseling of drug/chemical exposure. I have held this position since 1985. "Motherisk" is the first such program in North America and is a prospective project which assesses both exposed mothers and their offspring. Currently we are focusing on the developmental effect of intrauterine exposure to cocaine and carbon monoxide.
5. I also hold teaching roles. I am Professor of Pediatrics, Pharmacology, Pharmacy & Medicine, The University of Toronto. I have held this position since 1993. In 2004, I also became, Professor of Medicine, Paediatrics and Pharmacology/Physiology, University of Western Ontario and The Ivey Chair in Molecular Toxicology, The University of Western Ontario. I have supervised dozens of graduate or post-graduate applicants in their research thesis and fulfillment of degrees.
6. My curriculum vitae is attached as Exhibit A to my Declaration.
7. Thus, I have more than 25 years of clinical experience in the fields of paediatrics and neonatal drug toxicology. I have authored or co-authored over 900 publications in the paediatrics and pharmaceutical field. I have also written or co-written over 20 books and 90 book chapters in these fields. I was invited to give speeches or present research abstracts at different conferences all over the world. My expertise in the pharmaceutical field has been recognized by the honours and awards listed in my curriculum vitae.
8. I am the Editor, Referee or Editor-in-Chief of dozens of peer reviewed scientific journals or books. For example, I am a referee for at least 18 scientific journals including such renowned publications as The New England Journal of Medicine. I am also a long-time member of several professional associations.
- ii. UNITED STATES PATENT APPLICATION 10/811,803
9. I have read and considered United States Patent Application 10/811,803.

3

10. In a nutshell, the Application describes and claims the invention that oral dosage forms having visibly placed thereon, graphical indicia of a pregnant woman, were shown to greatly diminish the expectant mother's perception of risk of drug toxicity for the foetus. As a result of the diminished perception of risk, compliance with a prescribed drug regimen is greatly improved. This is a significant clinical result.

11. In my opinion,

- 11.1. The methodology and results reported in the '803 application are statistically probative;

- 11.2. The results reported in the '803 application are unexpected. One having practical knowledge of paediatrics and obstetrics would have expected little or no clinical effect stemming from graphical representations placed on dosage forms.

I have had a first hand opportunity to witness the clinical results of the invention of the '803 application. Indeed, I have been prescribing the drug sold under the "Diclectin" brand (and nauseant for nausea and vomiting during pregnancy).

13. Although a number of publications have proven Diclectin to be innocuous for the foetus, I note in my everyday practice that this drug is still suspected of causing teratogenicity, which clearly affects patient compliance.

14. Yet I have observed that once graphical indicia of a pregnant woman was placed on the pharmaceutical tablets, patient compliance was vastly improved. This, I attribute to the reliable behavioural conditioning effects of the graphical indicia and nothing else.

15. I have seen the "Orifer Prenatal Supplement" showing a graphical indicia of a pregnant woman on its cardboard outer packaging/labelling. However, the "Orifer" product does not present a graphical indicia of a pregnant woman on the dosage forms themselves, i.e. immediately visible prior to ingestion of the dosage form. Furthermore, it is not reported that the "Orifer" product has any effect on the perception of foetal toxicity.

VI. CONCLUSION

In my opinion, pharmaceutical tablets of drugs suspected of causing teratogenicity provided with a graphical indicia of a pregnant woman constitute an invention wholly deserving of patent protection and having the clinically observable and statistically reliable effect of diminishing the mother's perception of toxicity to the foetus. This is a highly useful tool for neonatal physicians who struggle with patient compliance because of the perceived risk of foetal toxicity. The invention is not obvious since, to my knowledge, this discovery was never reported in prior publications.

0.

I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the above-identified application or any patent issuing thereon.

Respectfully submitted,

Date

Sept 12/2006

  
Dr. Gideon Koren

**EXHIBIT A**  
**(Dr. Koren's *Curriculum Vitae*)**

**CURRICULUM VITAE**

**GIDEON KOREN**

**DATE OF BIRTH:** August 27, 1947

**PLACE OF BIRTH:** Tel Aviv, Israel

**CITIZENSHIP:** Canada and Israel

**BUSINESS ADDRESS,  
TELEPHONE & FAX** The Hospital for Sick Children  
555 University Avenue  
Toronto, Ontario, M5G 1X8  
(416) 813-5781  
FAX# (416) 813-7562  
e-mail: gkoren@sickkids.ca

**HOME ADDRESS &  
TELEPHONE** 84 Lynn Haven Road  
Toronto, Ontario, M6B 2K9  
(416) 787-6425

**EDUCATION:**

1961-1965 Tichon Hadash High School, Tel Aviv, Israel

1967-1973 Sackler School of Medicine, Tel Aviv, Israel

**POSTGRADUATE TRAINING:**

1976-1981 Residency in Pediatrics, Tel Hashomer Hospital, Tel Aviv University, Israel.

1981-1982 Fellowship in Pediatric Nephrology, Tel Hashomer, Tel Aviv University, Hospital, Israel

1982-1984 Fellowship in Pediatric Pharmacology and Toxicology, The Hospital for Sick Children, Toronto (Supervisor: Dr. S.M. MacLeod).

1984-1986 Combined Research Fellowship: Membrane Biology Group, University of Toronto and Pediatric Pharmacology-Toxicology (Supervisors: Drs. M. Silverman & S.M. MacLeod).

***POSITIONS HELD:***

Director, Motherisk Program, Division of Clinical Pharmacology and Toxicology (1985 - ).

Director, Division of Clinical Pharmacology/Toxicology, The Hospital for Sick Children, Toronto (1992-2000).

Staff Pediatrician and Acting Ward Chief, The Department of Pediatrics, The Hospital for Sick Children, Toronto (since July 1986).

Associate Director for Clinical Research, The Research Institute, and The Hospital for Sick Children (July 1988 - January 1998).

Head, Population Health Sciences, The Hospital for Sick Children (October 1997 -2000).

Staff Member of the Division of Clinical Pharmacology-Toxicology, and Division of Hematology/Oncology, The Hospital for Sick Children, Toronto.

Senior Scientist, Research Institute, Hospital for Sick Children.

Pediatric Consultant for The Clinical Institute, The Addiction Research Foundation, Toronto.

Member, University of Toronto, Institute of Bioethics.

Director, The Addiction Research Foundation - HSC Collaborative Program in Toxicology, (1994 - 1997).

Chair, The Steering Committee of the Obstetric Pharmacology Research Units at NIH from (June 2004).

***PROFESSIONAL BOARDS:***

1981 The Israeli Board of Pediatrics

1985 Diplomat, The American Board of Medical Toxicology

1989 Fellow of the Royal College of Physicians and Surgeons of Canada.

1996 Diplomat, The American College of Medical Toxicology.

***MEDICAL LICENSURE:***

General License, Israel Ministry of Health, No. 11689.

General License, College of Physicians & Surgeons of Ontario, No. 50992

Nov. 5, 2002 – Human Participant Protections Education for Research – NIH



**EDITORIAL BOARDS:**

1986 - 1997 The Journal of Toxicology-Clinical Toxicology  
1987 - 1996 Developmental Pharmacology and Therapeutics (Associate Editor – 1992 - 1996)  
1989 - Pediatric Therapeutics and Toxicology  
1990 - Therapeutic Drug Monitoring  
1992 - 94 Neonatal Pharmacology Quarterly  
1993 - Canadian Journal of Clinical Pharmacology (Associate Editor)  
1993 - Neurotoxicology & Teratology  
1994 - Annals of Pharmacotherapy  
1995 - Biology of The Neonate  
1998 - Paediatric Drugs  
1998 - Pediatric and Perinatal Drug Therapy.  
1999 - Pediatric Research (Consulting Editor).  
1999- Current Therapeutic Research  
1999 - Journal of Clinical Pharmacology  
2000 - J Pediatric Pharmacology & Therapeutics

**REGULAR REVIEWER FOR THE FOLLOWING JOURNALS:**

Journal of Rheumatology  
The New England Journal of Medicine  
Journal of Toxicology - Clinical Toxicology (until 1999)  
Developmental Pharmacology and Therapeutics (until 1994)  
Clinical Pharmacology and Therapeutics  
Journal of Pediatrics  
Journal of Cardiovascular Pharmacology  
Eur J Pediatrics  
Teratology  
Pediatric Research  
Obstetrics & Gynecology  
Pediatrics  
JAMA  
Annals of Pharmacotherapy  
Canadian Journal of Clinical Pharmacology  
Western J of Medicine  
Drug Disposition & Metabolism  
New England Journal of Medicine  
\*Pediatric Drugs  
\*American Journal of Obstetrics & Gynecology

**EDITORIAL ASSIGNMENTS:**

- 1) Editor in Chief: Clinical Toxicology book series. Marcel Dekker, NY, 1992-1994.
- 2) Co-editor: Poisoning Medicine North America, December, 1990–1994.
- 3) Editor: The Motherisk Newsletter, The Motherisk Program, 1993-2000.

- 4) Editor: Motherisk Update. Canadian Family Physician, 1994 -
- 5) Associate Editor: Can J of Clin. Pharmacology, 1994-2003.
- 6) Editor in Chief: Therapeutic Drug Monitoring, 2003 -
- 7) Editor in Chief - J FAS Intl., 2003 -
- 8) Editor: Motherisk Grand Rounds. Canadian Journal of Obstetrics & Gynecology, 2005.
- 9) Publisher: Canadian Journal of Clinical Pharmacology, 2004.

**MILITARY SERVICE:**

1965-1967 Israeli Defense Forces, Medic in Infantry

1974-1975 Israeli Air Force, Flight Surgeon

**MEMBERSHIP IN PROFESSIONAL SOCIETIES:**

Israeli Medical Association 1973 -  
Israeli Society of Clinical Pediatrics 1976 -  
The Canadian Society of Clinical Pharmacology 1985 -  
The American Board of Medical Toxicology 1985 -  
The Canadian Society of Poison Control Centers 1985 -  
Canadian Society of Clinical Investigation 1986 -  
American Society of Clinical Pharmacology & Therapeutics - 1987 (Vice Chairman of the Pediatric Section - 1988; Chairman 1990 - 1993  
American Academy of Toxicology 1988 -  
Royal College of Physicians & Surgeons of Canada 1989 -  
Organization of Teratogen Information Services (Executive committee until 1992) 1990 -  
European Society of Developmental Pharmacology 1990 -  
The Society for Pediatric Research 1990 -  
Teratology Society 1990 -  
New York Academy of Sciences 1991 - 1998  
Fetal Alcohol Canadian Expertise (FACE): (Founder and Chair) 2000

**ACADEMIC APPOINTMENTS:**

- 1977 Clinical Instructor in Pediatrics, Sackler School of Medicine, Tel-Aviv University, Israel.
- 1986 - 1989 Assistant Professor of Pediatrics and Pharmacology, the University of Toronto, Divisions of Clinical Pharmacology and Hematology/Oncology, The Hospital for Sick Children, Toronto.
- 1987 Cross appointment with the Institute of Medical Sciences and School of Graduate Studies, University of Toronto.

- 1989 - 1993 Associate Professor of Pediatrics, Pharmacology and Pharmacy, The University of Toronto.
- 1993 Professor of Pediatrics, Pharmacology, Pharmacy & Medicine, The University of Toronto.
- 1986 - 1996 Career Scientist of the Ontario Ministry of Health.
- 1998 Cross appointment in Medical Genetics & Microbiology.
- 2000 Senior Scientist, The Medical Research Council of Canada.
- 2004 The Ivey Chair in Molecular Toxicology, The University of Western Ontario.
- 2004 Professor of Medicine, Pediatrics and Pharmacology/Physiology, University of Western Ontario.

#### **EXTRAMURAL GRANTS**

- 2006 - 2009 RSQ/Conseil du Medicament du Quebec; Antidepressants in pregnancy and fetal outcome (A. Berrard PI) (\$50,000/yr).
- 2005 - 2008 Genom Canada: Adverse Drug Reactions in Children (B Carlton PI) (Total 8 m/3yr) Toronto: (\$100,000/yr).
- 2004 - The Ivey Chair in Molecular Toxicology
- 2004-2005 Health Canada; MotherNature Network (\$75,000/yr).
- 2003-2008 Tel Aviv University- HSC Motherisk Advanced Research (\$50,000/ yr).
- 2003-2008 CIHR: Renal handling of drugs during development (with Dr. Ito). (\$131,000/yr)
- 2002-2006 CIHR: The role of the placenta in fetal toxicology (with Drs. Ito and Einarson). (\$140,000/yr)
- 2002- The Research Leadership in Better Pharmacotherapy During Pregnancy and Lactation. (\$40,000/yr)
- 2003- 2002-2007 CIHR: New Emerging Team (NET): Oxidative damage and biomarkers of FAS (\$250,000/yr)
- 2001 - 2002 Pfizer: The teratogenicity of aspirin in humans. Meta-analysis: (\$120,000).
- 2002 - 2004 Centers for Disease Control: OTIS prospective study on Accutane in pregnancy. (\$120,000 US)
- 2001 - 2002 Glaxo SKB: The safety of ondansetron in pregnancy.

- 2002 – 2004 PSI: Pregnancy outcome in women with polycystic ovary syndrome exposed to metformin (\$50,000) (with Dr. Valois).
- 2002 – 2003 Canadian Foundation for Women's Health. Pregnancy outcome following exposure to beta-blockers (\$40,000) (with Dr. Ray).
- 2002 – 2003 Critical Care Foundation: Errors in drug dosing in children (\$50,000) (with Drs. Parshuram and Bohn).
- 2001 – 2004 Workplace Safety and Insurance Board's Research Advisory Council: Maternal occupational exposure to organic solvents during pregnancy and infant visual processing with: Drs. J. Rovet and C. Estall: (\$252,000).
- 2001 - 2003 Ontario Women's Health Council: Determinants of women's decision-making of antidepressants during pregnancy (\$138, 900).
- 2001 - 2002 Health Canada: Use of biotechnological products during pregnancy and lactation (\$56,000).
- 1999 - 2001 MRC: Comparison of amitriptyline and placebo for the reduction of pain in children with JRA (Brian Feldman PI) (\$16,000).
- 1999 - 2000 Pfizer: Amlodipine in children (PATH 1 & 2) (\$140,000).
- 1999 - 2001 Health Canada: Mother Net (\$350,000/yr).
- 1999 - 2002 Ontario HIV Treatment Network (OHTN): Evaluating safety and risk of antiretroviral drug exposure during pregnancy for infants born to HIV positive women in Ontario/ Investigators: SM King, G. Koren (\$175,000).
- 1999 - 2000 Medical Research Council of Canada: Paediatric Pharmacology Network. (with M. Rieder, S. MacLeod, J. Bend, B. Bailey).
- 1999 - 2002 Glaxo Wellcome - Biochem Pharma, Evaluating safety and risk of antiretroviral drug exposure during pregnancy for infants born to HIV positive women in Canada. Investigators: SM King, G Koren and CPARG.
- 1998 - 2001 March of Dimes (Michael Kramer, PI): Social Disparities in Preterm Births (\$249,978 (US)/yr).
- 1999 - 2001 Health Canada: Breaking The Cycle - Canadian of Substance Abuse project (\$130,000).
- 1998 - 2000 MRC-PMAC (Astra): Omeprazole in pregnancy (\$80,000/yr).
- 1998 - 2000 American Lung Foundation (Co-applicant): Tobacco smoke exposure and infant respiratory function. PI: Judith Groner, Cleveland (\$25,000 US/yr).

- 1990 - 2002 MRC MT 1797: The role of the placenta in perinatal toxicology: Study in a human placental perfusion system (with Dr. L. Derewlany and Dr. S. Ito) (\$70,000/yr).
- 1998 - 2000 Research Institute: Start Up Fund. Maternal smoking and neonatal HIE. (with Drs. Pelman & James) (\$19,000/yr).
- 1984 - 2004 MRC Grant MA 8544: Determinants of Renal Handling of Drugs During Development (\$80,000/yr).
- 1994 Health Canada: Breaking the Cycle Program (\$340,000/yr).
- 1993 - 1997 MRC-PMAC (Ciba Canada): Pregnancy outcome after exposure to antidepressants (\$185,000).
- 1997 - 1998 HIV/AIDS policy and prevention unit, Health Canada: Establishing a national HIV healthline, registry and assessment of outcome of fetal exposure to antiretroviral agents (\$70,000).
- 1997 - 1998 Glaxo Wellcome - Biochem Pharma: Establishing a national HIV healthline, registry and assessment of outcome of fetal exposure to antiretroviral agents. Investigators: SM King, G. Koren.
- 1995 - 1997 MRC-PMAC (Astra): Emla for circumcision pain (\$110,000).
- 1996 - 1998 Scottish Rite Canada: Piracetam for Down's Syndrome (\$30,000).
- 1996 - 1998 Glaxo Wellcome: AZT-TMP-SMX interaction in HIV. (R. BenDayan PI) (\$50,000/yr).
- 1994 Duchesnay, Laval Quebec: Treatment of morning sickness. (\$30,000/yr).
- 1994 Research Institute, Equipment competition: Actigraph unit (with Dr. J. Rovet) (\$6,813).
- 1995 - 1997 Pfizer Ltd: Measurement of compliance of antihypertensive therapy in children (\$42,000).
- 1992 - 1996 International Life Science Institute: "Caffeine intake, levels and effects in children. (with Drs. Kalow and Gillin) (\$35,450/yr (US)).
- 1992 Equipment competition, Research Institute (with Drs. Pencharz & Durie) for Thermoman Microplate reader (\$15,100).
- 1993 - 1996 MRC-Industry: (Apotex Inc.) Comparison of desferal and  $L_1$  in thalassemia (with Dr. N. Olivieri) (\$300,000/yr).
- 1994 - 1997 Janssen Pharmaceuticals: Studies of drugs' safety in pregnancy (\$30,000/yr).

- 1994 - 1995 PSI: The safety of beta blockers in pregnancy (with Dr. L. Magee) (\$13,000).
- 1994 - 1995 PSI: The use of oral acyclovir (with Dr. R. Lau) (\$15,000).
- 1995 - 1997 PSI: Pregnancy outcome in infants of binge drinkers (\$55,000/yr).
- 1997 - 1998 PSI: Organic solvents in pregnancy (with Dr. S. Khattak) (\$14,000).
- 1998 - 2001 Brewers' Association of Canada: Fetal Alcohol Syndrome (\$128,000/yr).
- 1994 - 1996 Astra: Studies of EMLA in circumcision (\$61,000).
- 1994 - 1996 Duchesney Ltd: The pharmacokinetics and dynamics of rectal Diclectin for morning sickness (\$50,000).
- 1994 - 1995 Apotex: Studies of  $L_1$  in acute iron poisoning (\$15,000).
- 1994 - 1995 Hospital for Sick Children Foundation. Trial of sequential use of intravenous and oral acyclovir in the therapy of varicella in immunocompromised (\$20,500).
- 1992 - 1993 Physician Services Incorporated Foundation, Randomized trial of one hour versus four hours amphotericin B infusions on febrile reactions in children (with D. Davis and other) (\$33,000).
- 1990 - 1991 PSI: The use of  $L_1$  in acute iron overdose (with Dr. Bentur) (\$14,300).
- 1990 - 1992 Ciba Ceigy, Basel & Canada: Effects of antiepileptics on pregnancy outcome. (\$98,000).
- 1991 - 1992 Sherring & Robins Canada Ltd: Safety of bromopheniramine in pregnancy (\$26,000).
- 1990 - 1992 PSI: Detection of intrauterine cocaine exposure (\$55,000/yr).
- 1991 Astra Ltd Canada: The use of EMLA for removal of warts (with Dr. N. Shear) (\$22,000).
- 1991 Astra Ltd Canada: The use of EMLA for vaccination (\$42,000).
- 1990 - 1991 Astra Ltd Canada: Feasibility study on EMLA cream (\$40,000).
- 1989 - 1992 MRC: A new oral iron chelator (with N. Olivieri) (\$80,000/yr).
- 1991 - 1993 Janssen Pharmaceutics: Pharmacokinetics & Dynamics of transdermal fentanyl (\$55,000).
- 1991 - 1993 Borroughs Wellcome Canada: Pharmacokinetics and TDM of acyclovir in children (with S. King) (\$25,000).

- 1993 Astra Canada: Pharmacokinetics of penile absorption of EMLA in newborn piglets, (\$35,000).
- 1991 - 1992 Pediatric Consultants: Cyclosporine to reverse multiple drug resistance (with H. Chan) (\$20,000).
- 1988 - 1993 Health and Welfare Canada; Outcome of Pregnancy Following First Trimester Exposure to Cocaine in Social, Non Addict Users in Toronto (\$27,000/yr).
- 1987 - 1989 Leukemia Research Foundation: Operating Grant: Pharmacologic determinants of survival in ALL (\$31,000/yr).
- 1987 Ontario Ministry of Health: The Motherisk Program for drug/chemical exposure in pregnancy (\$80,000/yr).
- 1989 Hoffman La-Roche: Teratogenicity of retinoids & Vitamin A (\$97,000).
- 1989 Astra Pharmaceuticals: EMLA for pain in 3 month - 3year old children (\$12,000).
- 1989 Equipment grant, the Research Institute, HPLC System, (\$35,000).
- 1988 - 1989 Ciba Geigy Pharmaceuticals: Stability Studies of Desferoxamine (\$8,000).
- 1987 - 1988 Pediatric Consultants: Pharmacokinetic Determinants of Desferal Toxicity (\$9,000).
- 1988 Squibb Canada: Pharmacokinetics and Pharmacodynamics of Captopril in Children with Scarred Kidneys (\$15,000).
- 1988 Astra Pharmaceuticals: Dermal anesthesia with EMLA for children (\$8,000).
- 1988 Knoll Pharmaceuticals: Propafenone use in children with arrhythmias (\$9,000).
- 1987 - 1988 Heart and Stroke Foundation of Ontario Operating Grant: New and improved assay procedures for the measurement of digoxin (with Drs. Soldin and Lingwood) (\$24,000/yr).
- 1987 - 1988 Ontario Ministry of Health Operating Grant: Counselling of Drug/Chemical Exposure During Pregnancy (\$10,000).
- 1986 Renewal of MRC grant MA - 8544.
- 1984 MRC grant MA - 8544: "Determinants of digoxin distribution and excretion in vitro and *in vivo*".
- 1977 Research Grant, Sam Isac, Tel-Aviv, Israel.

**FELLOWSHIPS, SCHOLARSHIPS AND AWARDS**

- 1982 Fellowship of the Canadian Foundation for the Advancement of Clinical Pharmacology.
- 1983 Tisdale Award, The Hospital for Sick Children, Toronto. First Research Prize, "Interaction of Digoxin with Co-Administered Drugs: Two Renal Mechanisms".
- 1983 The Pharmacological Society of Canada, Annual Graduate Student Award: Digoxin-Amiodarone Interaction: *In Vivo* and *In Vitro* Studies in Rats". The most outstanding research paper.
- 1983 The Annual Student Award - The Canadian Society of Clinical Investigation.
- 1983 - 1984 Fellowship of The Hospital for Sick Children Foundation.
- 1984 Tisdale Award, The Hospital for Sick Children, Toronto, First Research Prize "Significance of Endogenous Digoxin Like Substance in Newborn and Mothers".
- 1984 Student Award. The Canadian Society of Clinical Pharmacology Annual Meeting, Montreal.
- 1985 Fellowship of The Medical Research Council of Canada.
- 1986 - 96 Career Scientist Award of the Ontario Ministry of Health.
- 1986 Career Scientist Award of the Pharmaceutical Manufacturer Association of Canada (turned down in favor of the previous award).
- 1986 Pfafsky's Young Investigator Award of the Canadian Society of Clinical Pharmacology.
- 1986 Travel Award of the Canadian Society of Clinical Pharmacology.
- 1986 Travel Award of the American Federation of Clinical Research.
- 1989 MRC Queen Elizabeth II Visiting Professorship, Western University, London, Ontario.
- 1990 American Academy of Clinical Toxicology Fellowship.
- 1990 Roche Publication Award (NEJM 323: 17-22, 1990); Canadian Society of Clinical Pharmacology.
- 1993 The Distinguished Service Award - The Canadian Society of Clinical Pharmacology.
- 1994 Roche Publication Award (JAMA 1994; 271: 621-623); Canadian Society of Clinical Pharmacology.



- 1994 The Distinguished Service Award - The Research Institute, The Hospital for Sick Children.
- 1995 The Young Investigator Award - The Canadian Society for Psychoneuropharmacology.
- 1997 The Rawls Palmer Award & Lectureship: The American Society for Clinical Pharmacology & Therapeutics.
- 1997 The Roche Publication Award (N Engl J Med 1997; 62:1-5). The Can Society for Clin Pharmacology.
- 1999 The Irvine Sunshine Award for Excellence in Clinical Toxicology. The International Association for Therapeutic Drug Monitoring and Clinical Toxicology.
- 1999 The Canadian Society for Clinical Pharmacology Senior Scientist Award.
- 2000 - 2005 Senior Scientist Award. CIHR.
- 2001 - The Canadian Society for Clinical Pharmacology – Roche Publication Award.
- 2001 - The Duchesnay Research Leadership in Better Pharmacotherapy During Pregnancy and Lactation.
- 2003 - Canadian Society for Clinical Pharmacology Distinguished Scientist Award.
- 2003 - The International Association for Therapeutic Drug Monitoring and Clinical Toxicology. The Charlse Pippenger Award for Excellence in Therapeutic Drug Monitoring.
- 2004 - The Ivey Chair in Molecular Toxicology, University of Western Ontario..
- 2005 - Canadian Society for Clinical Pharmacology Publication Award (J PET: Placental handling of FACE).
- 2005 - Department of Paediatrics, University of Toronto, Innaugural Research Award for Career Excellence.
- 2005 - Canadian Society for Clinical Pharmacology, Roche Publication Award.

#### ***COMMITTEES & OFFICIAL POSITION***

- 2005 - Chair, Steering Committee, Breaking the Cycle.
- 2002 - Chair, Review Committee for the National Grant Competition for Pediatric CAM.

- 2000 - Mortality & Morbidity Committee, HSC.
- 2000 - Medication Incidents Committee HSC.
- 1998 - NIH: Review Committee for Pediatric Pharmacology Research Units.
- 1998 - 2000 Steering Committees, The Research Institute, HSC.
- 1998 - 2000 President, Canadian Society for Clinical Pharmacology.
- 1997 - 2000 Research Training Committee, HSC.
- 1997 - 1998 Quality Management Committee, The Hospital for Sick Children, Toronto.
- 1996 - 1998 Secretary Treasurer, Canadian Society for Clinical Pharmacology.
- 1998 - 1999 President, Canadian Society for Clinical Pharmacology.
- 1993 - 2000 Chairman, Pharmacy & Therapeutic Committee, The Hospital for Sick Children, Toronto.
- 1992 - 2000 Pharmaceutical Manufacturer Assoc. of Canada: A Member of Advisory Board.
- 1993 - 2000 Deputy Director: Toronto University Program in Clinical Pharmacology.
- 1993 - 1997 Member, MRC Drug Investigation Committee.
- 1982 - 1992 The Human Subject Experimentation Review Committee, The Hospital for Sick Children Toronto. Associate Chairman, 1987, Chairman 1989-92.
- 1987 The Clinical Pharmacology Residency Committee, University of Toronto, Toronto.
- 1988 - 1990 Secretary Treasurer, The Medical Staff Association, The Hospital for Sick Children, Toronto.
- 1988 - 1990 Patient Care Committee, The Hospital for Sick Children, Toronto.
- 1988 - 1996 Third year undergraduate Pharmacology Committee, Dept. of Pharmacology.
- 1988 - 1996 Research Advisory Committee, Research Institute.
- 1989 Coordinator: The Graduate Course in Clinical Pharmacology, Dept. of Pharmacology University of Toronto.
- 1989 - 1992 Chairman of Program Committee, Canadian Society of Clinical Pharmacology.
- 1990 - 1993 Pharmacology Medical Curriculum Renewal, Department of Pharmacology.

- 1990 - 1995 The United States Pharmacopeial Convention; The Pediatric Panel.
- 1992 - 1994 International Union of Pharmacology: Chairman of The Pediatric Pharmacology Section.
- 1992 - 1999 Chair, The Seed Grant Research Competition.
- 1993 - 1999 Chair, Pharmacy & Therapeutics Committee, HSC.
- 1997 Member, Duncan Gordon Fellowship Committee, HSC Foundation.
- 1993 - 1999 Member, Humanitarian Award Committee, HSC Foundation.
- 1995 Member, Steering Committee, Breaking The Cycle.
- 1998 - 1999 Chair, Recruitment & retention subcommittee of Steering Committee, Research Institute.
- 2000 - HSC Morbidity Mortality Committee.
- 2000 - HSC Drug Incidence Review Committee.
- 2003 - HSC Foundation Grant Committee on CAM - Chair.
- 2004 - CIHR Grant Committee on Pharmacology & Toxicology.

#### **AREAS OF RESEARCH INTEREST**

- 1) ***Pediatric pharmacology:*** The disposition and effects of drugs on the developing organism. Special interest in the very low birth weight infant and in pediatric cancer chemotherapy. Involves both basic and clinical studies. This work aims at tailoring a rational drug schedule for the developing infant and child.
- 2) ***Renal handling of drugs:*** Application of various in vitro and in vivo methods to study the handling of drugs by the kidney on a molecular and physiological level. Included are: Clearance studies; binding studies to the brush border and antiluminal membranes; the multiple indicator injection technique; tissue culture studies. Currently I am studying the renal handling of digoxin by the tubular cell. This work is being done in collaboration with Dr. M. Silverman from the membrane group, University of Toronto and supported by the MRC.
- 3) ***Perinatal Toxicology:*** Adverse effects of drugs and chemicals in the perinatal period. Special interest on the teratogenic and developmental effects of drugs and chemicals. I planned and currently direct the "Motherisk" program for antenatal counselling of drug/chemical exposure. This is the first such program in North America and is a prospective project which assesses both exposed mothers and their offspring. Currently we are focusing on the developmental effect of intrauterine exposure to cocaine and carbon monoxide.

## ARTICLES

- 1) Shenfeld Y, Koren G, Shapiro, Y: Cold damage, Part 1. *J Isr Med Assoc* 90:124-126, 1976.
- 2) Shapiro Y, Koren G, Shenfeld Y, Zohar E: Accidental hypothermia. *J Isr Med Assoc* 90:164-166, 1976.
- 3) Koren G, Shenfeld Y, Shapiro Y: Cold damage accidental hypothermia, Part 2. *J Isr Med Assoc* 90:179-183, 1976.
- 4) Shenfeld Y, Shapiro Y, Koren G: Cold damage, Part 3. *J Isr Med Assoc* 90:229-233, 1976.
- 5) Shachar E, Koren G, Frand M: Overdose of chloral derivatives in children. *J Isr Med Assoc* 98:21-22, 1980.
- 6) Koren G, Barzilay Z, Frand M, Brand N: Therapeutic failure with phenytoin in children. *Harefuah* 99:213-214, 1981.
- 7) Koren G, Brand N, Dani S, Halkin H: Poor bioavailability of phenytoin of local production. *Harefuah* 100:355-356, 1981.
- 8) Frand M, Koren G, Rubinstein Z: Reversible hypertrophic osteoarthropathy associated with cyanotic congenital heart disease. *Amer J Dis Children* 136:687, 1982.
- 9) Koren G, Brand N, Dani S, Halkin H: Therapeutic failure in epileptic children due to impaired diphenylhydantoin bioavailability. *Isr J Med Sci* 18:721-723, 1982.
- 10) Koren G, Soldin S, MacLeod S M: Interaction of digoxin with verapamil, indomethacin and other co-administered drugs. A comparative study in rat tissue. In: Proceedings of the International Congress on Developmental Pharmacology, Oct. 1982 (Eds: SM MacLeod, AB Okey, SP Spielberg), Toronto. *Alan R. Liss, Inc., New York*, pp 417-420, 1983.
- 11) Koren G, Soldin S, MacLeod S M: Digoxin-verapamil interaction. *In vitro* studies in rat tissue. *J Cardiovas Pharmacol* 5:443-446, 1983.
- 12) Koren G, Frand M, Barzilay Z, MacLeod SM: Corticosteroid treatment of laryngotracheitis vs spasmodic croup. *Am J Dis Child* 137:941-944, 1983.
- 13) Koren G, Rajchgot P, Good F, Harding L, MacLeod SM: Improved techniques for IV drug delivery in children. *Am J IV Ther Nutr* 10:33-38, 1983.
- 14) Koren G, Modan M, Barzilay Z: Errors in computing drug doses. *Can Med Assoc J* 129:721-723, 1983.

- 15) Koren G, Barzilay Z, Shachar E, Brand N, Dani S, Halkin H: CSF phenytoin in children. *Can J Neurol Sci* 10:195-197, 1983.
- 16) Koren G, Soldin S, MacLeod SM: Digoxin-Amiodarone interaction - in vivo and in vitro studies in rat tissues. *Can J Physiol Pharmacol* 61:1483-1486, 1983.
- 17) Koren G, Frand M, Barzilay Z, MacLeod SM: Corticotherapie compare de la laryngotrachite et de la laryngite striduleuse chez l'enfant. *J de Pediatrie* 3:21 - 24, 1983.
- 18) Aladjem M, Aladjem J, Koren G, Boichis H: Maturation of renal tubular transport of gentamicin. *Develop Pharmacol Ther* 7: 82-86, 1984.
- 19) Koren G, Aladjem M, Militiano B, Seegal B, Jhonash A, Boichis H: Ischemic colitis in chronic intermittent peritoneal dialysis. *Nephron* '36:272-274, 1984.
- 20) Koren G, Halkin H, Dani S, Shachar E, Brand N, Barzilay Z: Kinetics of intravenous phenytoin in children. *Pediatr Pharmacol*, 4:31-38, 1984.
- 21) Koren G, Hesslein P, MacLeod SM: Digitalis toxicity associated with amiodarone therapy in children. *J Pediatr* 104:467-470, 1984.
- 22) Koren G, Zarfin Y, Perlman M, MacLeod SM: The influence of indomethacin on digoxin pharmacokinetics in preterm infants. *Pediatr Pharmacol* 4:25-30, 1984.
- 23) Koren G, Brand N, MacLeod SM: Influence of bioavailability on the calculated Michaelis Menten parameters of phenytoin in children. *Ther Drug Monit* 6:11-14, 1984.
- 24) Koren G, Goresky G, Crean P, Klein J, MacLeod SM: Pediatric fentanyl dosing based on pharmacokinetics during cardiac surgery. *Anesthesia Analgesia*, 63:577-582, 1984.
- 25) Koren G, Boichis C, Rotem Y, Hertz M: The chest x-ray in the diagnosis of atypical nephritis due to infectious mononucleosis. *J Can Assoc Radio* 35:308-309, 1984.
- 26) Koren G, Crean P, Klein J, Goresky G, Villamater J, MacLeod SM: Sequestration of fentanyl by the cardiopulmonary bypass. *Eur J Clin Pharmacol* 27:51-56, 1984.
- 27) Koren G, MacLeod SM: Difficulty in achieving therapeutic serum concentration of salicylate in Kawasaki disease. *J Pediatr*, 105: 991-995, 1984.
- 28) Koren G, MacLeod SM: Characteristics of the digoxin-quindidine and a digoxin-verapamil interaction in rat kidney. *Res Comm Chem Pathol Pharmacol* 45: 3-18, 1984.
- 29) Koren G, Farine D, Maresky D, Taylor J, Heyes J, Soldin S, MacLeod SM: Significance of the endogenous digoxin-like substance in infants and mothers. *Clin Pharmacol Ther* 36: 759-764, 1984.

- 30) Koren G, Goresky G, Crean P, Klein J, MacLeod SM: The pharmacokinetics of fentanyl in children with renal disease. *Res Comm Chem Path Pharmacol* 46: 371-379, 1984.
- 31) Koren G, MacLeod SM: Postmortem redistribution of digoxin in rats. *J Forens Sci* 30: 92-96, 1985.
- 32) Koren G: Interaction between digoxin and commonly coadministered drugs in children. *Pediatrics* 75:1032-1037, 1985.
- 33) Zarfin Y, Koren G, Maresky D, Perlman M, MacLeod SM: Possible indomethacin aminoglycoside interaction in preterm infants. *J Pediatr* 106:511-513, 1985.
- 34) Butt W, Robert Gow, Whyte H, Smallhorn J, Koren G: Complications of arterial catheters: Retrograde Flow and Rapid Elevation in Blood Pressure. *Pediatrics* 76:250-254, 1985.
- 35) Butt W, Koren G, England S, Shear N, Whyte H, Bryan CA, Swyer PR: Hypoxemia associated with helium-oxygen therapy in children. *J Pediatr* 106:474-477, 1985.
- 36) Koren G, Rajcgot P, Harding E, Perlman M, MacLeod SM: Evaluating a filter device used for intermittent intravenous drug delivery to newborn infants. *Amer J Hosp Pharm* 42:106-108, 1985.
- 37) Koren G, Greenwald M: Decreased theophylline clearance causing toxicity in children during viral epidemics. *J Asthma* 22:75-80, 1985.
- 38) Koren G, Greenwald M: Summer Camp Medicine; The epidemiology of beta streptococcal infections. *Can J Pub Health* 73:63-64, 1985.
- 39) Koren G, Shear N, Macleod SM: In vitro assessment of the digoxin-quinidine interaction using cultured human cells. *JRCS of Med Sci* 13:72-73, 1985.
- 40) Koren G, Lavi S, Greenwald M, Roifman CH, MacLeod SM, Gelfand E: Cerebrospinal fluid pharmacokinetics of tobramycin, ceftazidime, phenobarbitone and phenytoin in a child. *Clin Pharmacokin* 10:371-375, 1985.
- 41) Koren G, Weitzman Z, Forstner G, Durie P: BT PABA test in evaluating exocrine pancreatic function in CF patients: A pharmacokinetic approach. *J Digest Dis Sci* 30:928-932, 1985.
- 42) Koren G, Barker C, Bohn D, Kent G, Biggar D: Influence of hypothermia on gentamicin and theophylline in piglets. *Crit Care Med* 13:844-847, 1985.
- 43) Koren G, Leeder S, Harding L, MacLeod SM: Optimization of gentamicin therapy in VLBW. *Pediatr Pharmacol* 5:79-88, 1985.
- 44) Koren G, Sloan I: Pharmacokinetics of N<sub>2</sub>O in children. *Res Comm Chem Pathol Pharmacol* 49:95-108, 1985

- 45) Koren G, Parker R: Interpretation of excessive serum concentration of digoxin in children. *Amer J Cardiol* 55:1210-1214, 1985.
- 46) Koren G, Chin T, Correia J, Tesoro A, MacLeod SM: Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. *Clin Invest Med* 8: 222-226, 1985.
- 47) Koren G, Soldin S, MacLeod SM: Organization and efficacy of a therapeutic drug monitoring consultation service in a pediatric hospital. *Ther Drug Monit* 7: 295-298, 1985.
- 48) Collins C, Koren G, Crean P, Klein J, Roy WL, MacLeod SM: The correlation between fentanyl pharmacokinetics and pharmacodynamics in preterm infants during ligation of PDA. *Anesth Analg* 64:1078-1080, 1985.
- 49) Koren G, Butt W, Chinyanga H, Pape K: Neonatal seizures associated with morphine sulphate. *Vet Hum Toxicol* 27:519-520, 1985.
- 50) Koren G, James A, Perlman M: A simple method for the estimation of GFR in newborn infants using routine gentamicin serum concentrations. *Clin Pharmacol Ther* 38:680-685, 1985.
- 51) Koren G, Lavi S, Rose U, Rowe R: Probable efficacy of high dose salicylate in reducing coronary involvement in Kawasaki disease. *JAMA* 254: 767-769, 1985.
- 52) Koren G, Butt W, Chinyanga H, Soldin S, Tan YK, Pape K: Postoperative morphine infusion in newborn infants: Assessment of disposition characteristics and safety. *J Pediatr* 107: 963-966, 1985.
- 53) Sirota L, Aladjem M, Laufer J, Boichis H, Koren G: Gentamicin-digoxin interaction in the rat kidney. *Isr J Med Sci* 21:535-536, 1985.
- 54) Koren G, Butt W: The efficacy of racemic epinephrine in subglottic stenosis in neonates: a controlled prospective study. *J Perinatol* 6:24-26, 1986.
- 55) Koren G, Butt W, Meyer J, Pape K, MacLeod SM: Paraldehyde pharmacokinetics and seizure control in newborn infants. *Neurology* 36:108-111, 1986.
- 56) Koren G, Zarfin Y, Maresky D, Spiro T, MacLeod SM: Pharmacokinetics of intravenous clindamycin in newborn and infants. *Pediatr Pharmacol* 5:287-292, 1986.
- 57) Crean P, Koren G, Goresky G, Klein J, MacLeod SM: Fentanyl-oxygen vs Fentanyl N2O/oxygen anesthesia in children undergoing cardiac surgery. *Can J Anesth* 33:32-36, 1986.
- 58) Koren G, Lavi S, Rose V, Rowe R: Kawasaki disease; a review of risk factors for coronary aneurysms. *J Pediatr* 108:388-392, 1986.

- 59) Koren G, Goresky G, Crean P, Klein J, MacLeod SM: Unexpected alterations in fentanyl pharmacokinetics in children undergoing cardiac surgery: Age related or disease related? *Devel Pharmacol Ther* 9:183-191, 1986.
- 60) Koren G, Barzilay Z, Greenwald M: Ten-fold errors in drug dose administration: A neglected iatrogenic disease in children. *Pediatrics* 77:848-849, 1986.
- 61) Koren G, Spielberg SP, MacLeod SM: Opinions of Canadian Pediatricians on controversial therapeutic issues. *J Med Ed* 61:769-771, 1986.
- 62) Sulh, H, Koren G, Whalen C, Soldin S, Zipursky A, Greenberg M: Unexpected pharmacokinetics of 6-mercaptopurine in children with acute lymphoblastic leukemia, *Clin Pharmacol Ther* 40:604-609, 1986.
- 63) Vaisman N, Koren G, Pencharz P: Pharmacokinetic considerations of oral and intravenous bromide exposure in humans. *J Clin Toxicol* 24:403-414, 1986.
- 64) Koren G, Feldman Y, Shear N: Motherisk - A new approach to drug/chemical teratogenicity. *Vet Hum Toxicol* 28:563-565, 1986.
- 65) Koren G, Klein J, MacLeod SM, Silverman M: Cellular mechanisms of digoxin transport and toxic interactions in the kidney. *Vet Hum Toxicol* 28:549-551, 1986.
- 66) Koren G, MacLeod SM: Monitoring and avoiding drug and chemical teratogenicity. *Can Med Assoc J* 135:1079-1081, 1986.
- 67) Koren G, Barker C, Kent J, Klein J, Goresky G, Bohn D, MacLeod SM, Biggar D: The effect of hypothermia on fentanyl pharmacokinetics. *Eur J Clin Pharmacol* 32:373-376, 1987.
- 68) James A, Koren G, Milliken J, Soldin S, Prober C: Vancomycin pharmacokinetics and dose recommendations for preterm infants. *Antimicrob Chemother* 31:52-54, 1987.
- 69) Koren G, Roifman C, Suraia D, Lavi S, Gelfand E, Stein L: Corticosteroids - salicylate interaction in Juvenile Rheumatoid Arthritis. *Ther Drug Monit* 9:177-179, 1987.
- 70) Balin A, Koren G, Bryan C, Kohelet D, Greenwald M, Zipursky A: Reduction of platelet counts induced by mechanical ventilation in newborn infants. *J Pediatr* 111:445-449, 1987.
- 71) Koren G, Brill-Edwards M, Miskin M: Antenatal sonography of fetal malformations associated with drugs and chemicals - a guide. *Am J Obstet Gynecol* 156:79-85, 1987.
- 72) Vaisman N, Koren G, Goldstein D, Canny GJ, Tan YK, Soldin S, Pencharz P: Pharmacokinetics of inhaled salbutamol in patients with cystic fibrosis versus healthy young adults. *J Pediatr* 111:914-917, 1987.



- 73) Vaisman N, Pencharz PB, Koren G, Johnson JK: Comparison of oral and intravenous administration of sodium bromide for extracellular water measurements. *Am J Clin Nutr* 46:1-4, 1987.
- 74) Koren G: Significance of the renal tubular secretion of digoxin. *Clin Pharmacokinetics* 13:334-343, 1987.
- 75) Koren G, James A: Vancomycin dosing for preterm infants. Prospective verification of new recommendations. *J Pediatr* 110:797-798, 1987.
- 76) Goresky GV, Koren G, Sabourin MA, Sale JP, Strunin L: Pharmacokinetics of alfentanil in children. *Anesthesiology* 67:654-659, 1987.
- 77) Langevin AM, Koren G, Soldin SJ, Greenberg M: Pharmacokinetic case for giving 6-mercaptopurine maintenance doses at night. *Lancet* 2:505-506, 1987.
- 78) Long D, Koren G, James A: Ethics of drug studies in infants: How many samples are required for accurate estimation of pharmacokinetic parameters in neonates. *J Pediatr* 111:918-921, 1987.
- 79) Koren G, Klein J, Silverman M: Evidence of digoxin metabolism by the kidney. *Can J Physiol Pharmacol* 65:2500-2503, 1987.
- 80) Koren G, Bologa-Campeanu M, Pellegrini E, Rieder M, McGuigan M: Information and consultation for drugs, chemicals and radiation exposure in pregnancy; What bothers women most commonly. *Vet Hum Toxicol* 29:456-458, 1987.
- 81) Koren G: Salicylates in Kawasaki Disease - a review of clinical pharmacokinetics and efficacy. In: Proceedings of 2nd International Kawasaki Disease Symposium. *Alan R Liss Inc, New York* pp 415-524, 1987.
- 82) Shahar E, Koren G: Recent advances of seizure control in children. Progress in Clinical Neurosciences 1987, *Neurological Society of India* 1:297-304, 1987.
- 83) Koren G: Why should you typeset your papers. *The Scientist Vol 1, No 16, June 29, 1987*.
- 84) Kohelet D, Perlman M, Kirpalani H, Bryan AC, Koren G: Reduced incidence of bronchopulmonary dysplasia with early initiation of high frequency oscillation for persistent pulmonary hypertension of the newborn. *Crit Care Med* 15:510-516, 1988.
- 85) Koren G, Litwack J, Biggar DW: Using infants in drug research when there is no direct benefit to them: A survey of Canadian health professionals serving in ethical committees. *Can Med Assoc J* 138:899-902, 1988.
- 86) Peters M, Koren G, Jakubovicz D, Zipursky A: Physicians' compliance and relapse rates of acute lymphoblastic leukemia in children. *Clin Pharmacol Ther* 43:228-232, 1988.

- 87) Koren G, Schaeffer F, Silverman E, Walker S, Duffy C, Stein L, Suria D, Schue S, Thiessen J, Gelfand E, Laxer R: Determinants of low serum concentrations of salicylates seen in Kawasaki Disease. *J Pediatr* 112:663-667, 1988.
- 88) Koren G, Long D, Klein J, Beatie D, Livne A, Kirplani H: Comparison of the digitalis receptor in erythrocytes from preterm infants and adults. *Pediatr Res* 23:414-417, 1988.
- 89) Koren G, Beatie D, Soldin SJ: Agonal elevation in digoxin serum concentrations in infants and children long after cessation of therapy. *Crit Care Med* 23:414-417, 1988.
- 90) Koren G, Farine D, Grundmann H, Heyes J, MacLeod SM, Soldin S, Taylor J: Endogenous digoxin like substance in uneventful and high risk pregnancies. *Develop Pharmacol Ther* 11:82-87, 1988.
- 91) Whiting WC, Sandler AN, Lau LC, Chovaz PM, Slovenchko P, Daley D, Koren G: Analgesic and respiratory effects of epidural sufentanil in post thoracotomy patients. *Anesthesiology* 69:36-43, 1988.
- 92) Koren G, Lau A, Klein J, Golas C, Bologa-Campeanu M, MacLeod SM, Prober C: Pharmacokinetics and adverse effects of amphotericin B in infants and children. *J Pediatr* 113:559-563, 1988.
- 93) Ballin A, Brown EJ, Koren G, Zipursky A: Vitamin C - induced erythrocyte damage in premature infants. *J Pediatr* 113:114-120, 1988.
- 94) Koren G, Klein J: Enhancement of digoxin clearance by mannitol diuresis: In vitro studies and their clinical implications. *Vet Hum Toxicol* 30:25-27, 1988.
- 95) Bologa-Campeanu M, Koren G, Rieder M, McGuigan M: Drugs and chemicals most commonly concerning pregnant women; A review of reproductive hazards. *Med Toxicol* 3:307-323, 1988.
- 96) Cribb A, Koren G: Pursuing teratogenic causes of multiple congenital contractures. *Clin Toxicol* 26:ix-xv, 1988.
- 97) Koren G, Klein J, Bendayan R, Soldin S, Giesbercht E, Sellers E, MacLeod SM, Silverman M: The effects of quinidine on the renal and biliary transport of digoxin in the dog. *J Pharmacol Exper Ther* 247:1193-1198, 1988.
- 98) Einarson TR, Leeder JS, Koren G: A method for meta-analysis of epidemiological studies. *Drug Intell Clin Pharm* 22:813-824, 1988.
- 99) Koren G, Klein J, MacLeod SM: Dissociation between serum concentrations and nephrotoxicity of aminoglycosides. *Life Science* 43:1817-1823, 1988.
- 100) Bentur Y, Koren G, McGuigan M, Spielberg S: An unusual skin exposure to copper: clinical and pharmacokinetic evaluation. *Clin toxicol* 26: 371-380, 1988.

- 101) Graham K, Demitrakoudis D, Pellegrini E, Koren G: Pregnancy outcome following first trimester exposure to cocaine in non addict social users in Toronto. *Vet Hum Toxicol* 31: 143-148, 1988.
- 102) Doyle JJ, Koren G, Cheng MY, Blanchette VS: Anticoagulation with sodium warfarin in children: Effects of loading regimen *J Pediatr*, 113: 1095-197, 1988.
- 103) Pellegrini E, Koren G: The Motherisk Program - Pregnancy and drug counselling. *On Continuing Practice* 15:2-6, 1988.
- 104) Bailey B, Morris P, McMartin KI, Klein J, Duhart HM, Gillam MP, Binienda Z, Slikker W, Paule MG, Koren G: Transplacental pharmacokinetics of cocaine and benzoylecgonine in plasma and hair of Rhesus monkeys. *Reprod Toxicol* 12: 517-523, 1988.
- 105) Bentur Y, Hummel D, Roifman CM, Koren G: Interpretation of excessive levels of inhaled tobramycin. *Ther Drug Monit* 11: 109-110, 1989.
- 106) Halperin DS, Koren G, Pellegrini E, Wyss M: Topical skin anesthesia for venous, subcutaneous drug reservoir and lumbar punctures in children. *Pediatrics* 84: 281-284, 1989.
- 107) Balin A, Koren G, Hasu M, Zipursky A: Evaluation of a new method for the prevention of neonatal anemia. *Pediatr Res* 25: 274-275, 1989.
- 108) Koren G, Barker C, Bohn D, Kent G, McGuigan M, Biggar WD: The effect of hypothermia on the pharmacokinetics of ethanol in piglets. *Ann Emerg Med* 18: 118-121, 1989.
- 109) Koren G: Nephrotoxic potential of drugs and chemicals: Pharmacological basis and clinical relevance. *Med Toxicol* 4:59-72, 1989.
- 110) Schimmel M, Eidelman AJ, Wilschanski MA, Shaw D, Ogilvie R, Koren G: Neonatal toxicity of antenolol consumed during breastfeeding. *J Pediatr* 114: 476-478, 1989.
- 111) Koren G, Beatie D, Soldin S, Einarson T, MacLeod SM: Interpretation of high postmortem concentrations of digoxin in children, *Arch Pathol Lab Med* 113: 758-761, 1989.
- 112) Koren G, Bologa-Campeneau M, Long D, Henderson K, Feldman Y, Shear N: Perception of teratogenic risk by pregnant women exposed to drugs and chemicals in early pregnancy. *Amer J Obstet Gynecol*, 160: 1190-1194, 1989.
- 113) Koren G, Klein J, Giesbrecht E, Bentur Y: The effect of mannitol diuresis on digoxin and phenobarbital handling by the kidney; Implications for tubular reabsorption and secretion of the cardiac glycoside, *Clin Invest Med* 12: 279-284, 1989.
- 114) Koren G, Bentur Y, Strong D, Harvey E, Klein J, Bauman R, Freedman M: Acute renal failure in patients receiving intravenous deferoxamine. *Amer J Dis Child* 143: 1077-1080, 1989.

- 115) Koren G, Demitrakoudis D, Weksberg R, Rieder M, Shear N, Sonely M, Shandling B, Spielberg S: Neuroblastoma after prenatal exposure to phenytoin: cause and effect? *Teratology*, 40: 157-162, 1989.
- 116) Tesoro A, Leeder S, Bentur Y, Klein J, Koren G: A new HPLC method for the measurement of deferoxamine in body fluids, *Ther Drug Monit* 11: 463-470, 1989.
- 117) Koren G, Sulh H, Soldin S, Greenberg M: The disposition of oral methotrexate in children with ALL and its relations to 6-MP pharmacokinetic. *Med Ped Oncol* 17: 450-454, 1989.
- 118) Koren G, Sandler A, Klein J, Lau LC, Chovaz PM, Slavochenko P, Daley P: Relationship between the pharmacokinetics and analgesic and respiratory pharmacodynamics of epidural sufentanil. *Clin Pharmacol Ther* 46: 458-462, 1989.
- 119) Bentur Y, Koren G, Klein J, Tesoro A, Leeder S: Pharmacokinetics of deferoxamine with and without iron overload. *Vet. Hum Toxicol* 31: 156-157, 1989.
- 120) Shahar E, Koren G, Brand N: Medical management of seizures during infancy and childhood. *Harefuah*, 117: 226-232, 1989.
- 121) Koren G, MacLeod SM: The State of Pediatric Clinical Pharmacology; An international survey of training programs. *Clin Pharmacol Ther* 46: 489-493, 1989.
- 122) Leonard MB, Koren G, Stevenson DK, Prober CG: Vancomycin pharmacokinetics in very low birth weight neonates. *Pediatr Inf Dis J* 8: 282-286, 1989.
- 123) Graham K, Koren G, Klein J, Schneiderman J: Detecting gestational exposure to cocaine by hair analysis. *JAMA* 262: 3328-3330, 1989.
- 124) Koren G, Graham K, Shear H, Einarson T: Bias against the null hypothesis; The reproductive hazards of cocaine. *Lancet* 2: 1440-1442, 1989.
- 125) Koren G: Aspirin in Kawasaki disease. A critical review, 1988 Proceedings of the 3rd International Kawasaki Disease Symposium, Tokyo, December 1988. *Japan Heart Foundation pp* 304-308, 1989.
- 126) Feldman Y, Koren G, Mattice D, Shear H, Pellegrini E, MacLeod SM: Determinants of recall and recall bias in studying drug and chemical exposure in pregnancy. *Teratology* 40: 37-46, 1989.
- 127) Shulman ST, Bass JL, Bierman F, Burns JC, Chung K, Dillon MJ, Duffy E, Fulton D, Gersony WM, Giddings, Gillespie SM, Golode MP, Koren G, et al: Management of Kawasaki syndrome: a consensus statement prepared by North American Participants of the Third International Kawasaki Disease Symposium, Tokyo, Japan, December 1988. *Pediatr Inf Dis* 8: 663-667, 1989.

- 128) Koren G: Drug therapy in pregnancy: What's right? What's wrong? *Journal of The Society of Obstetricians and Gynecologists of Canada* 11: 1, 1989.
- 129) Koren G, Pellegrini E: A clinical approach to drug, chemical and radiation exposure in pregnancy. *Journal of The Society of Obstetricians and Gynecologist of Canada* 11: 5-12, 1989.
- 130) Zalstein E, Koren G: Kawasaki Syndrome - Diagnosis and treatment. *Can J Pediatr* 1: 22-27, 1989.
- 131) Freedman MH, Bentur Y, Koren G: Biologic and toxic properties of deferoxamine therapy. In: Advances and controversies in thalassemia treatment. (G. Lucarelli, Ed.) *Alan R. Liss, New York* pp 115-124, 1989.
- 132) Koren G: Neonatal Toxicology. *Medicine North America Issue 2*, 121-130, 1989.
- 133) Koren G, Bologna M: Teratogenic risk of hair care products. *JAMA* 262: 2925, 1989.
- 134) Haslam RHA, Koren G: Screening of the epileptic patient. Is it worth the trouble? *Can J Neurol Sci* 16: 363-364, 1989.
- 135) Einaron T, Koren G, Mattice D, Schechter Tsafri O: Maternal Spermicide use and adverse reproductive outcome: A meta-analysis. *Amer J Obstet Gynecol* 162: 655-660, 1990.
- 136) Koren G, Pastuszak A: Medical research in infants and children in the eighties; Analysis of rejected protocols *Ped Res*, 27: 423-435, 1990.
- 137) Koren G, Pastuszak A, Pellegrini E: Prevention of unnecessary pregnancy termination by counselling women on drug, chemical and radiation exposure during the first trimester, *Teratology* 41: 657-662, 1990.
- 138) Koren G, Tesoro A, Leeder S, Bentur Y, Olivieri N: Studies of the stability of desferoxamine in aqueous solution, *Can J Hosp Pharm* 43: 57-60, 1990.
- 139) Chan W, Petric M, Wang E, Koren G, Read S, Blanchette V: Response to hepatitis B immunization in hemophiliac children: relationship to HIV-1 infection *J Pediatr* 113: 427-430, 1990.
- 140) Koren G, Langevin AM, Olivieri N, Giesbrecht E, Zipursky A, Greenberg M: Diurnal variation in the pharmacokinetics and myelotoxicity of 6-MP in children with ALL. *Amer J Dis Child* 144: 1135-1138, 1990.
- 141) Shahar E, Sagy M, Koren G: Calcium blocking agents in pediatric emergency care. *Pediatr Int Care* 6: 52-57, 1990.
- 142) Klein J, Colin P, Scherer E, Levy M, Koren G: Simple measurement of captopril in plasma by HPLC with UV detection. *Ther Drug Monitor* 12: 105-110, 1990.

- 143) Levy M, Egersegi P, Strong A, Tesoro A, Spino M, Bannantyne R, Fear D, Posnick JC, Koren G: Pharmacokinetic analysis of cloxacillin loss in children undergoing major surgery with massive bleeding. *Antimicrob Agents Chemother* 34: 1150-1153, 1990.
- 144) Lavi S, Zimmerman B, Koren G, Gold R: Administration of measles, mumps and rubella, rubella virus vaccine to egg-allergic children: *JAMA* 263: 269-271, 1990.
- 145) Koren G, Weiner L, Lishner M, Zemelickis D, Finnigan J: Cancer in pregnancy; Analysis of unanswered questions of fetal and maternal risks. *Obstet Gynecol Survey* 45: 509-514, 1990.
- 146) Zalstein E, Bryson SM, Freedom R, Koren G: Interaction between digoxin and propafenone in children. *J Pediatr* 116: 310-312, 1990.
- 147) Du Puis LL, Koren G, Shore A, Silverman ED, Laxer RM: Interaction between methotrexate and non-steroidal anti inflammatory drugs in children with juvenile arthritis. *J Rheumatol* 17: 1469-1473, 1990.
- 148) Zalstein E, Koren G, MacLeod SM, Freedom R: Once daily versus twice daily dosing of digoxin in the pediatric age group. *J Pediatr* 116: 137-139, 1990.
- 149) Kapelushnik J, Koren G, Greenberg M, DeVeber LL: Evaluating the efficacy of EMLA in alleviating pain associated with lumbar puncture: Comparison of open and double blinded protocols in children. *Pain* 40: 31-34, 1990.
- 150) Levy M, DuPuis L, Reid S, Koren G: Vancomycin induced red-man syndrome. *Pediatrics* 86: 572-580, 1990.
- 151) Levy M, Koren G: Atypical Kawasaki Disease; Clinical characteristics and diagnostic clues. *Ped Inf Dis J* 9: 122-126, 1990.
- 152) Levy M, Duffy C, Pollak P, Budd E, Koren G: Home based palliative care for children Part 1: The institution of a program. *J Palliative Care* 6: 11-15, 1990.
- 153) Duffy C, Pollak P, Levy M, Budd E, Koren G: Home based palliative care for children Part 2: The benefits of an established program. *J Palliative Care* 6: 8-14, 1990.
- 154) Robieux I, Kumar R, Radhakrishnan S, Koren G: The feasibility of using EMLA cream to relieve pain in pediatric outpatient clinics *Can J Hosp Pharm* 43: 235-236, 1990.
- 155) Koren G, Lau A, Canyon S, Knoppert D, Klein J: Clinical course and pharmacokinetics following a massive overdose of amphotericin B in a neonate. *J Clin Toxicol* 28: 371-378, 1990.
- 156) Robieux I, Koren G, Wandenberg H, Schneiderman J: Morphine excretion in breastmilk and resultant exposure in a nursing infant. *J Clin Toxicol* 28: 365-370, 1990.
- 157) Rieder M, Koren G, MacLeod SM: Paediatric Clinical Pharmacology and the health of the World's Children. *Dev Pharmacol Ther* 9: 1-3, 1990.

- 158) Koren G, Pellegrini E: Counselling pregnant women exposed to drugs and chemicals, *Drug Protocol*, 5: 23-32, 1990.
- 159) Greenwald M, Koren G: Viral induced changes of theophylline handling in children. *Amer J Asthma & Allergy Pediatr*. 3: 162-165, 1990.
- 160) Bentur Y, Koren G, Olivieri N, Tesoro A, Freedman M: Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity: *Clin Pharmacol Ther* 47: 478-482, 1990.
- 161) Malkin D, Koren G, Saunders F: Drug induced marrow aplasia. *Amer J Pediatr Hematol Oncol* 12: 402-410, 1990.
- 162) Olivieri N, Koren G, Hermann C, Bentur Y, Chung D, Klein J, St. Louis P, Freedman MH, McClelland RA, Templeton DM: Evaluation of the oral iron chelator 1,2 Dimethyl -3- Hydroxypyrid -4- one (L<sub>1</sub>) in iron loaded patients: A randomized crossover comparison with deferoxamine, effect on iron balance and dose response studies. *Lancet* 336: 1275-1279, 1990.
- 163) Jacobson S, Koren G: New approaches to topical anesthesia in children. *Curr Opinions Pediatr* 2: 234-237, 1990.
- 164) Bentur Y, Klein J, Levy M, Olivieri N, McGuigan M, Koren G: Methodological issues in studying the effect of the new oral chelator 1,2 - dimethyl -3- hydroxypyrid -4- one (L<sub>1</sub>) on absorption of iron. *Vet Hum Toxicol* 32: 159-161, 1990.
- 165) Badner NH, Sandler AN, Colmenares ME, Koren G: Lumbar epidural fentanyl infusions for post thoracotomy patients: Analgesic, respiratory and pharmacokinetic effects. *Card. Thor Anesth* 4: 543-551, 1990.
- 166) Koren G, Chang N, Gonen R, Klein J, Weiner LH, Demshar HP, Pizzolato S, Shime J: Lead exposure in mothers and their newborn babies in greater Toronto, 1989. *Can Med Assoc J* 142: 1241-1244, 1990.
- 167) Koren G: Counselling women on reproductive risks of drugs, chemicals and radiation. *Medicine North America*: 1781-1793, December 1990.
- 168) Koren G: Studying the safety of ribavirin in human pregnancy. *J Pediatr Inf Dis* 9: 5106-5107, 1990.
- 169) Koren G, Ferrazini G, Sulh H, Kapelushnik J, Giesbrecht E, Soldin S, Greenberg M: Systemic exposure to 6-MP: A prognostic factor in low and standard risk acute lymphocytic leukemia in children. *N Engl J Med* 323: 17-22, 1990.
- 170) Ferrazini G, Klein J, Sulh H, Chung D, Giesbrecht E, Koren G: Interaction between trimethoprim/sulfamethoxazole and methotrexate in children with leukemia. *J Pediatr* 117: 823-826, 1990.

- 171) Koren G: Ethical boundaries of medical research in infants and children in the eighty's: Analysis of rejected protocols and a new solution for drug studies. *Dev Pharmacol Ther* 15: 130-141, 1990.
- 172) Olivieri N, Koren G, St. Louis P, Freedman MH, McClelland RA, Templeton DM: Studies of the oral chelator 1,2-dimethyl 3-hydroxypyrid-4-one in thalassemia patients. *Semin Hematol* 27: 101-104, 1990.
- 173) Ito S, Harper PA, Koren G: Renal tubular cell handling of digoxin and ouabain - *in vitro* study using LLC-PK1 cell lines. *Toxicol Letters* 53: 189-192, 1990.
- 174) Olivieri NF, Templeton DM, Koren G, Chung D, Herman C, Freedman MH, McClelland RA: Evaluation of the oral iron chelator L<sub>1</sub> in iron loaded patients. *Ann NY Acad Sci* 612: 369-377, 1990.
- 175) Levy M, Koren G: Obstetric and neonatal effects of drugs of abuse. *Emerg Med N Amer* 8: 633-652, 1990.
- 176) Stone J, Bentur Y, Zalstein E, Soldin S, Giesbrecht E, Koren G: Effects of endogenous digoxin like substances on the interpretation of high concentrations of digoxin in children. *J Pediatr* 117: 321-325, 1990.
- 177) Koren G: The risks of pregnancy in epilepsy. In: *Neurology Specialist Program. Medifacts, Ottawa, Ontario, 1990.*
- 178) Zalstein E, Koren G, Einarson T, Freedom R: A Case Control Study on the association between Ebstein anomaly and lithium exposure in pregnancy. *Am J Cardiol*, 817-818, 1990.
- 179) Kirpalani H, Koren G, Schmidt B, Soldin S: Respiratory response and pharmacokinetics of intravenous salbutamol in infants with bronchopulmonary dysplasia. *Crit Care Med*, 18: 1374-1377, 1990.
- 180) Olivieri NF, McGee A, Liu P, Koren G, Freedman H, Benson L: Cardiac disease-free survival in patients with thalassemia major treated with subcutaneous deferoxamine. *Ann NY Acad Sci* 612: 585-586, 1990.
- 181) Freedman MH, Olivieri N, Benson L, Liu P, McClelland R, St. Louis P, Templeton D, Koren G: Clinical studies in iron chelation in patients with thalassemia major. *Hematologica* 75: 74-83, 1990.
- 182) Koren G, Pastuszak A, Bologna M: Women's perception of teratogenic risk. Proceedings of the International symposium on "Risk Estimation for Pharmaceuticals". Canadian Public Health Association, Health & Welfare Canada and World Health Organization. *Ottawa. November 20-21, 1990.*
- 183) Lavi S, Zimerman B, Koren G, Gold R: Administration of measles, mumps, and rubella virus vaccine to egg allergic children. *Crit Care Nurse* 10: 80-82, 1990.



- 184) O'Callaghan AC, Koren G, Sloan JAS: Effects of age and cardiac shunts on the measured uptake of nitrous oxide in children. *Res Commun Chem Pathol Pharmacol* 74: 299-315, 1991.
- 185) Koren G, Zemlickis D: Pregnancy outcome following first trimester exposure to H<sub>2</sub> receptor blockers *Amer J Perinatol* 8: 37-38, 1991.
- 186) Laufer D, Clegorn G, Forstner G, Ellis L, Koren G, Durie P: The Bentiromide test using plasma PABA for diagnosing pancreatic insufficiency in young children. The effect of two different doses and a liquid meal. *Gastroenterology* 101: 207-213, 1991.
- 187) Koren G, Sharav T, Pastuszak A, et al: A multicenter prospective study of reproductive outcome following carbon monoxide poisoning in pregnancy *Reproduct Toxicol* 5: 397-403, 1991.
- 188) Levy M, Buskila R, Gladman D, Koren G: Pregnancy outcome following first trimester exposure to chloroquine. *Am J Perinatol* 8: 174-178, 1991.
- 189) Levy M, Koren G: Maternal and fetal safety of Hepatitis B vaccine in pregnancy *Am J Perinatol* 8: 227-231, 1991.
- 190) Koren G, Kochavi-Atiya Y, Bentur Y, Olivieri N: The effects of subcutaneous deferoxamine administration on renal function in thalassemia major *Int J Hematol* 54: 371-375, 1991.
- 191) Ferrazini G, Sohl H, Robieaux I, Johnson D, Gilsbrecht EP, Koren G: Diurnal variation in the disposition of methotrexate in childhood leukemia *Eur J Clin Pharmacol* 41: 425-427, 1991.
- 192) Derewlany LO, Leeder JS, Kumar R, Radde IC, Knie B, Koren G: The transport of digoxin across the perfused human placental lobule. *J Pharmacol Exp Ther* 256: 1107-1111, 1991.
- 193) Levy M, Pastuszak A, Koren G: Fetal outcome following intrauterine amantadine exposure. *Reprod Toxicol* 5: 79-81, 1991.
- 194) Lutiger B, Graham K, Einarson T, Koren G: Reproductive risks of cocaine; A meta analysis *Teratology* 44: 405-414, 1991.
- 195) Bentur Y, Koren G: The three most common occupational exposures in pregnancy *Am J Obst Gynecol* 165: 429-437, 1991.
- 196) Bentur Y, St. Louis P, Klein J, Koren G: Misinterpretation of iron binding capacity in the presence of deferoxamine *J Pediatr* 118: 139-142, 1991.
- 197) Levy M, Benson L, Bentur Y, Johnson D, Jacobson S, Strong D, Koren G: Tissue plasminogen activator: Report of its use in infants and children: *J Pediatr* 118: 467-472, 1991.

- 198) Bentur G, Horlatch N, Koren G: Exposure to ionizing radiation during pregnancy; perception of teratogenic risk and outcome. *Teratology* 43: 109-112, 1991.
- 199) Zemlickis D, Lishner M, Degendorfer P, Panzarella T, Burke B, Sutcliffe S, Koren G: Maternal and fetal outcome following breast cancer in pregnancy. *Amer J Obstet & Gynecol* 9: 1956-1961, 1991.
- 200) Bentur Y, Koren G, McGuigan M: Deferoxamine: New toxicities of an old drug, *Med Toxicol Drug Safety* 6: 37-46, 1991.
- 201) Bologa M, Tang B, Klein J, Tesoro A, Giesbrecht E, Koren G: Pregnancy-induced changes in drug metabolism in epileptic women. *J Pharmacol Exp Ther* 257: 735-740, 1991.
- 202) Koren G, Reich A, Hales B: The role of clinical pharmacists in preventing potentially fatal tenfold medication errors in children. *J Pharm Tech* 7: 219-221, 1991.
- 203) Duffy C, Pollak P, Levy M, Budd E, Koren G: Home based palliative care in children: a feasibility study. Programs for dying children and families. Hemisphere Publishing Corporation, Washington DC, 209-216, 1991.
- 204) Olivieri NF, Matsui D, Hermann C, Koren G: Compliance assessed by the Medication Event Monitoring System. *Arch Dis Chil* 66: 1399-1402, 1991.
- 205) Klein J, Chung D, Epemoulu O, Olivieri N, Damani LA, Koren G: A high pressure liquid chromatographic method for the measurement of the iron chelator 1,2 -Dimethyl-3-hydroxyridin-4-one in human plasma. *Ther Drug Monit* 13: 51-54, 1991.
- 206) Levy M, Koren G, Klein J, Balf W: Captopril pharmacokinetics, blood pressure and plasma renin activity in children with scarred kidneys. *Dev Pharmacol Ther* 16: 185-193, 1991.
- 207) Koren G: Monitoring adverse drug reactions in pregnancy and lactation; The Motherisk model, *Braislava Medical Letters* 92: 615-618, 1991.
- 208) Klein J, Bentur Y, Cheung D, Moselhy G, Koren G: Renal handling of cisplatin: Interactions with organic anions and cations in the dog. *Clin Investig Med* 14: 388-394, 1991.
- 209) Zemlickis D, Lishner M, Degendorfer P, Panzarella T, Sutcliffe S, Koren G: Maternal and fetal outcome following invasive cervical cancer in pregnancy *J Clin Oncol* 9: 1956-1961, 1991.
- 210) Robieux I, Koren G: Assessing pain and analgesia with a lidocaine-prilocaine emulsion in infants and toddlers during venipuncture *J Pediatr* 118: 971-973, 1991.
- 211) Levy M, Koren G: Red Man Syndrome in children. *Can J Pediatr* April, 22-29, 1991.

- 212) Koren G, Robieux I, Pastuszak A: Ethics de la recherche medicale. Proceedings of the 5th Guigoz meeting. *December, 1990, Douville, France 115-132, 1991.*
- 213) Koren G, Forman R, Graham K, Klein J: Gestation effects of cocaine; What is real? Proceedings of the 5th Guigoz meeting, Douville, France, *December, 1990, 379-384, 1991.*
- 214) Matsui D, Klein J, Olivieri N, Hermann C, Koren G: Relationship between the pharmacokinetics and iron excretion pharmacodynamics of L<sub>1</sub> in children with thalassemia. *Clin Pharmacol Ther 50: 294-298, 1991.*
- 215) Graham K, Koren G: Characteristics of pregnant women exposed to cocaine in Toronto between 1985 and 1990. *Can Med Assoc J 144: 563-568, 1991.*
- 216) Koren G, Silverman E, Sundel R, Edney P, Newburger JW, Klein J, Robieux I, Laxer R, Giesbrecht E, Burns JC: Decreased protein binding of salicylates in Kawasaki disease. *J Pediatr 118: 456-459, 1991.*
- 217) Koren G, Klein N: Bias against the null hypothesis in reporting medical research; The Role of Newspapers. *JAMA 266: 1824-1826, 1991.*
- 218) Schimmel MS, Zylber Katz E, Shaag Y, Pastuszak A, Koren G: Toxic neonatal effects following maternal clomipramine therapy. *J Clin Toxicol 29: 479-484, 1991.*
- 219) Koren G, Bologa M, Pastuszak A: Women's perception of teratogenic risk. *Can J Publ Health 82: S11-S14, 1991.*
- 220) De Lannoy IAM, Koren G, Klein J, Charuk J, Silverman M: Cyclosporin and quinidine inhibition of digoxin excretion: evidence for luminal secretion of digoxin in the dog kidney in vivo *Am J Physiol 263 (Renal Fluid Electrolyte Physiol 32): F613-F622, 1992.*
- 221) Robieux I, Coppes MJ, Kelner JD, Koren G, Olivieri NF, Zipursky A: Comparison of intermittent opioids to continuous infusion of morphine in children with sickle cell crisis. *Pediatr Hematol Oncol 9: 317-326, 1992.*
- 222) Graham K, Feigenbaum A, Weksberg R, Einarson T, Goldberg S, Ashby S, Koren G: Pregnancy outcome and infant development following gestational cocaine use by social cocaine users in Toronto, Canada. *Clin Invest Med 15: 384-394, 1992.*
- 223) Koren G, Klein J, MacLeod SM: Comparison of methods for prediction of nephrotoxicity during development. *Dev Pharmacol Ther 19: 80-89, 1992.*
- 224) Olivieri NF, Koren G, Harris J, Khattak S, Bailey JD, Templeton DA, Reilly BJ: Growth failure and bony changes induced by deferoxamine *Am J Ped Hematol Oncol 14: 48-56, 1992.*

- 225) Lishner M, Zemlickis D, Degendorfer P, Panzarella T, Sutcliffe S, Koren G: Maternal and fetal outcome following Hodgkins disease in pregnancy. *Br J Cancer* 65: 114-117, 1992.
- 226) Koren G, Beatty K, Einarson T, Lishner M: The effects of impaired liver function on the elimination of antineoplastic agents. A review and clinical guide. *Ann Pharmacotherapy* 26: 363-371, 1992.
- 227) Koren G, Klein J, Graham K, Forman R: Hair test to varify gestational cocaine exposure. In: *Recent Developments in TDM and Clin Toxicology* Marcel Dekker, NY 569-574, 1992.
- 228) Koren G: TDM in Pregnancy. In: *Recent developments in TDM and Clinical Toxicology*, Marcel Dekker, NY, 53-62, 1992.
- 229) Koren G: Issues in TDM of digoxin in children; In: *Recent developments in TDM and Clinical Toxicology*. Marcel Dekker, NY, 63-64, 1992.
- 230) Koren G, Klein J, Forman R, Graham K: Hair Analysis for cocaine; Separating systemic exposure from external contamination *J Clin Pharmacol* 32: 671-675, 1992.
- 231) Levy M, Koren G: Characteristics of the Red Man Syndrome in children. *J Isr Med Assoc* 122: 36-38, 1992.
- 232) Sundel RP, Cleveland SS, Beiser AS, Newburger JW, McGill T, Koren G, Novak RE, Harris JP, Burns JC: Audiologic profiles of children with Kawasaki disease. *Am J Otol* 13: 1-5, 1992.
- 233) Levy M, Koren G: Clinical toxicology of the neonate. *Semin Perinatol* 16: 63-75, 1992.
- 234) Zemlickis D, Lishner M, Degendarfer P, Panzarella T, Sutcliffe S, Koren G: Outcome of babies exposed in utero to cancer chemotherapy *Arch Int Med* 152: 573-576, 1992.
- 235) Jacobson SJ, Jones K, Johnson K, Donnenfeld AE, Rieder M, Kaur P, Ceolin L, Santelli R, Smythe J, Pastuszak A, Einarson T, Koren G: A prospective multicenter study of pregnancy outcome following lithium exposure during the first trimester of pregnancy. *Lancet* 339: 530-33, 1992.
- 236) Klein J, Fernandes D, Pastuszak A, Koren G: Therapeutic drug monitoring of retinoids. *Ther Drug Monitor* 14: 197-202, 1992.
- 237) Zipursky A, Robieux IC, Brown EJ, Shaw D, O'Brodovitch H, Kellner J, Coppes MJ, Olivieri NF, Koren G: Oxygen therapy in Sickie Cell disease *Amer J Pediatr Hematol/Oncol* 14: 222-228, 1992.
- 238) Robieux I, Dorian P, Klein J, Chung D, Zobrowska Sluis, Ogilvie R, Koren G: The effects of cardiac transplantation and cyclosporine therapy on digoxin pharmacokinetics. *J Clin Pharmacol* 32: 338-343, 1992.

- 239) Gladstone D, Bologna M, Pastuszak A, Koren G: Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin; A prospective study. *Reprod Toxicol* 6: 257-261, 1992.
- 240) Klein J, Greenwald M, Becker L, Koren G: Fetal distribution of cocaine; Case analysis. *Ped Pathol* 12: 463-468, 1992.
- 241) Shore R, Greenberg M, Geary D, Koren G: Iphosphamide - induced nephrotoxicity in children. *Pediatr Nephrol* 6: 162-165, 1992.
- 242) Koren G, Graham K: Cocaine in pregnancy: Analysis of fetal risk. *Vet Hum Toxicol* 34: 263-264, 1992.
- 243) Peled N, Dagan O, Babyn P, Silver M, Barker J, Hellman J, Koren G: Neonatal gastric outlet obstruction induced by prostaglandin therapy. *N Engl J Med* 327: 505-510, 1992.
- 244) Olivieri NF, Koren G, Matsui D, Liu P, Blendis L, Cameron R, McClelland RA, Templeton DM: Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L<sub>1</sub> in thalassemia intermedia. *Blood* 79: 2741-2748, 1992.
- 245) Rosaeg OP, Kitts JB, Koren G, Byford LJ: Maternal and fetal effects of intravenous patient controlled fentanyl anaesthesia during labor in the thrombocytopenic parturient. *Can J Anaesth* 39: 277-281, 1992.
- 246) Koren G: Eutectic mixture of local anesthesia; Changing the risk benefit ratio in pediatric research. *IRB* 14: 4-5, 1992.
- 247) Taddio A, Nulman I, Koren G: Effect of lidocaine-prilocaine cream on pain from subcutaneous injection *Clin Pharm* 11: 347-349, 1992.
- 248) Koren G, Gladstone D, Robeson C, Robieux I: The perception of teratogenic risk of cocaine. *Teratology* 46: 567-571, 1992.
- 249) Robieux I, Eliopoulos C, Hwang P, Greenberg M, Olivieri NF, Klein N, Koren G: Pain perception and effectiveness of the eutectic mixture of local anesthetics in children undergoing venipuncture. *Pediatr Res* 32: 520-523, 1992.
- 250) Ito S, Koren G, Harper P: Handling of digoxin and ouabain by renal tubular cells LLC-PK<sub>1</sub>. *J Pharmacol Exp Ther* 262: 109-113, 1992.
- 251) Koren G: The Motherisk Program. *IM Print*. 4: 4-5, Fall 1992.
- 252) Forman R, Graham K, Klein J, Greenwald M, Koren G: Hair accumulation of cocaine in fetal hair. The dose response curve. *Life Sci* 50: 1333-1342, 1992.

- 253) Koren G, Klein J, Forman R, Graham K, My-Khan P: Biological Markers of intrauterine exposure to cocaine and cigarette smoking. *Dev Pharmacol Ther* 18: 228-236, 1992.
- 254) Taddio A, Nulman I, Reid E, Koren G: Effect of lidocaine-prilocaine cream (EMLA) on pain from intramuscular injections. *Can J Hosp Pharm* 11: 347-9, 1992.
- 255) Matsui D, Hermann C, Braudo M, Ito S, Olivieri N, Koren G: Clinical use of the Medication Event Monitoring System - A new window into pediatric compliance. *Clin Pharmacol Ther* 52: 102-103, 1992.
- 256) Koren G, Klein J: Postmortem redistribution of morphine in rats. *Ther Drug Monit* 14: 461-463, 1992.
- 257) Shear NH, Pastuszak A, Klein J, Koren G: Management program for retinoid therapy in women. *Can J Dermatol* 4: 249-252, 1992.
- 258) Sandler AN, Sringer D, Panos L, Badner N, Friedlander M, Koren G, Katz J, Klein J: A randomized, double blind comparison of lumbar epidural and intravenous fentanyl infusions for post thoracotomy pain relief. *Anesthesiology* 77: 626-634, 1992.
- 259) Ito S, Koren G, Einarson TR: Maternal non-compliance with antibiotics during breastfeeding. *Ann Pharmacother* 27: 40-42, 1992.
- 260) Olivieri NF, Koren G, Hermann C, Bentur Y, Chung D, Klein J, St.-Louis P, Freedman MH, McClelland RA, Templeton DM. Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L<sub>1</sub>) in iron loaded patients. *Hematol Reviews* 6: 147-152, 1992.
- 261) Olivieri NF, Koren G, Matsui D, Liu PP, Blendis LA, Cameron R, McClelland RA, Templeton DM. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L<sub>1</sub> in thalassemia intermedia. *Drugs of Today* 28 (suppl), 1992.
- 262) Koren G, Ferrazzini G, Sohl H, Robieux I, Johnson D, Giesbrecht E: Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. *Chronobiol Internat* 9: 434-438, 1992.
- 263) Koren G: A quality assurance program for Teratogen Information Services. *Reprod Toxicol* 6: 293-295, 1992.
- 264) Gorodischer R, Koren G: Salivary excretion of drugs in children: Theoretical and practical issues in TDM. *Dev Pharmacol Ther* 19: 161-177, 1992.
- 265) Ito S, Blachjman A, Stephenson M, Eliopoulos C, Horlatsh N, Koren G: Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medications. *Amer J Obstet Gynecol* 168: 1393-1399, 1993.

- 266) Graham K, Klein J, Forman R, Flynnk, Sakuma T, Davidson W, Koren G: Potential misclassification of a case of SIDS: Maternal and neonatal hair analysis for cocaine and heroin. *Maternal Fetal Med* 2: 91-93, 1993.
- 267) Koren G: Medications which can kill a toddler with one tablet or teaspoonful *J Clin Toxicol* 31: 407-414, 1993.
- 268) Koren G, Weitzman S, Klein J, Moselhy G: Comparison of carboplatin pharmacokinetics between an anephric child and 2 children with normal renal function. *Med Pediatr Onc* 25: 368-372, 1993.
- 269) Shilalukey K, Robieux I, Spino M, Koren G: Are current pediatric dose recommendations for intravenous theophylline appropriate? *J Asthma*, 30: 109-121, 1993.
- 270) Koren G, Graham K, Feigenbaum A, Einarson T: Evaluation and counseling of teratogenic risk; The Motherisk approach. *J Clin Pharmacol* 33: 405-411, 1993.
- 271) Scolnik D, Koren G: Changing trends in the treatment of asthma in a tertiary Canadian Pediatric hospital. *J Asthma* 30: 277-283, 1993.
- 272) Forman R, Klein J, Meta D, Barks J, Greenwald M, Koren G: Maternal and neonatal characteristics following exposure to cocaine in Toronto. *Reprod Toxicol* 7: 619-622, 1993.
- 273) Linder N, Edwards R, MacCleod R, Birenbaum E, Reichman B, Koren G: Safety of vancomycin and the vancomycin/gentamicin combination in the neonatal intensive care population. *Neonat Network* 12: 27-32, 1993.
- 274) Pennie RA, Koren G, Crevoisier C: Steady state pharmacokinetics of mefloquine in long term travellers. *J Roy Soc Trop Med Hyg* 87: 459-462, 1993.
- 275) Olivieri NF, Matsui D, Liu PP, Blendis L, Cameron R, McLelland RN, Templeton DM, Koren G: Oral iron chelation with L1 in non loaded thalassemia patients. *Bone Marrow Transpl* 12 Suppl 1: 9-11, 1993.
- 276) Klein J, Chitayat D, Koren G: Hair as a biological marker for intrauterine exposure to cigarette smoking. *N Engl J Med* 328: 66-67, 1993.
- 277) Ito S, Koren G: Exposure of pregnant women to ribavirin-contaminated air: risk assessment and recommendations. *J Ped Infect Dis* 12: 2-5, 1993.
- 278) Koren G, Nulman I: Antenatal sonographic findings in fetuses exposed to teratogenic agents. *Dev Brain Dysfunction* 6: 305-316, 1993.
- 279) Birenbaum Carmeli D, Carmeli Y, Koren G: Helpless and omnipotent. Incongruencies in Canadian perception of child. *Int J Sociology & Social Policy* 8: 31-48, 1993.

- 280) Koren G, Birenbaum Carmeli D, Carmeli Y, Haslam R: Maturity of children to consent to medical research; the Babysitter Test. *J Med Ethics* 19: 142-147, 1993.
- 281) Dagan O, Klein J, Bohn D, Barker G, Koren G: Morphine pharmacokinetics in children following cardiac surgery: Effects of disease and inotropic support. *J Cardiovasc Anesth* 7: 396-398, 1993.
- 282) Koren G: Awakening; Using a popular movie in teaching clinical pharmacology. *Clin Pharmacol Ther* 53: 3-5, 1993.
- 283) Koren G, Kriska M, Pons G, Shear N, Sance E, MacLeod SM: The Network of Pediatric Pharmacology Training Programs; *Clin Pharmacol Ther* 54: 1-6, 1993.
- 284) Koren G: Periconceptional folate and neural tube defects - Time for rethinking *Can J Publ Health* 84: 207-208, 1993.
- 285) Pastuszak A, Pinelli M, Koren G: Pregnancy outcome following fetal exposure to tiaprofenic acid in the first trimester. *Am J Perinatol* 10: 354-357, 1993.
- 286) Pastuszak A, Schick Boschetto-B, Zuber G, Feldkamp M, Pinelli M, Sihn S, Donnenfeld A, McCormack M, Leen-Michell M, Woodland C, Hom, Koren G: Pregnancy outcome following first trimester exposure to fluoxetine. *JAMA* 269: 2246-2248, 1993.
- 287) Walson P, Getschman, Koren G: Principles of drug prescribing in infants and children. *drugs* 46: 281-288, 1993.
- 288) Koren G: The Use of EMLA for Painful Procedures in Young Children. *J Pediatr* 122: (supp) 530-535, 1993.
- 289) Ito S, Harper P, Koren G, Silverman M: Energy dependent secretory transport of digoxin in renal tubular cells (LLC-PK1): *Can J Physiol Pharmacol* 71: 40-47, 1993.
- 290) Ito S, Woodland C, Harper PA, Koren G: P-glycoprotein-mediated renal tubular secretion of digoxin: The toxicological significance of the urine-blood barrier model: *Life Sci* 54: PL25-PL31, 1993.
- 291) Stobie S, Tyberg J, Matsui D, Bentur Y, Klein J, Koren G: Comparison of the pharmacokinetics of L<sub>1</sub> in healthy volunteers with and without coadministration of ferrous sulfate to thalassemia patients. *Int J Clin Pharmacol Ther Toxicol* 31: 602-605, 1993.
- 292) Koren G: Experience at the Hospital for Sick Children. *National Council on Bioethics in Human Research Communiqué* 4: 24-25, 1993.
- 293) Koren G: Current procedures for protection of children in research; a Toronto overview. *National Council on Bioethics in Human Research Communiqué* 4: 27-28, 1993.



- 294) Zemlickis D, Lishner M, Erlich R, Koren G: Teratogenicity and carcinogenicity in a twin exposed *in utero* to cyclophosphamide. *Teratogen Carcinogen Mutagen* 13: 139-143, 1993.
- 295) Koren G: Fetal exposure to cocaine; The concept of teratophilia. *Neurotoxicol & Teratol* 15: 301-304, 1993.
- 296) Koren G, Bologna M, Pastuszak A: How women perceive teratogenic risk and what they do about it. *Ann N Y Acad Sci* 78: 317-324, 1993.
- 297) Seto A, Einarson TR, Koren G: Evaluation of brompheniramine safety in pregnancy. *Reprod Toxicol* 7: 393-395, 1993.
- 298) Koren G, Graham K, Feigenbaum A, Einarson T: Evaluation and counseling of teratogenic risk: The Motherisk approach. *J Pharm Pract* 6: 1-7, 1993.
- 299) Ito S, Blachjman A, Stephenson M, Eliopoulos C, Hortlash N, Koren G: Prospective follow-up of adverse reactions in breastfed infants exposed to maternal medication. *Am J Obstet Gynecol* 168: 1393-1399, 1993.
- 300) Neuman MG, Koren G, Tiribelli C: Assessment of ethanol induced cytotoxicity *in vitro*, in Hep G2 cells. *Biochem Biophys Res Comm* 197: 932-941, 1993.
- 301) Burtin P, ul Qamar I, Eliopoulos C, Taddio A, Fassos F, Einarson TR, Koren G: Evaluation of the analgesic efficacy of floctafeine - A meta-analysis. *Today's Therapeutic Trends* 11: 143-156, 1993.
- 302) Dagan O, Peled N, Barker J, Babyn P, Koren G: Prostaglandin-Induced Antral Hyperplasia in Neonates: Clinical Experience and Dose-Response Characteristics. *Dev Pharmacol Ther* 20: 14-19, 1993.
- 303) Koren G, Klein N: Comparison of acceptance of clinical vs basic studies of drugs and therapeutics in infants and children. *Dev Pharmacol Ther* 20: 162-166, 1993.
- 304) Olivieri NF, MacMillan JA, Wayne A, Liu P, McGee A, Martin M, Koren G, Nathan D, Cohen A: Survival in medically-treated patients with homozygous beta-thalassemia *N Engl J Med* 331: 574-578, 1994.
- 305) Carmeli YS, Koren G: The fair's dwarf and circus midget as society's mirror. *Humane Med* 10: 119-122, 1994.
- 306) Forman R, Klein J, Meta D, Barks J, Greenwald M, Koren G: Prevalence of fetal exposure to cocaine in Toronto 1990-1991. *Clin Invest Med* 17: 206-211, 1994.
- 307) Dagan O, Bohn D, Greenwald C, Barker G, Koren G: Preliminary evaluation of the effect of ECMO on drug levels. *Ther Drug Monit* 8: 63-68, 1994.

- 308) Pastuszak AL, Koren G, Rieder MJ: Use of the retinoid pregnancy prevention program in Canada: Patterns of contraception use in women treated with the systemic retinoids isotretinoin and etretinate. *Reprod Toxicol* 8: 63-68, 1994.
- 309) Derewlany LO, Koren G: Biotransformation of carcinogenic arylamines and arylamides by human placenta. *J Pharmacol Exp Ther* 124: 134-141, 1994.
- 310) Derewlany LO, Knie B, Koren G: Human Placental transfer and metabolism of PABA. *J Pharmacol Exp Ther* 269: 761-765, 1994.
- 311) Derewlany LO, Knie B, Koren G: Arylamine-N-Acetyltransferase activity of the human placenta. *Lab Clin Med* 123: 756-760, 1994.
- 312) Simone CV, Derewlany LO, Knie B, Kalow W, Koren G: Acetylcholinesterase and butyrylcholinesterase activity in the human placenta: Implications for fetal cocaine exposure. *Lab Clin Med* 123: 400-406, 1994.
- 313) Simone CV, Derewlany LO, Knie B, Klein J, Koren G: Transplacental pharmacokinetics of cocaine; perfusion experiments with the human placenta. *Amer J Obst Gynecol* 170: 1404-1410, 1994.
- 314) Dagan O, Klein J, Bohn D, Koren G: The effects of ECMO on the pharmacokinetics of morphine in infants. *Crit Care Med* 22: 1099-1101, 1994.
- 315) Lishner M, Zemlickis D, Koren G: Non Hodgkin's lymphoma and pregnancy: A Review: *Leukemia & Lymphoma* 14: 411-413, 1994.
- 316) Scolnik D, Nulman I, Rovet J, Gladstone D, Czuchta D, Gardner A, Gladstone R, Ashby P, Weksberg R, Einarson T, Koren G: Neurodevelopment of children exposed *in utero* to phenytoin and carbamazepine monotherapy. *JAMA* 271: 767-770, 1994.
- 317) Collins A, Fassos F, Stobie S, Lewis N, Shaw D, Fernandes D, Fry M, Templeton D, Koren G, Olivieri N. Iron balance and dose response studies of the oral iron chelator 1,2 dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded patients with sickle cell disease. *Blood* 83: 2329-2333, 1994.
- 318) Ito S, Woodland C, Harper PA, Koren G: The mechanism of the verapamil-digoxin interaction in renal tubular cells (LLC-PK1). *Life Sci* 53: 399-403, 1994.
- 319) Pastuszak A, Levy M, Shick Boschetto B, Zuber C, Feldkamp M, Gladstone J, BarLevy F, Jackson E, Meschino W, Koren G: Pregnancy outcome following gestational varicella: A prospective, controlled multicenter study. *N Engl J Med* 330: 901-905, 1994.
- 320) Matsui D, Hermann C, Klein J, Berkovitch M, Olivieri N, Koren G: Critical comparison of a novel and existing methods of assessment of compliance during clinical trial of a new oral iron chelation. *J Clin Pharmacol* 34: 944-949, 1994.

- 321) Fassos F, Klein J, Fernandes D, Matsui D, Olivieri N, Koren G: Urinary iron excretion depends on the mode of administration of the oral iron chelator 1, 2 Dimethyl 3-Hydroxypyrid-0-One ( $L_1$ ) in homozygous  $\beta$  thalassemia patients. *Clin Pharmacol Ther* 55: 70-75, 1994.
- 322) Koren G, Haslam RH: Pediatric medication errors - Predicting and preventing tenfold disasters. *J Clin Pharmacol* 34: 1043-1045, 1994.
- 323) Pastuszek A, Klein J, Shear NH, Koren G. Therapeutic drug monitoring of retinoid concentrations in female patients. *Can Dermatol Assoc J* 5: 21-3, 1994.
- 324) Zemlickis D, Klein J, Moselhy G, Koren G: Cisplatin protein binding in pregnant women and in neonates *Med Pediatr Oncol* 231: 476-479, 1994.
- 325) Taddio A, Klein J, Koren G: Measurement of acyclovir in breast milk. *Ann Pharmacother* 28: 585-586, 1994.
- 326) Klein J, Forman R, Eliopoulos C, Koren G: A method of simultaneous measurement of cocaine and nicotine in neonatal hair. *Ther Drug Monit* 16: 67-70, 1994.
- 327) Berkovitch M, Matsui D, Lamm SH, Rosa F, Koren G: Recent increase in numbers and in risk of fatalities in young children ingesting iron preparations. *Vet Hum Toxicol* 36: 53-55, 1994.
- 328) Klein J, Fernandes D, Gazarian M, Kent G, Koren G: Simultaneous determination of lidocaine, prilocaine and the prilocaine metabolite 0-toluidine in plasma by HPLC. *J Chromatogr* 655: 83-88, 1994.
- 329) Potter S, Klein J, Valiante G, Stack DM, Papageorgiou A, Stott W, Lewis D, Koren G, Zelazo PR: Maternal cocaine use without evidence of fetal exposure. *J Pediatr* 125: 652-654, 1994.
- 330) Sandler AN, Baxter AD, Katz J, Samson B, Friedlander M, Norman P, Koren G, Roger S, Hull K: A double blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy. Analgesic, respiratory and pharmacokinetic effects. *Anesthesiology* 81: 1169-1180, 1994.
- 331) Forman R, Chou S, Koren G: The role of folic acid in preventing neural tube defects. *Contemp Ped* 6: 12-17, 1994.
- 332) Berkovitch M, Bitzan M, Matsui D, Finkelstein H, Balf JW, Koren G: Pediatric clinical use of the ketoconazole-cyclosporin interaction. *Ped Nephrol* 8: 492-493, 1994.
- 333) Donnenfeld AE, Pastuszek A, Salkoff Noah J, Schick B, Rose NC, Koren G: Methotrexate exposure prior to and during pregnancy. *Teratology* 49: 79-81, 1994.
- 334) Berkovitch M, Laxer RM, Matsui D, Fritzler MJ, Hedden D, Piloykzik D, Koren G, Klein J, Templeton DM, Pritzker PH, Olivieri NF: Analysis of adverse rheumatologic

- effects of iron chelators in patients with homozygous beta-thalassemia. *Lancet* 343: 1471-1472, 1994.
- 335) Eliopoulos C, Koren G: New insight into the effects of passive smoking in pregnancy. *Contemp Pediatr* 5: 18-19, 1994.
- 336) Berkovitch M, Pastuszak A, Gazarian M, Lewis M, Koren G: Safety of the new quinolones in pregnancy. *Obstet Gynecol* 84: 535-538, 1994.
- 337) Koren G, Gladstone D, Daneman D, Awang D, Randor S, Martin S: Periplocia in disguise; The need to regulate natural products. *Can J Clin Pharmacol* 1: 13-16, 1994.
- 338) Ito S, Koren G: Estimation of fetal risk from aerosolized pentamidine in pregnant health care workers. *Chest* 106: 1460-1462, 1994.
- 339) Ito S, Koren G: A novel index for expressing exposure of infants to drugs in breast milk. *Br J Clin Pharmacol* 38: 99-102, 1994.
- 340) Simone C, Derewlany LO, Koren G: Drug transfer across the placenta: Considerations in treatment and research. *Perinatol Clinics N Amer* 21: 463-481, 1994.
- 341) Eliopoulos C, Klein J, Phan MK, Knie B, Greenwald M, Chitayat D, Koren G: Hair concentrations of nicotine and cotinine in women and their newborn infants. *JAMA* 271: 621-623, 1994.
- 342) Eliopoulos C, Klein J, Koren G: Neonatal markers for intrauterine exposure to cocaine and nicotine. *Can J Obstet Gynecol* 6: 615-620, 1994.
- 343) Magee LA, Koren G: The use of teratogen information services for research; Assessment of reliability of data entry. *Reprod Toxicol* 8: 419-424, 1994.
- 344) Gorodischer R, Burtin P, Hwang P, Levine M, Koren G: Saliva vs blood sampling for therapeutic drug monitoring: Patient and parent preferences and an economic analysis. *Ther Drug Monit* 16: 437-443, 1994.
- 345) Nulman I, Rovet J, Altman D, Bradley C, Einarson T, Koren G: Neurodevelopment of adopted children exposed *in utero* to cocaine. *Can Med Assoc J* 151: 1591-1597, 1994.
- 346) Berkovitch M, Akilesh MR, Gerace R, Verjee Z, McGuigan M, Whyte H, Koren G: Acute digoxin overdose in a newborn with renal failure; Use of digoxin immune Fab and peritoneal dialysis. *Ther Drug Monit* 16: 531-533, 1994.
- 347) Johnson D, Schwartz H, Forman R, Klein J, Jacobson S, Greenwald M, Koren G: Assessment of *in utero* exposure to cocaine; Radioimmunoassay testing for benzoylecgonine in meconium, neonatal hair and maternal hair. *Can J Clin Pharmacol* 1: 83-86, 1994.
- 348) Taddio A, Nulman I, Goldbach M, Ipp M, Koren G: Use of lidocaine-prilocaine cream for vaccination pain in infants. *J Pediatr* 124: 643-648, 1994.

- 349) Gimenez F, Pennie RA, Koren G, Crevoisier C, Wainer IW, Farinotti R: Stereoselective pharmacokinetics of mefloquine in healthy caucasians after multiple doses. *J Pharmac Sci* 83: 824-827, 1994.
- 350) Pandit PB, Jeffries AL, Landes A, Kumar I, Chitayat D, Koren G; Tibial Hemimelia and Tetralogy of Fallot Associated with First Trimester Exposure to Amantadine. A Case Report. *Reprod Toxicol* 8: 89-92, 1994.
- 351) Levy M, Domaratzki J, Koren G: Amphotericin-induced heart rate decrease in children. *Clin Pediatr* 34: 358-364, 1995.
- 352) Dupuis LL, Koren G, Silverman ED, Laxer RM: Influence of food on the bioavailability of oral methotrexate *J Rheumatol* 22: 1570-1573, 1995.
- 353) Raman-Wilms L, Tseng AL, Wighardt S, Einarson TR, Koren G: Fetal genital changes related to maternal exposure to sex hormones during the first trimester of pregnancy; A meta-analysis. *Obstet Gynecol* 85: 141-149, 1995.
- 354) Olivieri NF, Matsui D, Berkovitch M, Collins A, Liu P, Blendis L, Cameron R, Templeton D, McClelland RA, Brittenham GM, Koren G: Efficacy of the oral iron chelator L<sub>1</sub> in the reduction of tissue and serum iron in thalassemia major. *N Engl J Med* 332: 918-922, 1995.
- 355) Gazarian M, Taddio A, Klein J, Kent G, Koren G: Systemic exposure to prilocaine and lidocaine after penile absorption of EMLA cream: Production of O-toluidine and methemoglobin in newborn piglets and implications for EMLA use in circumcision. *Biol Neonate* 68: 334-342, 1995.
- 356) Shear N, Malkiewicz IM, Klein D, Koren G, Randor S, Neuman M: Acetaminophen-induced toxicity to keratinocytes and hepatocytes *in vitro* is diminished by silymarin. *Skin Pharmacol* 8: 279-291, 1995.
- 357) Gazarian M, Berkovitch M, Koren G, Silverman R, Laxer R: Experience with misoprostol therapy for NSAID gastropathy in children *Ann Rheumatol* 54: 277-280, 1995.
- 358) Walson P, Koren G: Drug prescribing in infants and children. *NZJ Patient Management* 32: 99-104, 1995.
- 359) Ben David S, Einarson T, Nulman I, Pastuszak A, Koren G: The safety of nitrofurantoin during the first trimester of pregnancy: a meta-analysis. *Fundament Clin Pharmacol* 9: 503-507, 1995.
- 360) Dagan O, Margalit D, Barak I, Koren G: Prospective evaluation of lumbar puncture in the first episode of simple febrile seizures. *Can J Pediatr* 2: 261-265, 1995.
- 361) Berkovitch M, David S, Matsui D, Koren G, Olivieri N: Use of EMLA for chronic subcutaneous drug administration. *J Clin Pharmacol* 35: 295-297, 1995.

- 362) Joshi P, Klein J, MacLeod C, King S, Koren G: Single dose and steady state pharmacokinetics of acyclovir in children undergoing bone marrow and liver transplant. *J Pediatr Inf Dis* 14: 717-719, 1995.
- 363) Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G: Safety of metronidazole in pregnancy: A meta-analysis. *Amer J Obstet Gynecol* 172: 525-529, 1995.
- 364) Berkovitch M, Pope E, Phillips J, Koren G: Pemoline-associated fulminant hepatic failure; Evidence of causation. *Clin Pharmacol Ther* 57: 696-698, 1995.
- 365) Koren G: Measurement of drugs in neonatal hair: A window to fetal exposure. *Forens Sci Intl* 70: 77-82, 1995.
- 366) Berkovitch M, Keresteci AG, Koren G: Efficacy of prilocaine-lidocaine cream in the treatment of premature ejaculation *J Urol* 154: 1360-1361, 1995.
- 367) Koren G, Ben David S: Drug and chemical monitoring using neonatal hair. *Israel Med Assoc J* 129: 336-338, 1995.
- 368) Magee LA, Downar E, Sermer M, Koren G: Pregnancy outcome following gestational exposure to amiodarone in Canada. *Am J Obstet Gynecol* 172: 1307-1311, 1995.
- 369) Orenstein M, Einarson A, Koren G: Bendectin/Diclectin for morning sickness; A Canadian followup of an American tragedy. *Reprod Toxicol* 9: 1-6, 1995.
- 370) Press J, Berkovitch M, Laxer R, Giesbrecht E, Silverman ED, Klein J, Koren G: Evaluation of therapeutic drug monitoring of methotrexate in saliva of children with rheumatic diseases. *Ther Drug Monit* 17: 247-250, 1995.
- 371) Moncica I, Oh PI, UI Quamar IUL, Scolnik D, Arbus GS, Herbert D, Balf JW, Koren G: A cross over comparison of extended release felodipine with prolonged action nifedipine in hypertensive pediatric patients *Arch Dis Child* 73: 154-156, 1995.
- 372) Taddio A, Goldbach M, Ipp M, Stevens B, Koren G: Effect of neonatal circumcision on pain responses during vaccination in boys. *Lancet* 345: 291-292, 1995.
- 373) Koren G: Cocaine use by pregnant women in Toronto; An alarming note. *IM Paint* 11: 20-21, (Winter), 1995.
- 374) Klein J, Ursiti F, Koren G: Four year experience with the neonatal hair test for cocaine. In: Hair Analysis Forensic Toxicology. (Ed: Zeeuw RA): Abu Dhabi, 431-440, 1995.
- 375) Koren G: Fetal toxicology of environmental tobacco smoke. *Curr Opin Pediatr* 7: 128-131, 1995.
- 376) Taddio A, Nulman I, Koren BS, Stevens B, Koren G: A revised measure of acute pain in infants. *J Pain Sympnt Manag* 10: 456-463, 1995.

- 377) Koren G, Matsui D, Gladstone J, Gladstone D, Rieder M: Physicians' prescriptions to non patients; An Ontario perspective. *Can J Clin Pharmacol* 2: 107-108, 1995.
- 378) Theis J, Koren G: Camphorated oil: Still endangering the lives of Canadian children. *Can Med Assoc J* 152: 1821-1824, 1995.
- 379) Koren G: The Motherisk Program News. *Can J Clin Pharmacol* 2: 1995.
- 380) Ito S, Moretti M, Chu M, Koren G: Initiation and duration of breast-feeding in women receiving antiepileptics. *Am J Obstet Gynecol* 172: 881-886, 1995.
- 381) Jacobson S, McCarthur C, Joshi P, Forman R, Koren G: Availability of folic acid and knowledge about prophylactic use: A survey of urban pharmacies. *Can J Clin Pharmacol* 2: 29-31, 1995.
- 382) Rovet J, Cole S, Nulman I, Scolnik D, Altmann D, Koren G: Effects of maternal epilepsy on children's neurodevelopment *Child Neuropsychol* 1: 1-8, 1995.
- 383) Babyn P, Peled N, Manson D, Dagan O, Silver MM, Koren G: Radiologic features of gastric outlet obstruction in infants after long-term prostaglandin administration. *Pediatr Radiol* 25: 41-43, 1995.
- 384) Moretti M, Ito S, Koren G: Disposition of ketoconazole in human milk. *Am J Obstet Gynecol* 173: 1625-1626, 1995.
- 385) Taddio A, Ito S, Einarson T, Leeder JS, Koren G: Effect of counseling on maternal reporting of adverse effects in nursing infants exposed to antibiotics through breast milk. *Reprod Toxicol* 9: 153-157, 1995.
- 386) Simone C, Derewlany LO, Koren G: Cocaine transfer across a cocaine-exposed placental cotyledon perfused *in vitro*. *Life Sci* 57: 137-140, 1995.
- 387) Asano Y, Elliott K, Koren G, Levin M, Myers M, Nathwani D, Oxman MW, Schwarz TF, Whitley RJ: Reducing the burden of zoster associated pain-update. International Herpes Management Forum, University of Alabama. *PPS Europe Ltd*, 1995.
- 388) Forman R, Chou S, Koren G: Folic acid and neural tube defects. *Contemporary OBGYN*, 4: 16-22, 1995.
- 389) Koren G: Teratology Information Services - A new direction in clinical teratology. *Issues Rev Teratol* 7: 1995.
- 390) Taddio A, Shennon AT, Stevens B, Leeder SJ, Koren G: Safety of lidocaine-prilocaine cream in the treatment of preterm infants. *J Pediatr* 127: 1002-1005, 1995.
- 391) Koren G: Drug of choice for morning sickness. *Can Fam Phys* 41: 1671-1674, 1995.
- 392) Forman R, Chou S, Koren G: Prevention of spina bifida by folic acid. *Contep OB/Gyn*, 4: 16-22, 1995.

- 393) Koren G: *In utero* exposure to phenytoin or carbamazepine. *Can Fam Phys* 41: 1862-1863, 1995.
- 394) Koren G: Chickenpox during pregnancy; small but real risk. *Can Fam Phys* 41: 1477-1478, 1995.
- 395) Koren G: First trimester exposure to fluoxetine. *Can Fam Phys* 42: 43-44, 1995.
- 396) Blowey DL, BenDavid S, Koren G: Interaction of drugs with the developing kidney. *Ped Clin N Amer* 42: 1415-1432, 1995.
- 397) Koren G: Can folate prevent neural tube defects after conception? *Can Fam Phys* 41: 2099-2100, 1995.
- 398) Johnson D, Schuh S, Koren G, Jaffe D: Outpatient treatment of croup with nebulized dexamethasone. *Arch Pediatr & Adolesc Med* 150: 349-355, 1996.
- 399) Pastuszak A, Milich V, Chans, Chu J, Koren G: Prospective assessment of pregnancy outcome following first trimester exposure to benzodiazepines. *Can J Clin Pharmacol* 4: 167-171, 1996.
- 400) Magee LA, Innocencio G, Kambo JL, Rosetti, Koren G: The safety of first trimester exposure to H<sub>2</sub> blockers; A prospective cohort study. *Digest Dis Sci* 41: 1145-1149, 1996.
- 401) Fassos F, Olivieri NF, Klein J, Matsui D, Fernandes D, Koren G: The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone in relation to hemoglobin levels. *Int J Clin Pharmacol Ther* 34: 288-292, 1996.
- 402) Berkovitch M, Matsui D, Zipursky A, Blanchette V, Verjee Z, Giesbrecht E, Saunders F, Evans WE, Koren G: Hepatotoxicity of 6-mercaptopurine in childhood leukemia; pharmacokinetic characteristics. *Med Pediatr Oncol* 26: 85-89, 1996.
- 403) Fassos F, Berkovitch M, Daneman N, Koren L, Cameron R, Klein J, Koren G: The efficacy of the new iron chelator deferiprone in the treatment of acute iron intoxication in rats. *J Clin Toxicol* 34: 279-287, 1996.
- 404) Boylan JF, Cheng DCH, Sandler AN, Carmichael FJ, Koren G, Feindel C: Cocaine toxicity and isoflurane anesthesia: Hemodynamic, myocardial, metabolic and regional blood flow effects in the swine *J Cardiothor Vasc Anesth* 10: 772-777, 1996.
- 405) Magee LA, Schick B, Sage S, Conover B, Cook L, McElhaton, Raman-Williams L, Schmidt M, Koren G: The safety of calcium channel blockers in human pregnancy *Am J Obstet Gynecol* 174: 823-828, 1996.
- 406) Berkovitch M, Sher G, McClelland R, Matsui D, Halzialis G, Papadouris D, Olivieri NE, Koren G: Pharmacokinetics of arginine butyrate in patients with hemoglobinopathies *Environm Toxicol Pharmacol* 2: 403-405, 1996.



- 407) Koren G, Koren T, Gladstone J: Moderate alcohol drinking in pregnancy; perceived vs true risk. *Clin Chim Acta* 246: 155-162, 1996.
- 408) Chan HSL, Doboer G, Thiessen JJ, Kingston JE, O'Brien JM, Abramson DH, Koren G, Giesbrecht E, Haddad G, Verjee Z, Hungerford JL, Ling V, Gallie BL: Cyclosporine modulated chemotherapy with focal therapy as a new approach that avoids radiation of retinoblastoma *Clin Cancer Res* 2: 1499-1508, 1996.
- 409) Taddio A, Ito S, Koren G: Excretion of fluoxetine and its metabolite in human breast milk. *J Clin Pharmacol* 36: 42-47, 1996.
- 410) Simone C, Byrne BM, Derewlany LO, Koren G: Cocaine inhibits hCG secretion by the human term placental cotyledon *in vitro*. *Life Sci* 58: PL63-66, 1996.
- 411) Nulman I, Koren G: The safety of fluoxetine during pregnancy and lactation. *Teratology* 53: 304-308, 1996.
- 412) Gladstone J, Nulman I, Koren G: Reproductive risks of binge drinking during pregnancy. *Reprod Toxicol* 10: 1-11, 1996.
- 413) Knight J, Eliopoulos C, Klein J, Greenwald M, Koren G: Passive smoking in children; Racial differences in systemic exposure to cotinine by hair and urine analysis. *Chest* 109: 446-450, 1996.
- 414) Eliopoulos C, Klein J, Koren G: Validation of self reported smoking by analysis of hair for nicotine and cotinine. *Ther Drug Monit* 18: 532-536, 1996.
- 415) Nulman I, Koren G: Developmental outcomes of cocaine exposed infants who are adopted. *Imprint* 14: (Winter) 15-16, 1996.
- 416) Blowey D, Moncica I, Scolnik D, Arbus GS, Hebert D, Balfe JW, Koren G: The pharmacokinetics of extended release felodipine in children. *Eur J Clin Pharmacol* 50: 147-148, 1996.
- 417) Blowey D, Balfe JW, Gupta I, Gajaria MM, Koren G: Midocerule efficacy and pharmacokinetics in a patient with recurrent intradialytic hypotension. *Am J Kidney Dis* 28: 132-136, 1996.
- 418) Koren G: Hair care during pregnancy. *Can Fam Phys* 42: 625-626, 1996.
- 419) Khattack S, Huyer D, Ito S, Koren G: A pharmacokinetic approach to the diagnosis of pediatric Munchausen by proxy. *Can J Clin Pharmacol* 3: 25-28, 1996.
- 420) Forman R, Singal N, Perelman V, Chou S, Hoffman L, Parkin P, Koren G: Folic acid and prevention of neural tube defects; a study of Canadian women giving birth to children with spina bifida. *Clin Invest Med* 19: 195-201, 1996.
- 421) Koren G: Lead risk during pregnancy. *Can Fam Phys* 42: 414-415, 1996.

- 422) Koren G: Can pregnant patients safely take nitrofurantoin? *Can Fam Phys* 42: 245-246, 1996.
- 423) Eliopoulos C, Klein J, Chitayat D, Greenwald M, Koren G: Maternal and neonatal hair analysis for nicotine and cotinine as markers of gestational smoking. *Clin Invest Med* 19: 231-242, 1996.
- 424) Scolnik D, Koren G: Antihistamines, respiratory depression and SIDS-a review and recommendations. *Can J Clin Pharmacol* 3: 71-74, 1996.
- 425) Koren G: Alcohol consumption in early pregnancy; How much will harm the fetus. *Can Fam Phys* 42: 2141-2143, 1996.
- 426) Koren G: The fetus as a passive smoker. *Can Fam Phys* 42: 1301-1303, 1996.
- 427) Gallie BL, Buddning A, DeBoer G, Thiessen J, Koren G, Verjee Z, Ling V, Chan HSL: Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. *Arch Ophthalmol* 114: 1321-1328, 1996.
- 428) Koren G: Folic acid and neural tube defects; those who haven't heard yet. *Can Fam Phys* 42: 1911-1912, 1996.
- 429) Perelman V, Singal N, Einarson A, Kennedy D, Koren G: Knowledge and practice by Canadian Family Physicians regarding periconceptional folic acid supplementation for the prevention of neural tube defects. *Can J Clin Pharmacol* 3: 145-148, 1996.
- 430) Pastuszak A, Schick B, D'Alimonte D, Donnenfeld A, Koren G: The safety of astemizole in pregnancy. *J Allergy Clin Immunol* 98: 748-750, 1996.
- 431) Koren G: Use of the new quinolones during pregnancy. *Can J Fam Phys* 42: 1097-1099, 1996.
- 432) Koren G: Cocaine use by pregnant women in Toronto. *Can Fam Phys* 42: 1677-1679, 1996.
- 433) Koren G, Lishner M: Cancer in pregnancy; implications for the mother and fetus. *OBGYN Update (Israel)* 18: 4-6, 1996.
- 434) Simone C, Koren G: Cocaine clearance by the human placenta perfused *in vitro*. *Life Sci* 17: 125-134, 1996.
- 435) Blowey DL, Moncada I, Scolnik D, Arbus GS, Hebert D, Balfé JW, Koren G: The pharmacokinetics of extended release felodipine in children. *Eur J Clin Pharmacol* 50: 147-148, 1996.
- 436) Magee L, Innocencio G, Kamboj Laveena, Rosetti F, Koren G: Safety of first trimester exposure to histamine H<sub>2</sub> blockers-A prospective cohort study. *Digestive Diseases & Sciences* 41: 1145-1149, 1996.

- 437) Eliopoulos C, Klein J, Koren G: Validation of self-reported smoking by analysis of hair for nicotine and cotinine. *Ther Drug Monit* 18: 532-536, 1996.
- 438) Magee LA, Schick B, Donnenfeld AE, Sage SR, Conover B, Cook L, McElhatton PR, Schmidt MA, Koren G: The safety of calcium channel blockers in human pregnancy: A prospective, multicenter cohort study. *Am J Obstet Gynecol* 174: 823-8, 1996.
- 439) Fassos FF, Berkovitch M, Daneman N, Koren L, Cameron RG, Klein J, Falcitelli C, St. Louis, P, Daneman R, Koren G: Efficacy of deferiprone in the treatment of acute iron intoxication in rats. *Clin Toxicol* 34: 279-287, 1996.
- 440) Berkovitch M, Sher G, McClelland R, Matsui D, Hadzialic G, Olivieri NF, Koren G: Toxicology and Pharmacology of butyric acid. *Environ Toxicol/Pharmacol* 2: 403-405, 1996.
- 441) Koren G: Telling tails: Children's literature goes to the hospital. *The Looking Glass*. [http://www.fis.utoronto.ca/~easum/looking\\_glass/invention](http://www.fis.utoronto.ca/~easum/looking_glass/invention), 1997.
- 442) Nulman I, Scolnik D, Chitayat D, Farkas LD, Koren G: Dysmorphology in children exposed in utero to phenytoin and carbamazepine monotherapy; Independent effects of epilepsy and medications. *Am J Hum Genet* 68: 18-24, 1997.
- 443) Einarson A, Bailey B, Innocencio G, Koren G: Accidental electric shock in pregnancy: A prospective cohort study. *Am J Obstet Gynecol* 176: 678-681, 1997.
- 444) Shilalukey K, Kaufman M, Bradley S, Francombe WH, Amankwah K, Goldberg E, Shear N, Olivier NF, Koren G: Counseling sexually active teenagers treated with potential human teratogens. *J Adolesc Med* 21: 143-146, 1997.
- 445) Ursitti F, Klein J, Koren G: Clinical utilization of the neonatal hair test for cocaine; A four year experience in Toronto. *Biol Neonate* 72: 345-351, 1997.
- 446) Seto A, Einarson T, Koren G: Pregnancy outcome following first trimester exposure to antihistamines: A meta-analysis. *Am J Perinatol* 14: 119-124, 1997.
- 447) Berkovitch M, Barr J, Livne A, Lusbkov G, Tayber T, Eshel G, Ugwu MT, Koren G: Acute iron intoxication; significant differences between sexes. *Vet Hum Toxicol* 39: 265-267, 1997.
- 448) Pop RD, Spino M, Koren G, Roifman C: Tailoring of intravenous immune gammaglobulin replacement therapy. *Can J Allergy Clin Immunol* 2: 248-254, 1997.
- 449) Theis JGW, Koren G, Daneman R, Sherwin AL, Menzano E, Cortez M, Hwang P: Interactions of clobazam with conventional antiepileptics in children. *J Child Neurol* 12: 208-213, 1997.
- 450) Gladstone J, Levy M, Nulman I, Koren G: Characteristics of pregnant women exposed to binge alcohol consumption in Toronto. *Can Med Assoc J* 156: 789-794, 1997.

- 451) Gorodischer R, Burtin P, Verjee Z, Hwang P, Koren G: Is saliva suitable for therapeutic drug monitoring of anticonvulsants in children? An evaluation in the routine clinical setting. *Ther Drug Monit* 19: 637-642, 1997.
- 452) Pope E, Berkovitch M, Klein J, Koren G: Salivary measurement of deferiprone concentrations and its correlation with serum levels. *Ther Drug Monit* 9: 95-97, 1997.
- 453) Simone C, Byrne BM, Derewlany LO, Koren G: The transfer of cocaethylene across the human term placental cotyledon perfused *in vitro*. *Reprod Toxicol* 11: 215-219, 1997.
- 454) Davies HD, King SM, Doyle J, Matlow A, Koren G, Hamilton R, Portwine C: Randomized, blinded, and controlled pilot study of rapid amphotericin B infusions in children. *Arch Dis Child* 76: 165-166, 1997.
- 455) Kopecky EA, Jacobson S, Joshi P, Martin M, Koren G: Review of a home-based palliative care program for children with malignant and non malignant diseases. *J Palliat Care* 13: 28-33, 1997.
- 456) Koren G, Barker G, Mitchell V, Abramowitch L, Strofolino M, Buchwald M: Patient-Based research in a tertiary pediatric center: Markers of scientific activity and productivity. *Clin Invest Med* 20: 354-358, 1997.
- 457) Loebstein R, Koren G: Pregnancy outcome and neurodevelopment of children exposed *in utero* to psychoactive drugs: The Motherisk experience. *J Psychiatr Neurosci* 22: 192-196, 1997.
- 458) Koren G: TDM principles in the neonate. *Clin Chem* 43: 222-227, 1997.
- 459) Rowe C, Verjee Z, Koren G: Adolescent dimenhydrinate abuse: Resurgence of an old problem. *J Adolesc Health* 21: 47-49, 1997.
- 460) Taddio A, Stevens B, Craig K, Rastogi P, BenDavid S, Shennan A, Mulligan P, Koren G: The efficacy and safety of lidocaine prilocaine cream for neonatal circumcision pain. *N Engl J Med* 336: 1197-1201, 1997.
- 461) Taddio A, Katz J, Ilersch L, Koren G: Neonatal circumcision and pain response during routine vaccination 4 to 6 months later. *Lancet* 349: 599-603, 1997.
- 462) Theis JGW, Selby P, Ikizler Y, Koren G: Current management of the neonatal abstinence syndrome; A critical analysis of the evidence. *Biol Neonate* 71: 345-356, 1997.
- 463) Nulman I, Rovet J, Stewart D, Wolpin J, Gardner HA, Theis JGW, Kulin N, Koren G: Neurodevelopment of children exposed *in utero* to antidepressant drugs. *N Engl J Med* 336: 258-262, 1997.
- 464) Koren G: Bias against the null hypothesis in maternal-fetal drug therapy. *Clin Pharmacol Ther* 62: 1-5, 1997.

- 465) Koren G: Outcomes for babies exposed *in utero* to cocaine. *Im Print* 17: 18-20, 1996/97.
- 466) Loebstein R, Dalal I, Berkovitch M, Nisbet Brown E, Meydan N, Andrews D, Koren G, Roifman CM, Olivieri NF: Immune function in patients with beta-thalassemia receiving the orally active iron-chelating agent deferiprone. *Br J Haematol* 98: 597-600, 1997.
- 467) Koren G: Is the fetus safe when spermicides fail? *Can Fam Phys* 43: 431-432, 1997.
- 468) Loebstein R, Nulman I, Koren G: Fetal alcohol syndrome - An ongoing pediatric challenge. *Paediatr & Child Health J* 2: 102-105, 1997.
- 469) Blowey D, Hebert D, Arbus GS, Pool R, Korus M, Koren G: Compliance with cyclosporine in adolescent renal transplant recipients. *Pediatr Nephrol* 11: 547-551, 1997.
- 470) Koren G, Pastuszak A: How to ensure fetal safety when mothers use isotretinoin (Accutane). *Can Fam Phys* 43: 216-219, 1997.
- 471) Liao-Chu M, Theis JGW, Koren G: A mechanism of anaphylactoid reactions: Improper preparation of high dose intravenous cyclosporine leads to bolus infusion of chemaphare EL and cyclosporine. *Ann Pharmacother* 31: 1287-1290, 1997.
- 472) Pastuszak A, Burke B, Koren G: When potent teratogens are irreplaceable drugs: Lesions of thalidomide and isotretinoin. *Can J Clin Pharmacol* 4: 67-73, 1997.
- 473) Chattergoon DS, Saunders EF, Klein J, Calderwood S, Doyle J, Freedman MH, Koren G: An improved limited sampling method for individualized busulphan dosing in bone marrow transplantation in children. *Bone Marrow Transplant* 20: 347-354, 1997.
- 474) Koren G: The Children of Neverland. *Can Fam Phys* 43: 619-621, 1997.
- 475) Bailey B, Lee A, Addis A, Lau M, Koren G: Cisapride use during human pregnancy; A prospective, controlled multicenter study. *Dig Dis Sci* 42: 1848-1852, 1997.
- 476) Shapiro L, Pastuszak A, Curto G, Koren G: Safety of first trimester exposure to topical tretinoin: A prospective cohort study. *Lancet* 350: 1143-1144, 1997.
- 477) Mazzotta P, Magee L, Koren G: Therapeutic abortions due to severe morning sickness; Unacceptable combination. *Can Fam Phys* 43: 1055-1057, 1997.
- 478) Koren G: New expectations for the role of clinical pharmacologists and industry in protecting unborn babies and their mothers. *Can J Clin Pharmacol* 4: 62-63, 1997.
- 479) Rowe C, Koren G: Effectiveness of the medication error review process at a tertiary pediatric hospital. *Can J Clin Pharmacol* 4: 75-78, 1997.

- 480) Loebstein R, Diav-Citrin O, Atanackovic G, Olivieri N, Koren G: Deferiprone-induced agranulocytosis; A critical review of 5 rechallenged cases. *Clin Drug Invest* 13: 345-349, 1997.
- 481) Koren G: Periconception folic acid supplementation: Knowledge and practice of Canadian family physicians. *Can Fam Phys* 43: 851-852, 1997.
- 482) Rathnapalan S, King S, Koren G: Testing women for HIV. *Can Fam Phys* 43: 1349-1351, 1997.
- 483) Kopecky EA, Jacobson S, Klein J, Koren G: Correlation of morphine sulfate in blood plasma and saliva in pediatric patients. *Ther Drug Monit* 19: 530-534, 1997.
- 484) Koren G, Klein J: Neonatal hair test for cocaine; The Toronto experience. *Can Fam Phys* 43: 1215-1219, 1997.
- 485) Morris P, Binienda PZ, Gillam MP, Klein J, McMartin K, Koren G, Duhart HM, Slikker-W, Paule MG: The effect of chronic cocaine exposure throughout pregnancy on maternal and infant outcomes in the rhesus monkey. *Neurotoxicol Teratol* 19: 47-58, 1997.
- 486) Ito S, Koren G: The digoxin-itraconazole interaction. *Ann Pharmacother* 31: 1091-1092, 1997.
- 487) Woodland C, Verjee Z, Giesbrecht E, Koren G, Ito S: The digoxin-propafenone interaction: Identification of the mechanism using renal tubular cell monolayer. *J Pharmacol Exp Ther* 283: 39-45, 1997.
- 488) Einarson A, Bailey B, Jung G, Spizzirri D, Bailey M, Koren G: Prospective controlled study of hydroxyzine and cetirizine in pregnancy. *Ann Allergy, Asthma Immunol* 78: 183-186, 1997.
- 489) Bailey B, Klein J, Koren G: Noninvasive methods for drug measurement in pediatrics. *Pediatr Clin North Amer* 44: 15-26, 1997.
- 490) Diav-Citrin O, Koren G: Oral iron chelation with deferiprone. *Pediatr Clin North Amer* 44: 235-247, 1997.
- 491) Pope E, Berkovitch M, Klein J, Fassos F, Koren G: Salivary Measurement of deferiprone Concentrations and Correlation with serum levels. *Ther Drug Monit* 19: 95-97, 1997.
- 492) Loebstein R, Lalkin A, Koren G: Pharmacokinetic changes during pregnancy and their clinical relevance. *Clin Pharmacokinet* 33: 328-343, 1997.
- 493) Chattergoon DS, McGuigan MA, Koren G, Hwang P, Ito S: Multidrug dysfunction and disseminated intravascular coagulation in children receiving lamotrigine and valporic acid. *Neurology* 49: 1442-1444, 1997.
- 494) Lalkin A, Magee L, Addis A, Loebstein A, Koren G: Acid suppressing drugs during pregnancy. *Can Fam Phys* 43: 11923-1927, 1997.

- 495) Koren G: The placebo effect (Book Review). *N Engl J Med*, 337: 1855-1856, 1997.
- 496) Koren G: How to increase your funding chances: 15 pitfalls in medical grant applications. *Annals RCPSC* 30: 333-337, 1997.
- 497) Kennedy D, Pastuszak A, Koren G: Taking folic acid during pregnancy; Don't leave it too late. *Can Fam Phys* 43: 2113-2114, 1997.
- 498) Loebstein R, Koren G: The ethics of multiple sampling in children for research. *Ther Drug Monit* 19: 251, 1997.
- 499) Mazzotta P, Koren G: Nonsedating antihistamines in pregnancy; considering astemizole. *Can Fam Phys* 43: 1509-1511, 1997.
- 500) Nulman I, Laslo D, Koren G: Pregnancy outcome and neurodevelopment of children exposed *in utero* to antidepressant drugs. *IM Print* 20: Winter, 17-18, 1997/8.
- 501) Khattak S, Rogan J, Saunders F, Theis JGW, Arbus G, Koren G: The efficacy and safety of amlodipine in pediatric bone marrow transplant patients. *Clin Pediatr* 37: 3736, 1998.
- 502) Knight JM, Eliopoulos C, Klein J, Greenwald M, Koren G: Pharmacokinetic predisposition to nicotine from environmental tobacco smoke; A risk factor for pediatric asthma *J Asthma* 35: 113-117, 1998.
- 503) Einarson A, Koren G: Counseling psychiatric patients about drug exposures during pregnancy. *Can Fam Phys* 44: 981-983, 1998.
- 504) Thuma PE, Olivieri N, Mabeza G, Biemba G, Zulu S, Fassos F, Koren G, Brittenham GM, Gordeuk VR: The oral iron chelator L<sub>1</sub> fails to clear mild P. Falciparum parasitemia in humans. *Am J Tropical Med Hyg* 58: 358-364, 1998.
- 505) Lau R, Matsui D, Greenberg M, Koren G: Electronic measurement of compliance with mercaptopurine in pediatric patients with acute lymphoblastic leukemia. *Med Ped Oncol* 30: 85-90, 1998.
- 506) Dolovich LR, Bower JDB, Vaillancourt JMR, Koren G, Einarson T: Benzodiazepines in pregnancy and major malformations: A meta-analysis. *BMJ* 317: 839-843, 1998.
- 507) Gupta AK, Koren G, Shear N: A double blind, randomized, placebo controlled trial of EMLA for analgesia prior to cryotherapy for warts in children and adults. *J Ped Dermatol* 15: 146-150, 1998.
- 508) Fernandes O, Sabharwal M, Smiley T, Pastuszak A, Koren G, Einarson T: Moderate to heavy caffeine consumption during pregnancy and its relationship to spontaneous abortion and fetal growth; A meta-analysis *Reprod Toxicol* 12: 435-444, 1998.

- 509) Polygenis D, Wharton S, Malmberg C, Sherman N, Kennedy D, Koren G, Einarson T: Moderate alcohol consumption during pregnancy and the incidence of fetal malformations; A meta-analysis. *Neurotoxicol Teratol* 20: 61-68, 1998.
- 510) Rowe C, Koren T, Koren G: Errors by paediatric residents in calculating drug doses. *Arch Dis Child* 79: 56-58, 1998.
- 511) Taddio A, Ohlsson A, Einarson TR, Stevens B, Koren G: A systematic review of lidocaine-prilocaine (EMLA) cream in the treatment of acute pain in neonates. *Pediatrics* 101 (2): E1, (Feb) 1998.
- 512) Pastuszak A, Schuler L, Speck-Martins CE, Coelho KEFA, Vargas FR, Brunoni D, Schwarz IVD, Larrandaburu M, Safatle H, Lordello SM, Melon VFA, Koren G: Use of misoprostol during pregnancy and Mobius sequence in infants. *N Engl J Med* 338: 1881-1885, 1998.
- 513) Makarechian N, Agro K, Devlin J, Trepanier E, Koren G, Einarson T: The association between moderate alcohol consumption during pregnancy and spontaneous abortion, stillbirth and premature birth: A meta-analysis. *Can J Clin Pharmacol* 5: 169-176, 1998.
- 514) Diav-Citrin O, Koren G: The safety of 5-ASA in human pregnancy. A prospective-controlled cohort study. *Gastroenterology* 114: 23-28, 1998.
- 515) Koren G, Woodland C, Ito S: Toxic digoxin-drug interactions: The major role of renal P-glycoprotein. *Vet Hum Toxicol* 40: 45-46, 1998.
- 516) Theis J, Chan HS, Doyle J, Gallie B, Koren G: Increased systemic toxicity of sarcoma therapy due to combination with the P-glycoprotein inhibitor cyclosporines. *Int J Clin Pharmacol Ther* 36: 61-64, 1998.
- 517) Woodland C, Ito S, Spino M, Koren G: Hypothetical framework for enhanced renal tubular secretion of drugs in cystic fibrosis. *J Med Hypothesis* 51: 489-491, 1998.
- 518) Woodland C, Koren G, Ito S: A model for the prediction of digoxin-drug interactions at the renal tubular cell. *Ther Drug Monit* 20: 134-138, 1998.
- 519) Loebstein R, Koren G, Ito S: Strategies to prevent drug induced nephrotoxicity in children. *Bailliere's Clin Paed* 6: 481-504, 1998.
- 520) Ito S, Escobar M, Klein J, Koren G: Lack of cisplatin-ranitidine kinetic interactions: *In vitro*, and *in vivo* studies in children. *Life Sci* 62: PL 387-392, 1998.
- 521) Kulin N, Pastuszak AP, Sag SR, Schick B, Spivey G, Feldkamp M, Ormond K, Matsui D, Stein-schechman AK, Cook L, Brochu J, Rieder M, Koren G: Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. A perspective controlled multicenter study. *JAMA* 279: 609-610, 1998.
- 522) Koren G, Pastuszak AP, Ito S: Drugs in pregnancy. *N Engl J Med* 338: 1128-1137, 1998.



- 523) Koren G, Loebstein R, Nulman I: Fetal alcohol syndrome: Role of the family physician. *Can Family Phys* 44: 38-40, 1998.
- 524) Lalkin A, Loebstein R, Addis A, Ramezani-Namin F, Magee LA, Matroiacovo P, Mazzone T, Vial T, Bonati M, Koren G: Safety of omeprazole during pregnancy; A multicenter prospective cohort study. *Am J Obstet Gynecol* 179: 727-730, 1998.
- 525) Koren G: The Children of Neverland: The effects of poverty. *Patient Care* 9 (8): 18-22, 1998.
- 526) Koren G, Nulman I, Rovet J, Greenbaum R, Loebstein M, Einarson T: Long-term neurodevelopmental risks in children exposed in utero to cocaine. *Ann NY Acad Sci* 846: 306-313, 1998.
- 527) Chattergoon DS, Verjee Z, Anderson M, Johnson D, McGuigan M, Koren G, Ito S: Carbamazepine interference with an immune assay for tricyclic antidepressants in plasma. *Clin Toxicol* 36: 109-113, 1998.
- 528) Shapiro L, Pastuszak A, Curto G, Koren G: Is topical tretinoin safe during the first trimester? *Can Fam Phys* 44: 495-498, 1998.
- 529) Loebstein R, Koren G: Ifosfamide-induced nephrotoxicity in children: Critical review of predictive risk factors. *Pediatrics* 101 (6): E8, 1998.  
<http://www.pediatrics.org/cgi/content/full/101/6/e8>.
- 530) Kennedy D, Koren G: Valproic acid use in Psychiatry: Issues in treating women of reproductive age. *J Psychiatr Neurosci* 23: 223-228, 1998.
- 531) Shuhaiber S, Pastuszak A, Schick B, Rieder M, Spivey G, Brochu J, Koren G: Pregnancy outcome following first trimester exposure to sumatriptan. *Neurology* 51: 581-583, 1998.
- 532) Ondrusek N, Abramovitch R, Pencharz P, Koren G: Empirical examination of the ability of children to consent to clinical research. *J Med Ethics* 24: 158-165, 1998.
- 533) Carcao M, Lau RC, Gupta A, Huerter H, Koren G, King SM: Sequential use of intravenous and oral acyclovir in the therapy of varicella in immunocompromised children. *Ped Inf Dis* 17: 626-631, 1998.
- 534) Einarson A, Koren G, Bergan U: Nausea and vomiting in pregnancy: A comparative European study. *Eur J Obstet Gynecol Reprod Biol* 76: 1-3, 1998.
- 535) Taddio A, Ohlsson A, Einarson TR, Stevens B, Koren G: A systematic review of EMLA in the treatment of acute pain in neonates. *Pediatrics* 101 (2), 1998: E1.
- 536) Loebstein R, Addis A, Ho E, Andreou R, Sage S, Donnenfeld AE, Schick B, Bonati M, Moretti M, Lalkin A, Pastuszak A, Koren G: Pregnancy outcome following gestational

- exposure to fluoroquinolones: a multicenter prospective controlled study. *Antimicrob Agents Chemother* 42: 1336-1339, 1998.
- 537) Berkovitch M, Bistrizter T, Aladjem M, Burtin P, Dogan T, Chen Leviz, Freedom R, Koren G: Clinical relevance of TDM of digoxin and gentamicin in the saliva of children. *Ther Drug Monit* 20: 253-256, 1998.
- 538) Stevens B, Koren G: Evidence-based pain management for infants. *Curr Opin Pediatr* 10: 203-207, 1998.
- 539) Pastrakuljic A, Knie B, Derewlany L, Koren G: Transplacental transfer and biotransformation studies of nicotine in the human placental cotyledon perfused *in vitro*. *Life Sci* 60: 2333-2343, 1998.
- 540) Loebstein R, Koren G: Clinical pharmacology and TDM in neonates and children. *Pediatr Rev* 19: 423-428, 1998.
- 541) Mazzotta P, Gupta A, Maltepe C, Koren G, Magee L: Pharmacologic treatment of nausea and vomiting during pregnancy. *Can Fam Phys* 44: 1455-1457, 1998.
- 542) Pastrakuljic A, Knie B, Derewlany L, Koren G: Transplacental transfer and biotransformation. Studies of nicotine in the human placental cotyledon perfused *in vitro*. *Life Sci* 60: 2333-2342, 1998.
- 543) Koren G, Klein J, McMartin K: Diagnosing intrauterine exposure to cocaine by hair testing: Six years of clinical use. *Ther Drug Monit*, 20: 478-480, 1998.
- 544) Moienafshari R, Bar Oz B, Ford Jones L, Koren G: How long should someone wait after CMV infection to start pregnancy? *Can Fam Phys* 44: 2381-2382, 1998.
- 545) Koren G, Ito S: Do silicone breast implants affect breastfeeding? *Can Fam Phys*, 44: 2641-2642, 1998.
- 546) Ito S, Gow R, Verjee Z, Giesbrecht E, Dodd H, Freedom R, Tonn GR, Axelson JE, Zalstein E, Rosenberg HC, Koren G: Intravenous and oral propafenone for treatment of tachycardia in infants and children: Pharmacokinetics and clinical response. *J Clin Pharmacol* 38: 496-501, 1998.
- 547) Hackman R, King SM, Khattak S, D'Alimonte D, Koren G: A national Canadian HIV healthline and registry for women and their families. Proceedings, 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, pp113-116, 1998.
- 548) Lalkin A, Loebstein R, Addis A, Koren G: Therapeutic approach to hypertension during pregnancy. *Can Fam Phys* 44: 1245-1247, 1998.
- 549) Innocencio G, Loebstein R, Lalkin A, Geist R, Petric M, Koren G: Managing exposure to chickenpox during pregnancy. New Program. *Can Fam Phys* 44: 745-747, 1998.

- 550) McMartin KI, Chu M, Kopecky E, Einarson TR, Koren G: Pregnancy outcome following organic solvent exposure: A meta-analysis of epidemiologic studies. *Am J Industr Med* 34: 288-292, 1998.
- 551) Fassos F, Berkovitch M, Daneman N, Koren L, Cameron R, Klein J, Falcitelli C, St. Louis P, Daneman R, Koren G: The efficacy of diazepam in the treatment of acute iron overload in rats. *Can J Physiol Pharmacol* 76: 1-5, 1998.
- 552) Lalkin A, Koren G: Special consideration in the prescribing of medications for children with continuous ambulatory peritoneal dialysis/continuous cycle peritoneal dialysis. *Balliere Clin Paed* 6: 455-470, 1998.
- 553) Einarson A, Phillips E, Mawji F, D'Alimonte D, Schick B, Addis A, Mastroiacovo P, Mazzone T, Matsui D, Koren G: A prospective controlled multicentre study of clarithromycin in pregnancy. *Am J Perinatol* 9: 523-525, 1998.
- 554) Pastuszak A, Bhatia D, Okoture B, Koren G: Pre-conceptional counseling and women's compliance with folic acid supplementation. *Can Family Phys* 45: 2053-7, 1999.
- 555) Stevens B, Johnston C, Taddio A, Jack A, Narciso J, Stremler R, Koren G, Aranda J: Management of pain from heel lance with lidocaine-prilocaine (EMLA) cream: Is it safe and efficacious in preterm infants. *J Dev Behav Pediatr* 20: 216-21, 1999.
- 556) Schuller L, Pastuszak A, Sanseverino MTV, Ashton Prolla P, Silva daCosta F, Orioli IM, Brunoni D, Brandao SB, Couto AM, Giugliani R, Koren G: Pregnancy outcome after abortion attempt with misoprostol in Brazil: A prospective, controlled study. *Repr Toxicol* 13: 147-151, 1999.
- 557) Ito S, Woodland S, Sarkadi B, Walker S, Koren G: Modelling and simulation of P-glycoprotein-involved epithelial drug transport: disposition of digoxin and vinblastin in dog renal tubular epithelia. *Am J Physiol* 277: F84-F96, 1999.
- 558) Kennedy D, Koren G: Valporic acid use in psychiatry: *Can Fam Phys* 45: 1451-3, 1999.
- 559) Kopecky EA, Simone C, Knie B, Koren G: Transfer of morphine sulfate across the human term placenta perfused in vitro and its interaction with naloxone *Life Sci* 65: 2359-71, 1999.
- 560) Einarson A, Koren G: Dextromethorphan. Extrapolation of findings from reproductive studies in animals to humans. *Can Fam Phys* 45: 2309-10, 1999.
- 561) Appleby L, Sharp D, Koren G: Treating depression in pregnancy. *Br J Gen Pract* 49: 780-2, 1999.
- 562) Addis A, Spino M, Koren G: Meta-analytic review of the clinical effectiveness of oral deferiprone. *Eur J Clin Pharmacol* 55: 1-6, 1999.

- 563) Diav-Citrin O, Atanackovic G, Koren G: An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major. *Ther Drug Monit* 21: 74-81, 1999.
- 564) Pastrakuljic A, Derewlany L, Koren G: A critical review of maternal cocaine use and cigarette smoking in relation to amino acid transport and fetal growth. *Placenta* 20: 499-512, 1999.
- 565) Nulman I, Laslo D, Koren G: Treatment of epilepsy in pregnancy. *Drugs* 57: 535-544, 1999.
- 566) Mazzotta P, Loebstein R, Koren G: Treating allergic rhinitis in pregnancy. *Drug Safety* 20: 361-375, 1999.
- 567) Lalkin A, Kapur BM, Koren G: Contamination of antibiotics resulting in severe pediatric methadone poisoning. *Ann Pharmacother* 33: 314-317, 1999.
- 568) Khattak S, Moghtader GK, McMartin K, Barrera M, Kennedy D, Koren G: Pregnancy outcome following gestational exposure to organic solvents: A prospective controlled study. *JAMA* 281: 1106-1109, 1999.
- 569) Moienafshari R, Bar Oz B, Koren G: Occupational exposure to mercury: What is a safe level? *Can Fam Physician* 45: 43-45, 1999.
- 570) Atanackovic G, Koren G: Young women taking isotretinoin still conceive. Role of physicians in preventing disaster. *Can Fam Phys* 45: 289-292, 1999.
- 571) Bishai R, Mazzotta P, Atanackovic G, Levichek Z, Pole M, Magee L, Koren G: The efficacy and safety of dicyclanil for nausea and vomiting of pregnancy. *Today's Therapeutic Trends March*, 1999.
- 572) Mankuta D, Bar Oz B, Koren G: Erythema infectiosum and pregnancy. *Can Family Physician* 45: 603-605, 1999.
- 573) Klein J, Koren G: Hair analysis- a biological marker for passive smoking in pregnancy and childhood. *Hum Exp Toxicol* 18: 279-82, 1999.
- 574) Mazzotta P, Magee L, Koren G: The perception of teratogenic risk by women with nausea and vomiting in pregnancy. *Reprod Toxicol* 13: 313-319, 1999.
- 575) Emelianova S, Einarson A, Mazzotta P, Magee L, Koren G: Distribution of severity of nausea and vomiting in pregnancy and vitamin B6 supplementation. *Clin Invest Med* 22: 106-110, 1999.
- 576) Bishai R, Koren G: Maternal and obstetric effects of prenatal drug exposure. *Clin Perinatol* 26: 75-86, 1999.
- 577) Astrup ML, Koren G: Analgesic agents for the postoperative period: Opioids. *Surg Clin North Amer* 79: 253-274, 1999.

- 578) Berkovitch M, Eshel G, Lushkov G, Reznik S, Chen-Levy Z, Pinto O, Koren G: The effect of diazepam in the recovery of rabbits from acute acetaminophen overdose. *Ther Drug Monit* 21: 267-273, 1999.
- 579) Hackman R, Kapur B, Koren G: Nicotine patch in pregnancy. *N Engl J Med* 341: 1700, 1999.
- 580) Bar Oz B, Moretti M, Koren G: Reporting bias in retrospective teratology studies. *Lancet* 354: 1700-1701, 1999.
- 581) Koren G: Antimalarial drugs for rheumatoid disease during pregnancy. *Can Fam Phys* 45: 2869-70, 1999.
- 582) Einarson A, Ahmed F, Gallo M, Einarson TR, Koren G: Reproducibility of medical information obtained via the telephone vs personal interview. *Vet Hum Toxicol* 41: 397-400, 1999.
- 583) Koren G, Khattak S: Pregnancy outcome following gestational exposure to organic solvents: Author's response. *Teratology* 60: 330-1, 1999.
- 584) Koren G: Folic acid and neural tube defects. Good news at last! *Can Fam Phys* 45: 2605-6, 1999.
- 585) Magee LA, Nulman I, Rovet JF, Altmann D, Boulton BC, Koren G: Neurodevelopment after *in utero* exposure to amiodarone *Neurotoxicol Teratol* 21: 261-5, 1999.
- 586) Kapur B, HersHKop S, Koren G, Gaughan V: Urine fingerprinting-detection of sample tampering in an opiate dependency program. *Ther Drug Monit* 21: 243-50, 1999.
- 587) Woodland C, Ito S, Camille G, Wainer I, Klein J, Koren G: Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. *Life Sci* 68: 109-17, 2000.
- 588) Magee LA, Elran E, Bull SB, Logan A, Koren G: Risks and benefits of beta receptor blockers for pregnancy hypertension - overview of randomized trials. *Eur J Obstet Gynecol Reprod Biol* 88: 15-26, 2000.
- 589) Bailey B, Daneman R, Daneman N, Mayer JM, Leeder JS, Koren G: Discrepancy between CYP2D6 phenotype and genotype derived from postmortem-dextromethorphan blood level. *Forensic Sci Intnl* 110: 61-70, 2000.
- 588) Challis D, Pfaner CD, Ritchie K, Koren G, Tesoro A, Koren G: Glucose metabolism was elevated and vascular resistance and materno-fetal transfer normal in perfused placental cotyledons from severely growth restricted human fetuses. *Ped Res* 47: 309-15, 2000.
- 589) von Dadelszen P, Ornstein MP, Logan AG, Koren G, Magee L: Reduction in mean arterial pressure in women with mild-to-moderate pregnancy hypertension is associated with fetal growth restriction. A meta-regression of the randomized controlled trials. *Lancet* 355: 87-92, 2000.

- 590) Dallas S, Read SE, King S, Koren G, Bendayan R: Pharmacokinetic interaction between zidovudine and TMP-SMX in HIV-1 infected children. *Can J Inf Dis* 11: 254-258, 2000.
- 591) Einarson A, Mastroiacovo P, Arnon J, Ornoy A, Addis A, Malm H, Koren G: Prospective, controlled, multicentre study of loperamide in pregnancy. *Can J Gastroenterol* 14: 185-187, 2000.
- 592) Addis A, Dolovich LR, Einarson TR, Koren G: Can we use anxiolytics during pregnancy without anxiety? *Can Fam Phys* 46: 549-51, 2000.
- 593) Rathnapalan S, Diav-Citrin O, Koren G: Toward universal HIV testing in pregnancy. *Can Fam Phys* 46: 508-10, 2000.
- 594) Theis JG, Chan HS, Greenberg ML, Malkin D, Karaskov V, Moncica I, Koren G, Doyle J: Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma. *Med Pediatr Oncol* 34: 242-9, 2000.
- 595) Addis A, Koren G: Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. *Psychol Med* 30: 89-94, 2000.
- 596) Klein J, Karaskov T, Koren G: Clinical applications of hair testing for drugs of abuse-the Canadian experience. *Forensic Sci Int* 107: 281-8, 2000.
- 597) Berkovitch M, Livne A, Lushkov G, Segal M, Talmor C, Bentur Y, Klein J, Koren G: The efficacy of oral deferiprone in acute iron poisoning. *Am J Emerg Med* 18: 36-40, 2000.
- 598) Diav-Citrin O, Okotore B, Lucarelli K, Koren G: Zopiclone use during pregnancy. *Can Fam Phys* 46: 63-4, 2000.
- 599) Bailey B, Daneman R, Daneman N, Mayer JM, Koren G: Discrepancy between CYP2D6 phenotype and genotype derived from post-mortem dextromethorphan blood level. *Forensic Sci Int* 110: 61-70, 2000.
- 600) Koren G: Caffeine during pregnancy? In moderation. *Can Fam Phys* 46: 801-3, 2000.
- 601) Einarson A, Mastroiacovo P, Arnon J, Ornoy A, Addis A, Malm H, Koren G: Prospective, controlled, multicentre study of loperamide in pregnancy. *Can J Gastroenterol* 14: 185-7, 2000.
- 602) Addis A, Dolovich LR, Einarson TR, Koren G: Can we use anxiolytics during pregnancy without anxiety? *Can Fam Phys* 46: 549-51, 2000.
- 603) Rathnapalan S, Diav-Citrin O, King SM, Koren G: Universal HIV testing in pregnancy. *Can Fam Phys* 46: 508-10, 519-22, 2000.

- 604) Pole M, Einarson A, Pairedeau N, Einarson T, Koren G: Drug labeling and risk perceptions of teratogenicity: a survey of pregnant Canadian women and their health professionals. *J Clin Pharmacol* 294: 141-6, 2000.
- 605) Pastrakuljic A, Derewlany LO, Knie B, Koren G: The effects of cocaine and nicotine on amino acid transport across the human placental cotyledon perfused *in vitro*. *J Pharmacol Exp Ther* 294: 141-6, 2000.
- 606) Lee A, Moretti ME, Collantes A, Chung D, Mazzotta P, Koren G, Merchant SS, Ito S: Choice of breastfeeding and physicians' advice: a cohort study of women receiving propylthiouracil. *Pediatrics* 106: 27-30, 2000.
- 607) Koren G: Intranasal midazolam for febrile seizures. A step forward in treating a common and distressing condition. *BMJ* 321: 64-5, 2000.
- 608) Koren G: Drugs in pregnancy; the nausea and vomiting paradigm. *Arch Pediatr* 2: 409-410, 2000.
- 609) Klinger G, Koren G: Antenatal phenobarbital for prevention of intraventricular hemorrhage in preterm infants. *Can Fam Phys* 46: 1285-7, 2000.
- 610) Einarson A, Parshuram C, Koren G: Periconceptional use of folic acid to reduce the rates of neural tube defects: is it working? *Reprod Toxicol* 14: 291-2, 2000.
- 611) Kapur BM, Selby P, Latowsky M, Singh M, Koren G: CEDIA's EDDP immunoassay is a cost-effective compliance marker in an opiate dependency program. *Clin Biochem* 33: 230, 2000.
- 612) Bar-Oz B, Nulman I, Koren G, Ito S: Anticonvulsants and breastfeeding: a critical review. *Paediatr Drugs* 2: 113-26, 2000.
- 613) Diav-Citrin O, Rathnapalan S, Grouhi M, Roifman C, Koren G: Medication errors in paediatrics: a case report and systematic review of risk factors. *Paediatr Drugs* 2: 239-42, 2000.
- 614) Kopecky EA, Ryan ML, Baret JT, Seaward PG, Ryan G, Koren G, Amankwah K: Fetal response to maternally administered morphine. *Am J Obstet Gynecol* 183: 424-430, 2000.
- 615) Klinger G, Koren G: Controversies in antenatal corticosteroid treatment. *Can Fam Phys* 46: 1571-3, 2000.
- 616) Mazzotta P, Maltepe C, Navioz Y, Magee LA, Koren G: Attitudes, management and consequences of nausea and vomiting of pregnancy in the United States and Canada. *Int J Gynaecol Obstet* 70: 359-65, 2000.
- 617) Bar-Oz B, Moretti ME, Bishai R, Mareels G, Van Tittelboom T, Verspeelt J, Koren G: Pregnancy outcome after *in utero* exposure to itraconazole: a prospective cohort study. *Am J Obstet Gynecol* 183: 617-20, 2000.

- 618) Koren G: Appraisal of drug therapy for nausea and vomiting of pregnancy: I. The place effect-methodological and practical considerations. *Can J Clin Pharmacol* 7: 135-7, 2000.
- 619) Bishai R, Mazzotta P, Atanackovic G, Levichek Z, Pole M, Magee LA, Koren G: Critical appraisal of drug therapy for nausea and vomiting of pregnancy: II. Efficacy and safety of dicletrin (doxylamine-B6). *Can J Clin Pharmacol* 7: 138-43, 2000.
- 620) Rogan JW, Lyszkiewicz DA, Blowey D, Khattak S, Arbus GS, Koren G: A randomized prospective crossover trial of amlodipine in pediatric hypertens. *Pediatr Nephrol* 14: 1083-7, 2000.
- 621) Koren G: Varicella virus vaccine before pregnancy. Important breakthrough in protecting fetuses. *Can Fam Phys* 46: 1975-7, 2000.
- 622) Gallo M, Sarkar M, Au W, Pietrzak K, Comas B, Smith M, Jaeger TV, Einarson A, Koren G: Pregnancy outcome following gestational exposure to echinacea: A prospective controlled study. *Arch Intern Med* 160: 3141-3, 2000.
- 623) Mazzotta P, Stewart D, Atanackovic G, Koren G, Magee LA: Psychosocial morbidity among women with nausea and vomiting of pregnancy: prevalence and association with anti-emetic therapy. *J Psychosom Obstet Gynaecol* 21: 129-36, 2000.
- 624) Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, Friesen MH, Jacobson S, Kasapinovic S, Chang D, Diav-Citrin O, Chitayat D, Nulman I, Einarson TR, Koren G: Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. *Teratology* 62: 385-92, 2000.
- 625) Taddio A, Koren G: The pediatric forum: pain indication in circumcision *Arch Pediatr Adolesc Med* 154: 1275, 2000.
- 626) Lee J, Einarson A, Gallo M, Okotore B, Koren G: Longitudinal change in the treatment of nausea and vomiting of pregnancy in Ontario. *Can J Pharmacol* 205-8, 2000.
- 627) Koren G: Does breastfeeding have an effect on intelligence? *Can Fam Phys* 46: 2197-9, 2000.
- 628) Einarson A, Levichek Z, Einarson TR, Koren G: The antiemetic effect of cetirizine during pregnancy. *Ann Pharmacother* 34: 1486-7, 2000.
- 629) Bar-Oz B, Ito S, Parks V, Maurer MP, Koren G: Estimation of neonatal exposure after accidental ingestion of lufenuron in a breastfeeding mother. *J Hum Lact* 16: 229-30, 2000.
- 630) Shuhaiber S, Koren G: Occupational exposure to inhaled anesthetic. Is it a concern for pregnant women. *Can Fam Phys* 46: 2391-2, 2000.



- 631) Kozer E, Koren G: The risk of spontaneous abortion was increased with high levels but not with moderate levels of caffeine consumption. Evidenced-Based. *OBGYN* 2: 73, 2000.
- 632) Vargas FR, Schuler-Faccini L, Brunoni D, Kim C, Meloni VF, Sugayama SM, Albano L, Lere JC, Almeida JC, Duarte A, Cavalcanti DP, Goloni-Bertollo E, Conte A, Koren G, Addis A: Prenatal exposure to misoprostol and vascular disruption defects: a case-control study. *Am J Med Genet* 95: 302-6, 2000.
- 633) Kozer E, Verjee Z, Koren G: Misdiagnosis of a mexiletine overdose because of a nonspecific result of urina toxicologic screening. *N Engl J Med* 343: 1971-2, 2000.
- 634) Koren G, Magee L, Attard C, Kohli M, Atanackovic G, Bishai R, Chandra K, Navioz Y, Maltepe C: A novel method for the evaluation of the severity of nausea and vomiting of pregnancy. *Eur J Obstet Gynecol Reprod Biol* 94: 31-36, 2001.
- 635) Koren G: Misrepresentation and miscommunication of teratogenic risk of drugs; analysis three highly publicized international cases. *Reprod Toxicol* 15: 1-3, 2001.
- 636) Einarson A, Selby P, Koren G: Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. *J Psychiatr Neurosci* 26: 44-8, 2001.
- 637) Lishner M, Koren G: Cancer chemotherapy during pregnancy. Consortium of cancer in pregnancy evidence. *Can Fam Phys* 47: 41-2, 2001.
- 638) Stiskal JA, Kulin N, Koren G, Ho T, Ito S: Neonatal paroxetine withdrawal syndrome. *Arch Dis Child Fetal Neonatal Ed.* 84: F134-F135, 2001.
- 639) Einarson A, Lyszkiewicz D, Koren G: The Safety of Dextromethorphan in Pregnancy: Results of a Controlled Study. *Chest* 119: 466-469, 2001.
- 640) Magee LA, Bull SB, Koren G, Logan A: The generalizability of trial data: a comparison of beta-blocker trial participants with a prospective cohort of women taking beta-blockers in pregnancy. *Eur J Obstet Gynecol Reprod Biol* 94: 205-210, 2001.
- 641) Kapur B, Hackman R, Selby P, Klein J, Koren G: Randomized, double blind, placebo controlled trial of nicotine replacement therapy in pregnancy. *Curr Ther Res* 62: 274-280, 2001.
- 642) Kozer E, Koren G: Effects of prenatal exposure to marijuana. *Can Fam Phys* 47: 263-4, 2001.
- 643) Einarson A, Selby P, Koren G: Discontinuing antidepressants and benzodiazepines upon becoming pregnant: Beware of the risks of abrupt discontinuation. *Can Fam Phys* 47: 489-90, 2001.

- 644) Mazzotta P, Stewart DE, Koren G, Magee LA: Factors associated with elective termination of pregnancy among Canadian and American women with nausea and vomiting of pregnancy. *J Psychosom Obstet Gynaecol* 22: 7-12, 2001.
- 645) Lobaugh NJ, Karaskov V, Rombough V, Rovet J, Bryson S, Greenbaum R, Haslam RH, Koren G: Piracetam therapy does not enhance cognitive functioning in children with down's syndrome. *Arch Pediatr Adolesc Med* 155: 442-8, 2001.
- 646) Wong M, Koren G: Bias in maternal reports of smoking during pregnancy associated with fetal distress. *Can J Public Health* 92: 109-12, 2001.
- 647) Kozar E, Moretti ME, Koren G: Leflunomide: new antirheumatic drug. Effect on pregnancy outcomes. *Can Fam Phys* 47: 721-2, 2001.
- 648) Vohra S, Koren G: Hypothetical framework for a relationship between maternal thyroid function nausea and vomiting of pregnancy, and congenital heart disease. *Med Hypotheses* 56: 392-4, 2001.
- 649) Selby P, Hackman R, Kapur B, Klein J, Koren G: Heavily smoking women who cannot quit in pregnancy: evidence of pharmacokinetic predisposition. *Ther Drug Monit* 23: 189-91, 2001.
- 650) Roberts W, Weaver L, Brian J, Bryson S, Emelianova S, Griffiths AM, MacKinnon B, Yim C, Wolpin J, Koren G: Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo-controlled trial. *Pediatrics* 107: E71, 2001.
- 651) Atanackovic G, Wolpin J, Koren G: Determinants of the need for hospital care among women with nausea and vomiting of pregnancy. *Clin Invest Med* 24: 90-3, 2001.
- 652) Bar Oz B, Hackman R, Einarson T, Koren G: Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. *Transplantation* 71: 1051-5, 2001.
- 653) Koren G: The use of glyburide in gestational diabetes – an ideal example of “bench to bedside”. *Pediatr Res* 49: 734, 2001.
- 654) Koren G: Glyburide and fetal safety; transplacental pharmacokinetic considerations. *Reprod Toxicol* 15: 227-9, 2001.
- 655) Koren G, Schuler L: Taking drugs during pregnancy. How safe are the unsafe? *Can Fam Phys* 47: 951-3, 2001.
- 656) Kopecky EA, Jacobson S, Bch MB, Hubley P, Palozzi L, Clarke HM, Koren G: Safety and pharmacokinetics of EMLA in the treatment of postburn pruritus pediatric patients: a pilot study. *J Burn Care Rehabil* 22: 235-42, 2001.
- 657) Lyszkiewicz DA, Gerichhausen S, Bjornsdottir I, Einarson TR, Koren G, Einarson A: Evidence based information on drug use during pregnancy: a survey of community pharmacists in three countries. *Pharm World Sci* 23: 76-81, 2001.

- 658) McMartin KI, Klein J, Hackman R, Platt MS, Koren G: Measurements of lung tissue concentrations of nicotine and cotinine in SIDS. *J Pediatr* 140:205-9, 2002.
- 659) Klein J, Eliopoulos C, Ursitti F, Koren G: Issues in measuring cocaine and nicotine in neonatal hair. *NIDA monograph (In Press)*.
- 660) Koren G, Nulman I, Addis A: Outcome of children exposed *in utero* to fluoxetine; A critical review. *J Depression (Suppl 17)* 27:31, 1998.
- 661) Magee LA, Elran E, Bull SB, Logan A, Koren G. Risks and benefits of beta-receptor blockers for pregnancy and meta-analysis of the randomised studies. *Eur J Obstet Gynecol* 88: 15-26, 2000.
- 662) Bar Oz B, Moretti M, Koren G: The safety of intraconazole in pregnancy. *Am J Obstet Gynecol* 183: 617-20, 2000.
- 663) Einarson T, Koren G, Spino M: Sex differences in drug induced hospitalization: A meta-analysis. *Med Care* \_\_\_\_\_
- 664) Atanackovic G, Koren G: Fetal exposure to oral isotretinoin: failure to comply with the Pregnancy Prevention Program. *Can Med Assoc J* 160: 1719-20, 1999.
- 665) Aleksa K, Ito S, Koren G: Developmental renal tubular toxicity: A hypothetical and experimental approaches. *Curr Ther Res* 62:930-41, 2001.
- 666) Till C, Koren G, Rovet JF: Prenatal exposure to organic solvents and child neurobehavioral performance. *Neurotoxicol Teratol* 23: 235-45, 2001.
- 667) Bar-Oz B, Berkovitch M, Ford-Jones L, Koren G: Congenital cytomegalovirus infection. Is there a breakthrough? *Can Fam Phys* 47: 1179-81, 2001.
- 668) Gesundheit B, Cividalli G, Freeman A, Yatziv S, Koren G, Baruchel S: Cyclosporin A in the treatment of refractory immune thrombocytopenia purpura in children *Eur J Haematol* 66: 347-51, 2001.
- 669) Nulman I, Rovet J, Greenbaum R, Loebstein M, Wolpin J, Pace-Asciak P, Koren G: Neurodevelopment of adopted children exposed *in utero* to cocaine: The Toronto Adoption Study. *Clin Invest Med* 24: 129-37, 2001.
- 670) Kozier E, Koren G: Management of paracetamol overdose: current controversies. *Drug Saf* 24: 503-12, 2001.
- 671) Ursitti F, Klein J, Koren G: Confirmation of cocaine use during pregnancy: a critical review. *Ther Drug Monit* 23: 347-53, 2001.
- 672) Hard ML, Einarson TR, Koren G: The role of acetaldehyde in pregnancy outcome after prenatal alcohol exposure. *Ther Drug Monit* 23: 427-34, 2001.

- 673) Addis A, Moretti ME, Ahmed Syed F, Einarson TR, Koren G: Fetal effects of cocaine: an updated meta-analysis. *Reprod Toxicol* 15: 341-69, 2001.
- 674) Kapur B, Koren G: Motherisk alert: Folic acid fortification of flour—three years later. *Can J Clin Pharmacol* 8: 91-2, 2001.
- 675) Bailey B, Lalkin A, Kapur BM, Koren G: Is chronic poisoning with acetaminophen in children a frequent occurrence in Toronto? *Can J Clin Pharmacol* 8: 96-101, 2001.
- 676) Koren G: Maternal obesity and risk of neural tube defects. *Can Fam Phys* 47: 1385-1387, 2001.
- 677) Atanackovic G, Navioz Y, Moretti ME, Koren G: The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy. *J Clin Pharmacol* 41: 842-5, 2001.
- 678) Brunner M, Guo W, Mitchell GF, Buckett PD, Nerbonne JM, Koren G: Characterization of mice with a combined suppression of I(to) and I(K, slow). *Am J Physiol Heart Circ Physiol* 281: H1201-9, 2001.
- 679) Till C, Westall CA, Rovet JF, Koren G: Effects of maternal occupational exposure to organic solvents on offspring visual functioning: a prospective controlled study. *Teratology* 64: 134-41, 2001.
- 680) Kramer MS, Goulet L, Lydon J, Seguin L, McNamara H, Dassa C, Platt RW, Chen MF, Gauthier H, Genest J, Kahn S, Libman M, Rozen R, Masse A, Miner L, Asselin G, Benjamin A, Klein J, Koren G: Socio-economic disparities in preterm birth: causal pathways and mechanisms. *Paediatr Perinat Epidemiol* 15 (suppl 2): 104-23, 2001.
- 681) Ursitti F, Klein J, Sellers E, Koren G: Use of hair analysis for confirmation of self-reported cocaine use in users with negative urine tests. *J Toxicol Clin Toxicol* 39: 361-6, 2001.
- 682) Fouladi M, Stempak D, Gammon J, Klein J, Grant R, Greenberg ML, Koren G, Baruchel S: Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. *Cancer* 92: 914-23, 2001.
- 683) Nikfar S, Koren G: Managing hypothyroidism during pregnancy. *Can Fam Phys* 47: 1555-6, 2001.
- 684) Klinger G, Morad Y, Westall CA, Laskin C, Spitzer KA, Koren G, Ito S, Buncic RJ: Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. *Lancet* 358: 813-4, 2001.
- 685) Gallo M, Koren G: Can herbal products be used safely during pregnancy? Focus on echinacea. *Can Fam Phys* 47: 1727-8, 2001.

- 686) Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C, Mastoiacovo P, Addis A, Matsui D, Schuler L, Einarson TR, Koren G: Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. *Am J Psychiatry* 158: 1728-30, 2001.
- 687) Ho E, Collantes A, Kapur BM, Moretti M, Koren G: Alcohol and breastfeeding: calculation of time to zero level in milk. *Biol Neonate* 80: 219-22, 2001.
- 688) Stempak D, Dallas S, Klein J, Bendayan R, Koren G, Baruchel S: Glutathione stability in whole blood: effects of various deproteinizing acids. *Ther Drug Monit* 23: 542-9, 2001.
- 689) Loebstein R, Koren G: Clinical relevance of therapeutic drug monitoring during pregnancy. *Ther Drug Monit* 24: 15-22, 2002.
- 690) Aleksa K, Woodland C, Koren G: Young age and the risk for ifosfamide-induced nephrotoxicity: a critical review of two opposing studies. *Pediatr Nephrol* 16: 1153-8, 2001.
- 691) Hard ML, Raha S, Spino M, Robinson BH, Koren G: Impairment of pyruvate dehydrogenase activity by acetaldehyde. *Alcohol* 25: 1-8, 2001.
- 692) Jasper JD, Goel R, Einarson A, Gallo M, Koren G: Effects of framing on teratogenic risk perception in pregnant women. *Lancet* 358: 1237-8, 2001.
- 693) Koren G: Nicotine replacement therapy during pregnancy. *Can Fam Phys* 47: 197: 1-2, 2001.
- 694) Einarson A, Shuhaiber S, Koren G: Effects of antibacterials on the unborn child: what is known and how should this influence prescribing. *Paediatr Drugs* 3: 803-16, 2001.
- 695) Carver V, Coyle B, Koren G, Lavigne S, Martinez L, Robertson J, Polifka J, Stepanuk K: A call for action-prevention of fetal exposure to isotretinoin. A position paper by the organization of teratology information services public affairs committee. *Reprod Toxicol* 15: 729, 2001.
- 696) Nulman I, Laslo D, Fried S, Uleryk E, Lishner M, Koren G: Neurodevelopment of children exposed *in utero* to treatment of maternal malignancy. *Br J Cancer* 85: 1611-8, 2001.
- 697) Boskovic R, Klein J, Woodland C, Karaskov T, Koren G: The role of the placenta in variability of fetal exposure to cocaine and cannabinoids: a twin study. *Can J Physiol Pharmacol* 79: 942-5, 2001.
- 698) Costei AM, King SM, Koren G: Update on perinatal HIV. *Can Fam Phys* 47: 2221-2, 2001.
- 699) Koren G, Cohn T, Chitayat D, Kapur B, Remington G, Reid DM, Zipursky RB: Use of Atypical Antipsychotics During Pregnancy and the Risk of Neural Tube Defects in Infants. *Am J Psychiatry* 159: 136-137, 2002.

- 700) Anand KS, Abu-Saad HH, Aynsley Green A, Bancalari E, Benini F, Champion GD, Craig KD, Dangel T, Fournier-Charrier E, Franck LS, Eckstein Grunau R, Hertel SA, Jacq Z, Aigrain E, Jorch G, Kopelman BI, Koren G, Larsson B, Marlow N, McIntosh N, Ohlsson A, Olsson G, Porter F, Richter R, Stevens B, Taddio A. Treating pain in the newborn. *Arch Pediatr Adolesc Med* 155: 173-80, 2001.
- 701) Ho E, Tabesh L, Koren, G: Characteristics of pregnant women who use Ecstasy. *Neurotoxicol Teratol* 23: 561-67, 2001.
- 702) Koren G, Chan D, Klein J, Karaskov T: Estimation of fetal exposure to drugs of abuse, environmental tobacco smoke, and ethanol. *Ther Drug Monit* 24: 23-25, 2002.
- 703) Sgro MD, Barozzino T, Mirghnai HM, Sermer M, Moscato L, Akoury H, Koren G, Chitayat DA: Pregnancy outcome post renal transplantation. *Teratology* 65: 5-9, 2002.
- 704) Koren, G: Drinking alcohol while breastfeeding. Will it harm my baby? *Can Fam Phys* 48: 39-41, 2002.
- 705) Nevin AC, Parshuram C, Nulman I, Koren G, Einarson A: A survey of Physicians knowledge regarding awareness of maternal alcohol use and the diagnosis of FAS. *BMC Fam Pract* 3: 2, 2002.
- 706) Koren G, Cohn T, Chitayat D, Kapur B, Remington G, Reid DM, Zipursky RB: Use of atypical antipsychotics during pregnancy and the risk of neural tube defects in infants. *Am J Psychiatry* 159: 136-7, 2002.
- 707) Pole M, Koren G: Finasteride. Does it affect spermatogenesis and pregnancy? *Can Fam Phys* 47: 2469-70, 2001.
- 708) Koren G, Money D, Boucher M, Aoki F, Petric M, Innocencio G, Wolosk M, Rempel V, Pelland F, Geist R, Ho T, Bar-Oz B, Loebstein R: Serum concentrations, efficacy, and safety of a new intravenously administered varicella zoster immune globulin in pregnant women. *J Clin Pharmacol* 42: 267-74, 2002.
- 709) Levichek Z, Atanackovic G, Oepkes D, Maltepe C, Einarson A, Magee L, Koren G: Nausea and vomiting of pregnancy. Evidence based treatment algorithm. *Can Fam Phys* 48: 267-8, 277, 2002.
- 710) Schmid R, Koren G, Klein J, Katz J: The stability of a ketamine-morphine solution. *Anesth Analg* 94: 898-900, 2002.
- 711) Taddio A, Gurguis MG, Koren G: Lidocaine-Prilocaine Cream Versus Tetracaine Gel for Procedural Pain in Children. *Ann Pharmacother* 36: 687-692, 2002.
- 712) Koren G: SSRI's in Pregnancy-Are they safe? *Pediatr Res* 51: 424-425, 2002.
- 713) Koren L, Mokady O, Karaskov T, Koren G, Geffen E: A novel method using hair for determining hormonal levels in wildlife. *Animal Behavior* 63: 403-6, 2002.

- 714) Koren G, Klinger G, Ohlsson A: Fetal Pharmacotherapy. *Drugs* 62: 757-73, 2002.
- 715) Bailey B, Forget S, Koren G: Pregnancy outcome of women who failed appointments at a teratogen information service clinic. *Reprod Toxicol* 16: 77-80, 2002.
- 716) Liaschko A, Koren G: Cystic fibrosis during pregnancy. Review *Can Fam Phys* 48: 463-4, 467, 2002.
- 717) Kozar E, Scolnik D, Keays T, Shi K, Luk T, Koren G: Large errors in the dosing of medications for children. *N Engl J Med* 346: 1175-6, 2002.
- 718) Koren G: Ethical framework for observational studies of medicinal drug exposure in pregnancy. *Teratol* 65: 191-5, 2002.
- 719) Aleksa K, Koren G: Ethical issues in including pediatric cancer patients in drug development trials. Review. *Pediatr Drugs* 4: 257-65, 2002.
- 720) Koren G, Boskovic R, Hard M, Maltepe C, Navioz Y, Einarson A: Motherisk-PUQE (pregnancy-unique quantification of emesis and nausea) scoring system for nausea and vomiting of pregnancy. *Am J Obstet Gynecol* 185 (5 Suppl Understanding): S228-31, 2002.
- 721) Magee LA, Chandra K, Mazzotta P, Stewart D, Koren G, Guyatt GH: Development of a health-related quality of life instrument for nausea and vomiting of pregnancy. *Am J Obstet Gynecol* 185 (5 Suppl Understanding): S323-8, 2002.
- 722) Koren G, Levichek Z: The teratogenicity of drugs for nausea and vomiting of pregnancy: perceived versus true risk. *Am J Obstet Gynecol Review* 185 (5 Suppl Understanding): S248-52, 2002.
- 723) Magee LA, Mazzotta P, Koren G: Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy. (NVP). Review *Am J Obstet Gynecol* 185 (5 Suppl Understand): S256-61, 2002.
- 724) Kozar E, Parvez S, Minassian BA, Kobayashi J, Verjee Z, Koren G: How high can we go with phenytoin? *Ther Drug Monit* 24: 386-9, 2002.
- 725) Abadi S, Einarson A, Koren G: Use of warfarin during pregnancy. *Can Fam Phys* 48: 695-7, 2002.
- 726) Freedman B, Koren G: Reliability of maternal reporting in identifying major congenital malformations. *Vet Hum Toxicol* 44: 180-1, 2002.
- 727) Einarson A, Koren G: Bacterial vaginosis during pregnancy. Should we screen for and treat it? *Can Fam Phys* 48: 877-8, 2002.
- 728) Koren G: Trends of medication errors in hospitalized children. *J Clin Pharmacol* 42: 707-10, 2002.

- 729) Ratnapalan S, Koren G: Taking ACE inhibitors during pregnancy. Is it safe? Review. *Can Fam Phys* 48: 1047-9, 2002.
- 730) Nikfar S, Abdollahi M, Moretti ME, Magee LA, Koren G: Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. *Dig Dis Sci* 47: 1526-9, 2002.
- 731) Koren G: Adverse effects of assisted reproductive technology and pregnancy outcome. *Pediatr Res* 52: 136, 2002.
- 732) Chandra K, Magee L, Koren G: Discordance between physical symptoms versus perception of severity by women with nausea and vomiting in pregnancy. (NVP). *BMC Pregnancy Childbirth* 1; 2: 5, 2002.
- 733) Von Dadelszen P, Magee LA, Lee SK, Stewart SD, Simone C, Koren G, Walley KR, Russell JA: Activated protein C in normal human pregnancy and pregnancies complicated by severe preeclampsia: a therapeutic opportunity? *Crit Care Med* 30: 1883-92, 2002.
- 734) Till C, Koren G, Rovet JF: Agreement between prospective and retrospective reports of maternal exposure to chemicals during pregnancy. *J Occup Environ Med* 44: 708-13, 2002.
- 735) Hemels ME, Koren G, Einarson TR: Increased use of antidepressants in Canada: 1981-2000. *Ann Pharmacother* 36: 1375-9, 2002.
- 736) Einarson A, Portnoi G, Koren G: Update on motherisk updates. Seven years of questions and answers. *Can Fam Phys* 48: 1301-4, 2002.
- 737) Kapur B, Soldin OP, Koren G: Potential prevention of neural tube defects by assessment of women of childbearing age through monitoring of folate. *Ther Drug Monit* 24: 628-30, 2002.
- 738) Kozar E, Scolnik D, Macpherson A, Keays T, Shi K, Luk T, Koren G: Variable associated with medication errors in pediatric emergency medicine. *Pediatrics* 110: 737-42, 2002.
- 739) Geshundheit B, Kirby M, Lau W, Koren G, Abdelhaleem M: Thrombocytopenia and megakaryocyte dysplasia: an adverse effect of valproic acid treatment. *J Pediatr Hematol Oncol* 24: 589-90, 2002.
- 740) Chandra K, Einarson A, Koren G: Taking ginger for nausea and vomiting during pregnancy. *Can Fam Phys* 48: 1441-2, 2002.
- 741) Goldman RD, Koren G: Biologic markers of pain in the vulnerable infant. *Clin Perinatol* 29: 415-25, 2002.



- 742) Forman R, Koren G, Shear NH: Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. *Drug Saf* 25: 965-72, 2002.
- 743) Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, Koren G: Child development following exposure to tricyclic antidepressants of fluoxetine throughout fetal life: a prospective, controlled study. *Am J Psychiatry* 159: 1189-95, 2002.
- 744) Kagan-Kreiger S, Selby P, Vohra S, Koren G: Paternal alcohol exposure and turner syndrome. *Alcohol* 37: 613-7, 2002.
- 745) Costei AM, Kozer E, Ho T, Ito S, Koren G: Perinatal outcome following third trimester exposure to paroxetine. *Arch Pediatr Adolesc Med* 156: 1129-32, 2002.
- 746) Stempak D, Gammon J, Klein J, Koren G, Baruchel S: Single-dose and steady state pharmacokinetics of celecoxib in children. *Clin Pharmacol Ther* 72: 490-7, 2002.
- 747) Yagev Y, Koren G: Eating fish during pregnancy. Risk of exposure to toxic levels of methylmercury. *Can Fam Phys* 48:1619-21, 2002.
- 748) Koren G: Comment on antiepileptics and antipsychotics. *Teratology* 66: 273, 2002.
- 749) Goldman RD, Koren G: Influenza vaccination during pregnancy. *Can Fam Phys* 48: 1768-9, 2002.
- 750) Klein J, Chan D, Koren G: Neonatal hair analysis as a biomarker for *in utero* alcohol exposure. *N Engl J Med* 347: 2086, 2002.
- 751) Kozer E, Nikfar S, Costei A, Boskovic R, Nulman I, Koren G: Aspirin consumption during the first trimester of pregnancy and congenital anomalies: A meta-analysis. *Am J Obstet Gynecol* 187: 1623-30, 2002.
- 752) Knoppert DC, Stempak D, Baruchel S, Koren G: Celecoxib in human milk: a case report. *Pharmacother* 23: 97-100, 2003.
- 753) Kozer E, Scolnik D, Agamata WM, Weiss SK, Verjee ZH, Koren G: Utility of antiepileptic drug monitoring in the pediatric emergency department. *Ther Drug Monit* 25: 17-21, 2003.
- 754) Hard ML, Iqbal U, Brien JF, Koren G: Binding of acetaldehyde to human and Guinea pig placenta *in vitro*. *Placenta* 24: 149-54, 2003.
- 755) Greenbaum R, Nulman I, Rovet J, Koren G: The Toronto experience in diagnosing alcohol-related neurodevelopmental disorder: a unique profile of deficits and assets. *Can J Clin Pharmacol* 9: 215-25, 2002.
- 756) Bar-Oz B, Klein J, Karaskov T, Koren G: Comparison of meconium and neonatal hair analysis for detection of gestational exposure to drugs of abuse. *Arch Dis Child Fetal Neonatal Ed* 88: F98-F100, 2003.

- 757) Goldman RD, Koren G: Taking St. John's wort during pregnancy. *Can Fam Phys* 49: 29-30, 2003.
- 758) Shuhaiber S, Einaron A, Radde IC, Sarkar M, Koren G: A prospective-controlled study of pregnant veterinary staff exposed to inhaled anesthetics and x-rays. *Int J Occup Med Environ Health* 15: 363-73, 2002.
- 759) Uziel Y, Berkovitch M, Gazarian M, Koren G, Silverman ED, Schneider R, Laxer RM: Evaluation of Eutectic Lidocaine/Prilocaine Cream (EMLA<sup>®</sup>) for Steroid Joint Injection in Children with Juvenile Rheumatoid Arthritis: A Double Blind, Randomized, Placebo Controlled Trial. *J Rheumatol* 30: 594-6, 2003.
- 760) Koren G: Exposure to electromagnetic fields during pregnancy. *Can Fam Phys* 49: 151-153, 2003.
- 761) Koren G, Kearns GL, Reed M, Pons G: Use of healthy children as volunteers in drug studies: the ethical debate. *Clin Pharmacol Ther* 73: 147-52, 2003.
- 762) Cohen-Kerem R, Koren G: Antioxidants and fetal protection against ethanol teratogenicity. I. Review of the experimental data and implications to humans. *Neurotoxicol Teratol* 25: 1-9, 2003.
- 763) Moretti ME, Caprara D, Coutinho CJ, Bar-Oz B, Berkovitch M, Addis A, Jovanovski E, Schuler-Faccini L, Koren G: Fetal safety of loratadine use in the first trimester of pregnancy: A multicenter study. *J Allerg Clin Immunol* 111: 479-83, 2003.
- 764) Garcia-Bournissen F, Feig DS, Koren G: Maternal-fetal transport of hypoglycaemic drugs. *Clin Pharmacokinet* 42: 303-13, 2003.
- 765) Bologa M, Cheng C, Klein J, Koren G: Gestational changes in protein binding of antiepileptic drugs. \_\_\_\_\_
- 766) Elit LM, Murphy KJ, Farine D, Zemlickis D, Hudek A, Koren G: Oligohydramnios Associated with Cisplatin Therapy. A Case Report and Review of the Literature. (Submitted J Ped).
- 767) Gorodischer R, Levine M, Holbrook A, Pelric M, Pastuszak A, Koren G: Economic analysis of the use of varicella-zoster immune globulin (VZIG) in exposed pregnant women in the province of Ontario. (Submitted Can J Clin Pharmacol).
- 768) Simone C, Byrne , Knie B, Koren G: Cocaine does not cause vasoconstriction in the human term placenta. (Submitted Life Sci).
- 769) Polacek H, Pastuszak A, Polacek J, Koren G: Fetal safety of recombinant hepatitis B vaccine in pregnancy (Submitted Ped Inf Dis).

- 770) Woodland C, Koren G, Ito S: From bench to bedside: utilization of an *in vitro* model to predict potential drug-drug interactions in the kidney: the digoxin mifepristone example. *J Clin Pharmacol* 43: 743-50, 2003.
- 771) Woodland C, Wainer I, Koren G, Ito S: Verapamil metabolites - potential P-glycoprotein mediated multidrug resistance reversal agents. *Can J Physiol Pharmacol* 81: 800-5, 2003.
- 772) Mungan N, Wilson TW, Nischalk K, Khattak S, Ho T, Koren G, Levin A: Life-threatening complications of Alphagan in infants. *JAAPOS* 7: 69-70, 2003.
- 773) Koren G: Advancing FASD prevention and care through research. *JFAS Int* 1: e1, 2003.
- 774) Koren G: We work in boxes that do not talk to each other. *JFAS Int* 1: e12, 2003.
- 775) Rouleau M, Levichek Z, Koren G: Are mothers who drink heavily in pregnancy victims of FAS. *JFAS Int* 1: e4, 2003.
- 776) Chandra K, Ho E, Sarkar M, Wolpin J, Koren G: Characteristics of women using marijuana in pregnancy and their reported effects on symptoms of NVP. *JFAS Int* 1: e13, 2003.
- 777) Boskovic R, Einarson A, Maltepe C, Wolpin J, Koren G: Diclectin therapy for nausea and vomiting of pregnancy: effects of optimal dosing. *J Obstet Gynaecol Can* 25: 830-3, 2003.
- 778) Parshuram CS, Ng GY, Ho TK, Klein J, Moore AM, Bohn D, Koren G: Discrepancies between ordered and delivered concentrations of opiate infusion in critical care. *Crit Care Med* 31: 2483-7, 2003.
- 779) Sivojelezova A, Einarson A, Shuhaiber S, Koren G: Motherisk Team. Trimethoprim-sulfonamide combination therapy in early pregnancy. *Can Fam Phys* 49: 1085-6, 2003.
- 780) French AE, Grant R, Weitzman S, Ray JG, Vermeulen MJ, Sung L, Greenberg M, Koren G: Folic acid food fortification is associated with a decline in neuroblastoma. *Clin Pharmacol Ther* 74: 288-94, 2003.
- 781) Michael O, Goldman RD, Koren G: Motherisk Team. Safety of colchicine therapy during pregnancy. *Can Fam Phys* 49: 967-9, 2003.
- 782) Koren G: Healthy children as subjects in pharmaceutical research. *Theor Med Bioeth.* 24: 149-59, 2003.
- 783) Sung L, Greenberg ML, Koren G, Tomlinson GA, Tong A, Malkin D, Feldman BM: Vitamin E: the evidence for multiple roles in cancer. *Nutr Cancer* 46: 1-14, 2003.
- 784) Larsen LA, Ito S, Koren G: Prediction of milk/plasma concentration ratio of drugs. *Ann Pharmacother* 37: 1299-306, 2003.

- 785) Ratnapalan S, Bona N, Koren G: Motherisk Team. Ionizing radiation during pregnancy. *Can Fam Phys* 49: 873-4, 2003.
- 786) Koren G, Matsui D, Bailey B: DEET-based insect repellents: safety implications for children and pregnant lactating women. *CMAJ* 169: 209-12, 2003.
- 787) Till C, Rovet JF, Koren G, Westall CA: Assessment of visual functions following prenatal exposure to organic solvents. *Neurotoxicol* 24: 725-31, 2003.
- 788) Kozer E, Verjee Z, Emelianova S, Koren G: A patient with seizures and a positive drug screen: three wrongs don't make a right. *Can J Clin Pharmacol* 10: 63-6, 2003.
- 789) Chandra K, Magee L, Einarson A, Koren G: Nausea and vomiting in pregnancy: results of a survey that identified interventions used by women to alleviate their symptoms. *J Psychosom Obstet Gynaecol* 24: 71-5, 2003.
- 790) Kozer E, Costei AM, Boskovic R, Nulman I, Nikfar S, Koren G: Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. *Birth Defects Res Part B Dev Reprod Toxicol* 68: 70-84, 2003.
- 791) Ratnapalan S, Potylitsina Y, Tan LH, Roifman M, Koren G: Measuring a toddler's mouthful: toxicologic considerations. *J Pediatr* 142: 729-30, 2003.
- 792) Moretti ME, Sgro M, Johnson DW, Sauve RS, Woolgar MJ, Taddio A, Verjee Z, Giesbrecht E, Koren G, Ito S: Cyclosporine excretion into breast milk. *Transplantation* 75: 2144-6, 2003.
- 793) Juurlink DN, Tenenbein M, Koren G, Redelmeier DA: Iron poisoning in young children: association with the birth of a sibling. *CMAJ* 168: 1539-42, 2003.
- 794) French AE, Koren G: Motherisk Team. Effect of methotrexate on male fertility. *Can Fam Phys* 49: 577-8, 2003.
- 795) French AE, Soldin SJ, Soldin OP, Koren G: Milk transfer and neonatal safety of tacrolimus. *Ann Pharmacother* 37: 815-8, 2003.
- 796) Shuhaiber S, Koren G, Boskovic R, Einarson TR, Soldin OP, Einarson A: Seroprevalence of Toxoplasma gondii infection among veterinary staff in Ontario, Canada (2002): Implications for teratogenic risk. *BMC Infect Dis* 3: 8, 2003.
- 797) Moretti ME, Koren G, Verjee Z, Ito S: Monitoring lithium in breast milk: an individualized approach for breast-feeding mothers. *Ther Drug Monit* 25: 364-6, 2003.
- 798) Chan D, Bar-Oz B, Pellerin B, Paciorek C, Klein J, Kapur B, Farine D, Koren G: Population baseline of meconium fatty acid ethyl esters among infants of nondrinking women in Jerusalem and Toronto. *Ther Drug Monit* 25: 271-8, 2003.
- 799) Ratnapalan S, Griffiths K, Costei AM, Benson L, Koren G: Digoxin-carvedilol interactions in children. *J Pediatr* 142: 572-4, 2003.

- 800) Koren G, King S, Knowles S, Phillips E: Ribavirin in the treatment of SARS: A new trick for an old drug? *CMAJ* 168: 1289-92, 2003.
- 801) Lyszkiewicz DA, Levichek Z, Kozar E, Yagev Y, Moretti M, Hard M, Koren G: Bioavailability of a pediatric amlodipine suspension. *Pediatr Nephrol* 18: 675-8, 2003.
- 802) Goldman RD, Koren G: Anorexia nervosa during pregnancy. *Can Fam Phys* 49: 425-6, 2003.
- 803) Boskovic R, Feig DS, Derewlany L, Knie B, Portnoi G, Koren G: Transfer of Insulin Lispro Across the Human Placenta: *In vitro* perfusion studies. *Diabetes Care* 26: 1390-4, 2003.
- 804) Goldman RD, Einarson A, Koren G: Electric shock during pregnancy. *Can Fam Phys* 49: 297-8, 2003.
- 805) Koren G, Navioz Y: Historical perspective: the original description of fetal alcohol spectrum disorder in France, 1967. *Ther Drug Monit* 25: 131, 2003.
- 806) Einarson A, Bonari L, Voyer-Lavigne S, Addis A, Matsui D, Johnson Y, Koren G: A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. *Can J Psych* 48: 106-10, 2003.
- 807) Chan B, Koren G: Pharmacological treatment for pregnancy women who smoke cigarettes. *Tobacco Induced Diseases* 1: 165-75, 2003.
- 808) Bonari L, Bennett H, Einarson A, Koren G: Risks of untreated depression during pregnancy. *Can Fam Phys* 50: 37-39, 2004.
- 809) Guttman R, Goldman RD, Koren G: Appendicitis during pregnancy. *Can Fam Phys* 50: 355-357, 2004.
- 810) Nava-Ocampo AA, Soldin OP, Koren G: Hypothyroidism during pregnancy. *Can Fam Phys* 50: 549-551, 2004.
- 811) Ahn E, Nava-Ocampo AA, Koren G: Multivitamin supplements for pregnant women. *Can Fam Phys* 50: 705-706, 2004.
- 812) Talaie H, Nava-Ocampo AA, Koren G: Antiretroviral treatment of maternal HIV infection. *Can Fam Phys* 50: 865-868, 2004.
- 813) Chan D, Caprara D, Blanchette P, Klein J, Koren G: Recent developments in meconium and hair testing methods for the confirmation of gestational exposures to alcohol and tobacco smoke. *Clin Biochem* 37: 429-438, 2004.
- 814) Chow LM, Capra M, Levichek Z, Koren G, Grant RM: Toxic ingestion of 6-mercaptopurine by young siblings of pediatric oncology patients. *J Pediatr* 144: 669-71, 2004.

- 815) Nava-Ocampo AA, Soldin OP, Koren G: Hypothyroidism during pregnancy. *Can Fam Phys* 50: 549-51, 2004.
- 816) Ratnapalan S, Bona N, Chandra K, Koren G: Physicians' perceptions of teratogenic risk associated with radiography and CT during early pregnancy. *AJR Am J Roentgenol* 182: 1107-9, 2004.
- 817) Nava-Ocampo AA, Velazquez-Armenta Y, Brien JF, Koren G: Elimination kinetics of ethanol in pregnancy women. *Reprod Toxicol* 18: 613-7, 2004.
- 818) Koren G, Avner M, Shear N: Generic isotretinoin: a new risk for unborn children. *CMAJ* 170: 1567-8, 2004.
- 819) Chan D, Klein J, Koren G: Validation of meconium fatty acid ethyl esters as biomarkers for prenatal alcohol exposure. *J Pediatr* 144: 692, 2004.
- 820) Ahn E, Nava-Ocampo AA, Koren G: Multivitamin supplements for pregnant women. New insights. *Can Fam Phys* 50: 705-6, 2004.
- 821) Koren G: Electrical remodeling and arrhythmias in long-QT syndrome: lessons from genetic models in mice. *Ann Med* 1: 22-7, 2004.
- 822) Goldman RD, Koren G: Amphotericin B nephrotoxicity in children. *J Pediatr Hematol Oncol* 26: 421-6, 2004.
- 823) Ipp M, Taddio A, Goldbach M, Ben David S, Stevens B, Koren G: Effects of age, gender and holding on pain response during infant immunization. *Can J Clin Pharmacol* 11: 2-7, 2004.
- 824) Baggley A, Navioz Y, Maltepe C, Koren G, Einarson A. Determinants of women's decision making on whether to treat nausea and vomiting of pregnancy pharmacologically. *J Midwifery Womens Health* 49: 350-4, 2004.
- 825) Nulman I, Rovet J, Kennedy D, Wasson C, Gladstone J, Fried S, Koren G: Binge alcohol consumption by non-alcohol-dependent women during pregnancy affects child behaviour, but not general intellectual functioning; prospective controlled study. *Arch Women Ment Health* 7: 173-81, 2004.
- 826) Gesundheit B, Grisar-Soen G, Greenberg D, Levizion-Korach O, Malkin D, Petric M, Koren G, Tendler MD, Ben-Zeev B, Vardi A, Dagan R, Engelhard D: Neonatal genital herpes simplex virus type 1 infection after Jewish ritual circumcision: modern medicine and religious tradition. *Pediatrics* 114: 259-63, 2004.
- 827) Einarson A, Bonari L, Sarkar M, McKenna K, Koren G: Exposure to sibutramine during pregnancy: a case series. *Eur J Obstet Gynecol Reprod Biol* 116: 112, 2004.
- 828) Koren G: Breakthrough in treating gestational diabetes mellitus. *Can Fam Phys* 50: 987-989, 2004.

- 829) Guttman R, Goldman RD, Koren G: Appendicitis during pregnancy. *Can Fam Phys* 50: 355-7, 2004.
- 830) Einarson A, Maltepe C, Navioz Y, Kennedy D, Tan MP, Koren G: The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. *BJOG* 111: 940-3, 2004.
- 831) Boskovic R, Rudic N, Danieliewska-Nikiel B, Navioz Y, Koren G: Is lack of morning sickness teratogenic? A prospective controlled study. *Birth Defects Res A Clin Mol Teratol* 70: 528-30, 2004.
- 832) Ahn E, Kapur B, Koren G: Iron bioavailability in prenatal multivitamin supplements with separated and combined iron and calcium. *J Obstet Gynaecol Can* 26: 809-14, 2004.
- 833) Pregnancy outcome following rubella vaccination: a prospective controlled study. *Am J Med Genet A* 130: 52-4, 2004.
- 834) Koren G, Maltepe C: Pre-emptive therapy for severe nausea and vomiting of pregnancy and hyperemesis gravidarum. *J Obstet Gynaecol* 24: 530-3, 2004.
- 835) Chan D, Klein J, Karaskov T, Koren G: Fetal exposure to alcohol as evidenced by fatty acid ethyl esters in meconium in the absence of maternal drinking history in pregnancy. *Ther Drug Monit* 26: 474-81, 2004.
- 836) Klein J, Blanchette P, Koren G: Assessing nicotine metabolism in pregnancy – a novel approach using hair analysis. *Forensic Sci Int* 145: 191-4, 2004.
- 837) Kozer E, Seto W, Verjee Z, Parshuram C, Khattak S, Koren G, Jarvis DA: Prospective observational study on the incidence of medication errors during simulated resuscitation in a paediatric emergency department. *BMJ* 329: 1321, 2004.
- 838) Oren D, Nulman I, Makhija M, Ito S, Koren G: Using corticosteroids during pregnancy. Are topical, inhaled, or systemic agents associated with risk? *Can Fam Phys* 50: 1083-5, 2004.
- 839) Laslo-Baker D, Barrera M, Knittel-Keren D, Kozer E, Wolpin J, Khattak S, Hackman R, Rovet J, Koren G: Child neurodevelopmental outcome and maternal occupational exposure to solvents. *Arch Pediatr Adolesc Med* 158: 956-61, 2004.
- 840) Koren G, Selby P, Kapur B: Is a fetus a non-consenting patient? *Can Fam Phys* 50: 1219-21, 2004.
- 841) Einarson A, Bonari L, Koren G: Pregnancy and antidepressant counseling. *Am J Psych* 161: 2137, 2004.
- 842) Hancock R, Koren G: Celiac disease during pregnancy. *Can Fam Phys* 50: 1361-3, 2004.

- 843) Cohen-Kerem R, Kisilevsky V, Einarson TR, Kozer E, Koren G, Rutka JA: Intratympanic gentamicin for Meniere's disease: a meta-analysis. *Laryngoscope* 114: 2085-91, 2004.
- 844) O'Brien L, Taddio A, Ipp M, Goldbach M, Koren G: Topical 4% amethocaine gel reduces the pain of subcutaneous measles-mumps-rubella vaccination. *Pediatrics* 114: 720-4, 2004.
- 845) Koren G: Welcome to cyberspace. *Can J Clin Pharmacol* 11: e1, 2004.
- 846) Aleksa K, Halachmi N, Ito S, Koren G: Renal ontogeny of ifosfamide nephrotoxicity. *J Lab Clin Med* 144: 285-93, 2004.
- 847) Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G: Perinatal risks of untreated depression during pregnancy. *Can J Psych* 49: 726-35, 2004.
- 848) Koren G, Shear N: Patient-physician-regulator triad. *CMAJ* 172: 18, 2005.
- 849) Boskovic R, Gargaun L, Oren D, Djulus J, Koren G: Pregnancy outcome following high doses of Vitamin E supplementation. *Reprod Toxicol* 20: 85-88, 2005.
- 850) Koren G, Caprara D, Jacobson S, Chan D, Portr K: Is it all right to drink a little during pregnancy? *Can Fam Phys* 50: 1643-4, 2004.
- 851) Groner J, Wadwa P, Hoshaw-Woodard S, Hayes J, Klein J, Koren G, Castile RG: Active and passive tobacco smoke exposure: a comparison of maternal and child hair cotinine levels. *Nicotine Tob Res* 6: 789-95, 2004.
- 852) Ahn E, Kapur B, Koren G: Study on circadian variation in folate pharmacokinetics. *Can J Clin Pharmacol* 12: e4-9, 2005.
- 853) Sarkar M, Djulus J, Koren G: When a cocaine-using mother wishes to breastfeed: proposed guidelines. *Ther Drug Monit* 27: 1-2, 2005.
- 854) Hard ML, Abdolell M, Robinson BH, Koren G: Gene-expression analysis after alcohol exposure in the developing mouse. *J Lab Clin Med* 145: 47-54, 2005.
- 855) Jacqz-Aigrain E, Koren G: Effects of drugs on the fetus. *Semin Fetal Neonatal Med* 10: 139-47, 2005.
- 856) Moretti ME, Bar-Oz B, Fried S, Koren G: Maternal hyperthermia and the risk for neural tube defects in offspring: systematic review and meta-analysis. *Epidemiol* 16: 216-9, 2005.
- 857) Sung L, Hayden J, Greenberg ML, Koren G, Feldman BM, Tomlinson GA: Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study. *J Clin Epidemiol* 58: 261-8, 2005.



- 858) Nava-Ocampo AA, Pastrak A, Cruz T, Koren G: Pharmacokinetics of high doses of cyanocobalamin administered by intravenous injection for 26 weeks in rats. *Clin Exp Pharmacol Physiol* 32: 13-8, 2005.
- 859) Gareri J, Chan D, Klein J, Koren G: Motherisk Team. Screening for fetal alcohol spectrum disorder. *Can Fam Phys* 51: 33-4, 2005.
- 860) Stempak D, Gammon J, Halton J, Champagne M, Koren G, Baruchel S: Modulation of celecoxib pharmacokinetics by food in pediatric patients. *Clin Pharmacol Ther* 77: 226-8, 2005.
- 861) Chun-Fai-Chan B, Koren G, Favez I, Kalra S, Voyer-Lavigne S, Boshier A, Shakir S, Einarson A: Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. *Am J Obstet Gynecol* 192: 932-6, 2005.
- 862) Many A, Koren G: Low-molecular-weight heparins during pregnancy. *Can Fam Phys* 51: 199-201, 2005.
- 863) Mirabella G, Westall CA, Asztalos E, Perlman K, Koren G, Rovet J: Development of contrast sensitivity in infants with prenatal and neonatal thyroid hormone insufficiencies. *Pediatr Res* 57: 902-7, 2005.
- 864) O'Brien L, Taddio A, Lyszkiewicz DA, Koren G: A critical review of the topical local anesthetic amethocaine (Ametop) for pediatric pain. *Paediatr Drugs* 7: 41-54, 2005.
- 865) Chan B, Einarson A, Koren G: Effectiveness of bupropion for smoking cessation during pregnancy. *J Addict Dis* 24: 19-23, 2005.
- 866) Hemels ME, Einarson A, Koren G, Lancot KL, Einarson TR: Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. *Ann Pharmacother* 39: 803-9, 2005.
- 867) Han JY, Nava-Ocampo AA, Koren G: Unintended pregnancies and exposure to potential human teratogens. *Birth Defects Res A Clin Mol Teratol* 73: 245-8, 2005.
- 868) Djulus J, Moretti M, Koren G: Marijuana use and breastfeeding. *Can Fam Phys* 51: 349-50, 2005.
- 869) Boskovic R, Gargaun L, Oren D, Djulus J, Koren G: Pregnancy outcome following high doses of Vitamin E supplementation. *Reprod Toxicol* 20: 85-8, 2005.
- 870) McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, Levinson A, Zipursky RB, Einarson A: Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. *J Clin Psychiatry* 66: 444-9, 2005.
- 871) Mills E, Montori V, Perri D, Phillips E, Koren G: Natural health product-HIV drug interactions: a systematic review. *Int J STD AIDS* 16: 181-6, 2005.

- 872) Schechter T, Finkelstein Y, Koren G: Pregnant "DES daughters" and their offspring. *Can Fam Phys* 51: 493-4, 2005.
- 873) Groner JA, Hoshaw-Woodard S, Koren G, Klein J, Castile R: Screening for children's exposure to environmental tobacco smoke in a pediatric primary care setting. *Arch Pediatr Adolesc Med* 159: 450-5, 2005.
- 874) Aleksa K, Matsell D, Krausz K, Gelboin H, Ito S, Koren G: Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity. *Pediatr Nephrol* 20: 872-85, 2005.
- 875) Einarson A, Koren G: SSRI's and other antidepressant use during pregnancy and potential neonatal adverse effects: Impact of a public health advisory and subsequent reports in the news media. *BMC Pregnancy Childbirth* 5: 11, 2005.
- 876) Koren G, Matsui D, Einarson A, Knoppert D, Steiner M: Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates? *CMAJ* 172: 1457-9, 2005.
- 877) Shrim A, Koren G: Tumour necrosis factor alpha and use of infliximab. Safety during pregnancy. *Can Fam Phys* 51: 667-8, 2005.
- 878) Bonari L, Koren G, Einarson TR, Jasper JD, Taddio A, Einarson A: Use of antidepressants by pregnant women: Evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making. *Arch Women Ment Health* Jun 17, 2005.
- 879) Taddio A, Soin HK, Schuh S, Koren G, Scolnik D: Liposomal lidocaine to improve procedural success rates and reduce procedural pain among children: a randomized controlled trial. *CMAJ* 172: 1691-5, 2005.
- 880) Tan MP, Koren G: Chickenpox in pregnancy: Revisited. *Reprod Toxicol* Jun 22, 2005.
- 881) Schechter T, Finkelstein Y, Doyle J, Koren G: Pregnancy after stem cell transplantation. *Can Fam Phys* 51: 817-8, 2005.
- 882) Selby P, Kapur B, Hackman R, Koren G: No one asked the baby – an ethical issue in placebo-controlled trials in pregnant smokers. *Can J Clin Pharmacol* 12: e180-1, 2005.
- 883) Lavi E, Sarkar M, Djulus J, Moretti M, Koren G: Characteristics of the callers to the Motherisk alcohol and substance use line. *J FAS Int* 3: e1, 2005.
- 884) Goh YI, Rovet J, Ungar W, Koren G: The antioxidant effect: Can we mitigate FASD with antioxidants? *J FAS Int* 3: e10, 2005.
- 885) Blondin B, Koren G: Frozen baby. *J FAS Int* 3: e5, 2005.
- 886) Koren G: February 2005 Surgeon General Statement on FASD – A Second Thought. *J FAS Int* 3: e16, 2005.

- 887) Koren G: Setting the record straight on drinking in pregnancy – A letter to the Editor of the National Post. *J FAS Int* 3: e8, 2005.
- 888) Eisner MD, Klein J, Hammond SK, Koren G, Lactao G, Iribarren C: Directly measured second hand smoke exposure and asthma health outcomes. *Thorax* 60: 814-21, 2005.
- 889) Boskovic R, Wide R, Wolpin J, Bauer DJ, Koren G: The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. *Neurology* 65: 807-11, 2005.
- 890) Berlin CM, LaKind JS, Fenton SE, Wang RY, Bates MN, Brent RL, Condon M, Crase BL, Dourson ML, Ettinger AS, Foos B, Furst P, Giacoia GP, Goldstein DA, Haynes SG, Hench KD, Kacew S, Koren G, Lawrence RA, Mason A, McDiarmid MA, Moy G, Needham LL, Paul IM, Pugh LC, Qian Z, Salamone L, Selevan SG, Sonawane B, Tarzian AJ, Rose Tully M, Uhl K: Conclusions and recommendations of the expert panel: technical workshop on human milk surveillance and biomonitoring for environmental chemicals in the United States. *J Toxicol Environ Health A*. 68: 1825-31, 2005.
- 891) LaKind JS, Brent RL, Dourson ML, Kacew S, Koren G, Sonawane B, Tarzian AJ, Uhl K: Human milk biomonitoring data: interpretation and risk assessment issues. *J Toxicol Environ Health A*. 68: 1713-69, 2005.
- 892) Raitlon CJ, Kapur B, Koren G: Subtherapeutic risperidone serum concentrations in an adolescent during hemodialysis: A pharmacological puzzle. *Ther Drug Monit* 27: 558-561, 2005.
- 893) Finkelstein Y, Schechter T, Rokach B, Koren G: Smoke Screen: Increase in movie stars' smoking on the big screen and its effect on teen smoking. *Ther Drug Monit* 27: 547-548, 2005.
- 894) Stempak D, Bukaveckas BL, Linder M, Koren G, Baruchel S: Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient. *Clin Pharmacol Ther* 78: 309-10, 2005.
- 895) Koren G, Piwko C, Ahn E, Boskovic R, Maltepe C, Einarson A, Navioz Y, Ungar WJ: Validation studies of the Pregnancy Unique-Quantification of Emesis (PUQE) scores. *J Obstet Gynaecol* 25: 241-4, 2005.
- 896) Tetelbaum M, Finkelstein Y, Nava-Ocampo AA, Koren G: Back to basics: understanding drugs in children: pharmacokinetic maturation. *Pediatr Rev* 26: 321-8, 2005.
- 897) Gesundheit B, Greenberg D, Walfish S, Dagan R, Koren G, Malkin D, Tendeler MD: Infectious complications with herpes virus after ritual Jewish circumcision: a historical and cultural analysis. *Harefuah* 144: 126-32, 2005.
- 898) Rezvani M, Koren G: Pregnancy outcome after exposure to injectable ribavirin during embryogenesis. *Reprod Toxicol* Aug. 22, 2005.

- 899) Kalra S, Einarson A, Koren G: Motherisk Team. Taking antidepressants during late pregnancy. How should we advise women? *Can Fam Physician* 51: 1077-8, 2005.
- 900) Gilbert CJ, Koren G: Safety of metformin use during the first trimester. *Can Fam Physician* 51: 1070-1073, 2005.
- 901) Cohen-Kerem R, Railton C, Oren D, Lishner M, Koren G: Pregnancy outcome following non-obstetric surgical intervention. *Am J Surg* 190: 467-73, 2005.
- 902) Finkelstein Y, Chitayat D, Schechter T, Keating S, Toi A, Koren G: Motherisk rounds. Warfarin embryopathy following low-dose maternal exposure. *J Obstet Gynaecol Can* 27: 702-6, 2005.
- 903) Florescu A, Koren G: Nonsteroidal anti-inflammatory drugs for rheumatoid arthritis during pregnancy. *Can Fam Physician* 51: 961-2, 2005.
- 904) Koren G: How to increase your funding chances: common pitfalls in medical grant applications. *Can J Clin Pharmacol* 12: e1 182-5, 2005.
- 905) Till C, Westall CA, Koren G, Nulman I, Rovet JF: Vision abnormalities in young children exposed prenatally to organic solvents. *Neurotoxicol* 26: 599-613, 2005.
- 906) Aleksa K, Halachmi N, Ito S, Koren G: A tubule cell model for ifosfamide nephrotoxicity. *Can J Physiol Pharmacol* 83: 499-508, 2005.
- 907) Gilbert C, Mazzotta P, Loebstein R, Koren G: Fetal Safety of drugs used in the treatment of allergic rhinitis: a critical review. *Drug Saf* 28: 707-19, 2005.
- 908) Feig DS, Briggs GG, Kraemer JM, Ambrose PJ, Moskovitz DN, Nageotte M, Donat DJ, Padilla G, Wan S, Klein J, Koren G: Transfer of glyburide and glipizide into breast milk. *Diabetes Care* 28: 1851-5, 2005.
- 909) Einarson A, Costei A, Kalra S, Rouleau M, Koren G: The use of topical 5% imiquimod during pregnancy: A case series. *Reprod Toxicol* July 20, 2005.
- 910) Chen N, Aleksa K, Woodland C, Rieder M, Koren G: Ontogeny of drug elimination by the human kidney. *Pediatr Nephrol* December 6, 2005.
- 911) Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A, Koren G: Citalpram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. *Am J Obstet Gynecol* 2005; 193: 2004-9.
- 912) Kozar E, Scolnik D, MacPherson A, Rauchwerger D, Koren G: Using a preprinted order sheet to reduce prescription errors in a pediatric emergency department: a randomized, controlled trial. *Pediatrics* 2005; 116: 1299-302.
- 913) Gedeon C, Koren G: Designing pregnancy centered medications: Drugs which do not cross the human placenta. *Placenta* November 25, 2005.

- 914) Caprara DL, Klein J, Koren G: Baseline measures of fatty acid ethyl esters in hair of neonates born to abstaining or mild social drinking mothers. *Ther Drug Monit* 2005; 27: 811-5.
- 915) Pinto N, Halachmi N, Verjee Z, Woodland C, Klein J, Koren G: Ontogeny of renal P-glycoprotein expression in mice: correlation with digoxin renal clearance. *Pediatr Res* 2005; 58: 1284-9.
- 916) Caprara DL, Brien JF, Iqbal U, Reynolds JN, Klein J, Koren G: A guinea pig model for the identification of *in utero* alcohol exposure using fatty acid ethyl esters in neonatal hair. *Pediatr Res* 2005; 58: 1158-63.
- 917) Finkelstein Y, Nurmohamed L, Avner M, Benson LN, Koren G: Clopidogrel use in children. *J Pediatr* 2005; 147: 657-661.
- 918) Koren G, Matsui D, Einarson A, Knopper D, Steiner M: Using antidepressants during pregnancy. *CMAJ* 2005; 173: 1205-1206.
- 919) Koren G: Congenital varicella syndrome in the third trimester. *Lancet* 2005; 366: 1591-2.
- 920) Shrim A, Berger H, Kingdom J, Hamoudi A, Shah PS, Koren G: Prolonged exposure to angiotensin-converting enzyme inhibitors during pregnancy. Fetal toxicity could be reversible. *Can Fam Physician* 2005; 51: 1335-7.
- 921) Robertson J, Polifka JE, Avner M, Chambers C, Delevan G, Koren G, Lavigne SV, Martinez LP, Miller RK, Carey JC: A survey of pregnant women using isotretinoin. *Birth Defects Res A Clin Mol Teratol* 2005; 73: 881-7.
- 922) Koren G: Teratogen Information Services – The Clinical Reason D'Etre. *Reprod Toxicol* 2004; 19: 241-2.
- 923) Koren G: The role of the Pharmaceutical industry in maternal-fetal toxicology. *Reprod Toxicol* 2004; 249-50.
- 924) Koren G: Cancer chemotherapeutic agents in pregnancy. *Reprod Toxicol* 2004; 12: 252-3.

#### BOOK CHAPTERS

- 1) Koren G: Calcium channel blockers. *American Assoc Clin Chem Ther Drug Monit*, 2:2, pp. 1-9, 1983.
- 2) Koren G, MacLeod SM: Pharmacologic modulation of endocrine neurotransmitters. *Clin Med, Harper & Row Pub. Philadelphia, Vol. 8, Chapt. 6, pp. 1-27, 1984.*
- 3) Soldin S, Koren G: Optimization of a therapeutic drug monitoring program. *Am Assoc Clin Chem - Ther Drug Monit, Vol. 2, (No. 8) pp. 1-6, 1984.*

- 4) Spielberg SP, Koren G: Drugs, chemicals and CNS malformations: Disorders of the developing nervous system. Editors: Drs. H.J. Hoffman, and F. Epstein. *Blackwell Scientific Publications*, pp. 301-312, 1986.
- 5) Koren G: Adjustment of antimicrobial dose schedule in renal failure. In: Antimicrobial therapy in infants and children (Koren G, Prober C, Gold R, editors), Marcel Dekker Inc., New York, pp 70-76, 1987.
- 6) Koren G, Soldin S: Digitalis glycosides. *Lab Med N Amer* 7:587 - 606, 1987.
- 7) Koren G: The clinical relevance of pharmacokinetic principles in antimicrobial therapy. In: Antimicrobial therapy in infants & children. (Koren G, Prober C, Gold R, editors). *Marcel Dekker Inc., New York*, pp 33-46, 1988.
- 8) Koren G: Clinical pharmacology of antimicrobial drugs during developments; How are infants and children different? In: Antimicrobial therapy in infants & children. (Koren G, Prober C, Gold R, editors). Marcel Dekker Inc., New York, pp 47-52, 1988.
- 9) Greenwald M, Koren G: Specific problems associated with drug administration in small infants. In: Antimicrobial therapy in infants & children. (Koren G, Prober C, Gold R, editors). Marcel Dekker Inc., New York, pp 99-104, 1988.
- 10) Koren G: Therapeutic drug monitoring of antimicrobial drugs in children. In: Antimicrobial therapy in infants and children. (Koren G, Prober C, Gold R, editors). Marcel Dekker Inc., New York, pp 77-88, 1988.
- 11) Koren G: Exposure of the embryo and fetus to antimicrobial agents. In: Antimicrobial therapy in infants and children. (Koren G, Prober C, Gold R, editors). Marcel Dekker Inc., New York, pp 89-98, 1988.
- 12) Koren G: Lincosamides. In: Antimicrobial therapy in infants and children. (Koren G, Prober C, Gold R, editors). Marcel Dekker Inc., New York, pp 355-372, 1988.
- 13) Shahar E, Koren G: Calcium channel blockers. In: *Pediatric Intensive Care (Nussbaum E, ed.) 2nd edition, Futura Publishing Co. NY* pp 871-886, 1989.
- 14) Rieder E, Koren G: The pharmacology of acute severe asthma. In: *Pediatric Intensive Care (Nussbaum E, ed.), Futura Publishing Co., NY 2nd edition*, pp 887-913, 1989.
- 15) Koren G, Levy M: Opioid use in children. In: *Pediatric Clinics of North America (Blummer J, Ried M, eds.)*, WB Saunders, Philadelphia. 36: 1141-1156, 1989.
- 16) Koren G: Topical skin anesthesia. In: *Clinics in Dermatology (Shear N, ed.)* 7: 136-141, 1989.
- 17) Koren G, Klein J, Bologa-Campeanu M: Developmental pharmacology of aminoglycosides and vancomycin. In: *Drug Toxicity and Metabolism in Pediatrics (Kacew S, ed.)*. CRC Uniscience, Boca Raton, Fl. pp 173-184, 1990.

- 18) Koren G: The need for a new approach. In: *Maternal - Fetal Toxicology*, (G Koren, ed.), Marcel Dekker, NY v-v1, 1990.
- 19) Koren G: Changes in drug disposition in pregnancy and their clinical relevance. In: *Maternal - Fetal Toxicology*, (G Koren, ed.), Marcel Dekker, NY 3-14, 1990.
- 20) Koren G: Teratogenic drugs and chemicals in humans. In: *Maternal - Fetal Toxicology*, (G Koren, ed.), Marcel Dekker, NY 15-28, 1990.
- 21) Koren G, Bologna M: Drugs and chemicals most commonly used by pregnant women. In: *Maternal - Fetal Toxicology*, (G Koren, ed.), Marcel Dekker, NY 29-52, 1990.
- 22) Smith J, Koren G: Drugs of choice in pregnancy. In: *Maternal - Fetal Toxicology*, (G Koren, ed.), Marcel Dekker, NY 53-62, 1990.
- 23) Koren G, Bologna M: Direct drug toxicity to the fetus. In: *Maternal - Fetal Toxicology*, (G Koren, ed.), Marcel Dekker, NY 115-142, 1990.
- 24) Koren G, Zalstein E: Occupational exposure to chemicals. In: *Maternal - Fetal Toxicology*, (G Koren, ed.), Marcel Dekker, NY 191-204, 1990.
- 25) Pellegrini E, Koren G: Motherisk I: A new model for counselling in reproductive toxicology. In: *Maternal -Fetal Toxicology*, (G Koren, ed.), Marcel Dekker, NY 355-372, 1990.
- 26) Koren G, Bologna M: The way pregnant women perceive their teratogenic risk and its influence on their decision to continue or terminate pregnancy. In: *Maternal - Fetal Toxicology*, (G. Koren, ed.), Marcel Dekker, NY 373-382-, 1990.
- 27) Koren G, Feldman Y, S. MacLeod: Motherisk II: Summary of first year. In: *Maternal - Fetal Toxicology*, (G Koren, ed.), Marcel Dekker, NY 383-402, 1990.
- 28) Koren G, Bologna-Campeanu M: Morphine infusion in neonates. In: *Current Therapy in Neonatal/Perinatal Medicine* (Nelson NM, ed.). BC Decker Inc., Toronto, 436-438, 1990.
- 29) Koren G, Brill Edwards M, Miskin M: Fetal malformations associated with drugs and chemicals: visualization by sonography. In: *Maternal-Fetal Toxicology*, (G. Koren, ed), Marcel Dekker NY, 297-308, 1990.
- 30) Koren G, Gordischer R: Digoxin. In: S. Yaffee, J. Aranda (eds.): *Pediatric Pharmacology*. WB Saunders, New York, 2nd Edition pp 355-364, 1992.
- 31) Gorodischer R, Koren G: Cardiac drugs. In: S. Yaffee, J. Aranda (eds.): *Pediatric Pharmacology*, WB Saunders, Philadelphia, 2nd Edition pp 345-354, 1992.

- 32) Jacobson S, Koren G: Drug administration in the newborn infants In: *Pediatric Pharmacology*, (Yaffe S, Aranda J, eds), WBS Saunders Co, Philadelphia *pp 178-182, 1992.*
- 33) Klein J, Pastuszak AL, Koren G: Clinical relevance of retinoid pharmacokinetics. In: *Retinoids in clinical practice*. Koren G (ed). Marcel Dekker, New York *pp. 129-146, 1993.*
- 34) Pastuszak A, Koren G: The retinoid pregnancy prevention program. In: *Retinoids in clinical practice*. Koren G (ed). Marcel Dekker, New York *pp. 147-176, 1993.*
- 35) Pastuszak AL, Koren G: Analysis of contraception failure in Canadian women treated with systemic retinoids. In: *Retinoids in clinical practice*. Koren G (ed). Marcel Dekker, New York *pp. 177-200, 1993.*
- 36) Koren G: A new approach to counseling women on their teratogenic risk. In: *Retinoids in clinical practice*. Koren G (ed) *pp. 201-208, 1993.*
- 37) Koren G: Isotretinoin benefits and risks; Assessment of the ration. In: *Retinoids in Clinical Practice*. Koren G (ed) *pp. 261-266, 1993.*
- 38) Koren G: Changes in drug disposition in pregnancy and their clinical implications. In: Koren G (ed): *Maternal-Fetal Toxicology*, 2nd edition, Marcel Dekker NY, *pp. 3-14, 1994.*
- 39) Koren G, Nulman I: Teratogenic drugs and chemicals in humans. In: Koren G (ed): *Maternal-Fetal Toxicology*, 2nd edition, Marcel Dekker NY *pp. 33-48, 1994.*
- 40) Scolnik D et al: The effects of phenytoin and carbamazepine monotherapy on infant's development. In: Koren G (ed): *Maternal-Fetal Toxicology*, 2nd edition, Marcel Dekker NY *pp. 49-58, 1994.*
- 41) Koren G et al: The safety on antidepressants in pregnancy. Koren G (ed): *Maternal-Fetal Toxicology*, 2nd edition, Marcel Dekker NY *pp 59-76, 1994.*
- 42) Pastuszak A, Koren G et al: Prospective assessment of pregnancy outcome following first-trimester exposure to benzodiazepines. Koren G (ed): *Maternal-Fetal Toxicology*, 2nd edition, Marcel Dekker NY *pp 79-88, 1994.*
- 43) Bologa M, Koren G et al: Drugs and chemicals most commonly used by pregnant women. Koren G (ed): *Maternal-Fetal Toxicology*, 2nd edition, Marcel Dekker NY *pp 89-114, 1994.*
- 44) Smith J et al: Drug of choice for pregnant women. Koren G (ed): *Maternal-Fetal Toxicology*, 2nd edition, Marcel Dekker NY *pp 115-128, 1994.*
- 45) Koren G et al: A multicenter, prospective study of fetal outcome following accidental carbon monoxide poisoning in pregnancy. Koren G (ed): *Maternal-Fetal Toxicology*, 2nd edition, Marcel Dekker NY *pp 253-266, 1994.*



- 46) Bologa M et al: Direct drug toxicity to the fetus. Koren G (ed): Maternal-Fetal Toxicology, 2nd edition, Marcel Dekker NY *pp 267-300, 1994.*
- 47) Lutiger B et al: Relationship between gestational cocaine use and pregnancy outcome. Koren G (ed): Maternal-Fetal Toxicology, 2nd edition, Marcel Dekker NY *pp 353-370, 1994.*
- 48) Graham K et al: Pregnancy outcome and infant development following gestational cocaine use by social cocaine user. Koren G (ed): Maternal-Fetal Toxicology, 2nd edition, Marcel Dekker NY *pp 371-386, 1994.*
- 49) Koren G et al: Biological markers of intrauterine exposure to cocaine and cigarette smoking. Koren G (ed): Maternal-Fetal Toxicology, 2nd edition, Marcel Dekker NY *pp 387-398, 1994.*
- 50) Bentur Y et al: Occupational exposures known to be human reproductive toxins. Koren G (ed): Maternal-Fetal Toxicology, 2nd edition, Marcel Dekker NY *pp 399-424, 1994.*
- 51) Bentur Y, Koren G: The common occupational exposures encountered by pregnant women. Koren G (ed): Maternal-Fetal Toxicology, 2nd edition, Marcel Dekker NY *pp. 425-446, 1994.*
- 52) Randor S, et al: Maternal fetal toxicology of medicinal plants. Koren G (ed): Maternal-Fetal Toxicology, 2nd edition, Marcel Dekker NY *pp. 447-514, 1994.*
- 53) Koren G, Nulman I: Fetal malformations associated with drugs and chemicals: Visualization by sonography. Koren G (ed): Maternal-Fetal Toxicology, 2nd edition, Marcel Dekker NY *pp 627-640, 1994.*
- 54) Gonen R et al: Maternal disorders leading to increased reproductive risks. Koren G (ed): Maternal-Fetal Toxicology, 2nd edition, Marcel Dekker NY *pp 641-682, 1994.*
- 55) Koren G, Pastuszak A: Teratogen information services. Koren G (ed): Maternal-Fetal Toxicology, 2nd edition, Marcel Dekker NY *pp 683-706, 1994.*
- 56) Pellegrini EM, Koren G: Motherisk I: A new model for counseling in reproductive toxicology. Koren G (ed): Maternal-Fetal Toxicology, 2nd edition, Marcel Dekker NY *pp 683-706, 1994.*
- 57) Koren G et al: The way women perceive teratogenic risk. Koren G (ed): Maternal-Fetal Toxicology, 2nd edition, Marcel Dekker NY *pp 727-736, 1994.*
- 58) Koren G et al: Motherisk II: The first year of counseling. Koren G (ed): Maternal-Fetal Toxicology, 2nd edition, Marcel Dekker NY *pp 737-756, 1994.*
- 59) Koren G et al: Use of EMLA in infants and children undergoing venipuncture. In: EMLA, A Breakthrough in Skin Anesthesia (G. Koren ed), Marcel Dekker NY, *pp 37-54, 1995.*

- 60) Koren G et al: Topical skin anesthesia for subcutaneous drug reservoir and lumbar punctures in children. In: *EMLA, A Breakthrough in Skin Anesthesia* (G. Koren ed), Marcel Dekker NY, pp 55-62, 1995.
- 61) Koren G et al: Use of EMLA cream and EMLA patch in outpatient clinics. In: *EMLA, A Breakthrough in Skin Anesthesia* (G. Koren ed), Marcel Dekker NY, pp 63-74, 1995.
- 62) Taddio A, Koren G: Effect of EMLA on infection and vaccination pain. In: *EMLA, A Breakthrough in Skin Anesthesia* (G. Koren ed), Marcel Dekker NY, pp 101-110, 1995.
- 63) Berkovitch M et al: A study investigating the use of EMLA for chronic subcutaneous drug administration. In: *EMLA, A Breakthrough in Skin Anesthesia* (G. Koren ed), Marcel Dekker NY, pp 187-192, 1995.
- 64) Koren G: The impact of EMLA on the ethics of pediatric research. In: *EMLA, A Breakthrough in Skin Anesthesia* (G. Koren ed), Marcel Dekker NY, pp 193-202, 1995.
- 65) Koren G: Perception of teratogenic risk by women and their physicians. In: (G. Koren, ed) *Folic acid for the prevention of neural tube defects. The Motherisk Program*, pp 47-49, 1995.
- 66) Chou S et al: Folic acid and prevention of neural tube defects; those who should know about it haven't heard yet. In: (G. Koren, ed) *Folic acid for the prevention of neural tube defects. The Motherisk Program*, pp 131-144, 1995.
- 67) Jacobson S et al: Availability of folic acid and knowledge about prophylactic use: A survey of urban pharmacies. In: (G. Koren, ed) *Folic acid for the prevention of neural tube defects. The Motherisk Program*, pp 151-154, 1995.
- 68) Koren G, Cohen MS: Special aspects of perinatal and pediatric pharmacology, In: *Basic & Clin Pharmacology* (Katzung BG, ed). Appleton & Lange, pp. 913-922, 1995.
- 69) Matsui D, Koren G: Perinatal toxicology. In: *Pediatrics & Perinatology - The Scientific Basis*, (Gluckman PD, Heymann MA, eds). Arnold, London, 2nd Edition pp968-970, 1996.
- 70) Matsui D, Koren G: Drug transfer into human milk. In: *Pediatrics & Perinatology - The Scientific Basis* (Gluckman PD, Hymann MA, ed). Arnold, London 2nd Edition. pp 971-972, 1996.
- 71) Scolnik D, Koren G: Principles of pharmacokinetics and pharmacodynamics. In: *Pediatrics & Perinatology - The Scientific Basis*. (Gluckman PD, Heymann MA, eds). Arnold, London, 2nd Edition pp 963-967, 1996.
- 72) Theis JGW, Koren G: Maternal and Fetal Clinical Pharmacology. In: *Avery's Drug Treatment*. 4th Edition (Speight TM, Holford NHG, eds) ADIS, Auckland, NZ, pp75-126, 1997.

- 73) Gladman DD, Koren G: Second line agents in rheumatic diseases during pregnancy. In: *Therapy of Systemic Rheumatic Disorder*. Marcel Dekker NY, pp. 657-666, 1998.
- 74) Koren G, Eliopoulos C, Klein J: Measuring fetal exposure to nicotine. In: (Benowitz NL, ed) *Nicotine Safety and Toxicity*. Oxford University Press, NY, pp 99-106, 1998.
- 75) Nulman I, O'Hayon B, Gladstone J, Koren D: The effects of alcohol on the fetal brain: The Central Nervous System Tragedy. In: (Slikker W, Chang L, eds). *Handbook of Developmental Neurotoxicology*, Academic Press, San Diego pp 567-586, 1998.
- 76) Kennedy D, Delaney KA, Koren G: Mutagens, Carcinogens and Teratogens. In: Goldfrank's Toxicologic Emergencies. Appleton & Lange, Stamford, CT. pp261-273, 1998.
- 77) Diav Citrin O, Ben David S, Koren G: Drug exposure during pregnancy and lactation. In: *Therapeutic choices*, 2nd Edition, (Jean Gray, ed), Canadian Pharmacists Association, Ottawa pp 577-584, 1998.
- 78) Kopecky EA, Koren G: Maternal drug abuse: Effects on the fetus and neonate. In: *Fetal and Neonatal Physiology*, (Polin RA, Fox WW, eds), Saunders, Philadelphia pp.203-219, 1998.
- 79) Diav-Citrin O, Koren G: Drug exposure during pregnancy and lactation. In: *Therapeutic Choices* (J Gray, Editor) 3rd Edition, Canadian Pharmacist Assoc. Ottawa, Ont., pp 916-924, 2000.
- 80) Mazzotta P, Magee L, Koren G: The association between abortion and nausea and vomiting of pregnancy. In: *Nausea and vomiting of pregnancy: State of the art 2000*. The Motherisk Program, Toronto. (G. Koren, R. Bishai, ed) pp. 149-150, 2000.
- 81) Mazzotta P, Magee L, Maltepe C, Lifshitz A, Navioz Y, Koren G: The perception of teratogenic risk by women with NVP. In: *Nausea and Vomiting of Pregnancy: State of the art 2000*. The Motherisk Program, Toronto. (G. Koren, R. Bishai, ed) pp. 157-173, 2000.
- 82) Emelianova S, Mazzotta P, Einarson A, Koren G: Prevalence and severity of NVP and effect of vitamin supplementation. In: *Nausea and vomiting of pregnancy: State of the art 2000*. The Motherisk Program, Toronto. (G. Koren, R. Bishai, etc.) pp. 174-180, 2000.
- 83) Koren G, Diav-Citrin O: Human teratogens: A clinical evaluation. In: *Nausea and vomiting of pregnancy: State of the art 2000*. The Motherisk Program, Toronto. (G. Koren, R. Bishai, ed) pp. 181-196, 2000.
- 84) Maltepe C, Magee LA, Einarson A, Bishai R, Mazzotta P, Koren G: Nausea and vomiting of pregnancy healthline. In: *Nausea and vomiting of pregnancy: State of the art 2000*. The Motherisk Program, Toronto. (G. Koren, R. Bishai, ed) pp. 201-202, 2000.

- 85) Loebstein R, Vohra S, Koren G: Drug therapy in pediatric patients. In: Melman & Morelli's Clinical Pharmacology, 4th Edition, (SG Carrauthers, ed). pp.117-1142, 2000.
- 86) Koren G: Special aspects of perinatal and pediatric pharmacology. In: Katzung BG, ed: Basic & Clinical Pharmacology. Lange Medical Books/McGraw-Hill. NY. 8th Edition, 2001.
- 87) Shilalukey K, Koren G: Special considerations in pregnant women In: Clinical Toxicology, (Ford, Delaney, Ling, Erickson, ed) WB Saunders, Philadelphia. pp. 101-110, 2001.
- 88) Lishner M, Koren G: Fetal risks of cancer chemotherapy in pregnancy. Allen HH, Nisker JA, Sutcliffe SB (eds). *MT Kisco, NY. Futura Publishing Company Inc. (In Press)*.
- 89) Koren G: Perinatal Toxicology. In: Textbook of Clinical Toxicology (Lovejoy F, McGuigan M, editors). In preparation.
- 90) Scolnik D, Koren G: Principles of pharmacokinetics and Pharmacodynamics In: Pediatric Pathophysiology (Gluckman & Heymann, eds), Edward Arnold, Ltd., London (*In Press*).
- 91) Matsui D, Koren G: Perinatal toxicology, In: Pediatric Pathophysiology. (Gluckman & Heymann, eds), Edward Arnold, Ltd, London (*In Press*).
- 92) Matsui D, Koren G: Drug transfer, into human milk, In: Pediatric pathophysiology, (Gluckman & Heymann, eds). Edward Arnold, Ltd, London (*In Press*).
- 93) Bentur Y, Koren G: Toxic effects of drugs and chemicals on the lungs. In: Textbook of Pediatric Pulmonology (Ed. Levison, Branski, Kerem). (*In Press*).
- 94) Koren G: Therapeutic drug monitoring principles in the neonate. Am Assoc Clin Chem-Ther Drug Monit (*In Press*).

#### COMMENTARIES, SHORT COMMUNICATIONS AND LETTERS

- 1) Koren G, Barzilay Z, Frand M, Brand: More on therapeutic failure with phenytoin in children. *Harefuah* 99:215, 1981.
- 2) Koren G: Theophylline and diet. *Pediatrics* 68:746, 1981.
- 3) Koren G: Quinidine-Digoxin interaction. *J Pharm Sci* 71:R2, 1982.
- 4) Koren G, Chin TWF: Hypothermia, alkalosis and barbiturate clearance. *J Pediatr* 102:643, 1983.
- 5) Koren G: Digoxin-verapamil interaction-Is it mutual? *Circulation* 67:707, 1983.

- 6) Koren G: The efficacy of racemic epinephrine in croup. *J Pediatr* 103:661, 1983.
- 7) Koren G: Cardiovascular effects of cimetidine. *Ann Int Med* 98:673, 1983.
- 8) Koren G: Predicting phenytoin serum concentrations. *Neurology* 33:1251-1252, 1983.
- 9) Koren G, Barzilay Z, Modan M: Errors in computing drug doses. *Pediatr Alert* 8:88, 1983.
- 10) Koren G: Renal tubular interactions of digoxin. *Am J Cardiol* 53:1208, 1984.
- 11) Koren G, Frand M, Barzilay Z, MacLeod SM: Corticosteroid treatment of laryngotracheitis vs spasmodic croup in children. *Family Practice Survey*, 1984.
- 12) Koren G: Steroid treatment of croup. *Am J Dis Child*, 138:699, 1984.
- 13) Koren G: Epilepsy refractory to anticonvulsants. *Neurology* 34:136, 1984.
- 14) Koren G, Frand M, Barzilay Z, MacLeod SM: Steroid behandlung der Laryngotracheitis bZW. der spastischen croup bei Kindern. *Extracta Pediatrica* 8:251-254, 1984.
- 15) Koren G, Frand M, Barzilay Z, MacLeod SM: Corticosteroid treatment of laryngotracheitis vs spasmodic croup in children. *Yearbook of Pediatrics*, 1984.
- 16) Koren G, Barzilay F, Modan M: Errors in computing drug doses. *Ped News*, 1984.
- 17) Zarfin Y, Koren G, Perlman M: Digoxin and indomethacin in preterm infants with PDA. *J Pediatr* 105:678, 1984.
- 18) Koren G: Laryngotracheitis and croup. *Amer J Dis Child* 138:992, 1984.
- 19) Koren G: Monitoring pediatric drugs. *Drug Intell Clin Pharm* 19:210, 1985.
- 20) Koren G: Aspirin therapy in Kawasaki disease. *J Pediatr* 106:859, 1985.
- 21) Koren G: Salicylates in Kawasaki disease. *J Pediatr* 106:859, 1985.
- 22) Koren G, Butt WW, Shear NH: Hypoxia with helium-oxygen therapy. *J Pediatr* 107:648, 1985.
- 23) Koren G: Acetylsalicylic acid and Kawasaki disease. *JAMA* 107:649-650, 1985.
- 24) Koren G: Theophylline clearance during viral infection. *J Resp Dis* 7:38-39, 1986.
- 25) Koren G: Embryopathy associated with retinoic acid. *N Engl J Med* 315:262, 1986.
- 26) Koren G, MacLeod SM: Difficulty in achieving therapeutic serum concentrations of salicylate in Kawasaki disease. *Year Book of Pediatrics* 1986.

- 27) Koren G, Barker R: Interpretation of excessive serum concentration of digoxin in children. *Year Book of Cardiology* 1986.
- 28) Rieder MJ, Goldstein DA, Koren G: VDT's: Is there a danger of radiation? *Can Med Assoc J* 135: 1986.
- 29) Koren G: A simple way to improve the acceptance rate of your scientific paper. *N Engl J Med* 315:1298, 1986.
- 30) Koren G: Errors in drug administration. *Pediatr* 79:171-172, 1987.
- 31) Rieder MJ, Goldstein DA, Zinman H, Koren G: Tenfold errors in drug dosage. *Can Med Assoc J* 139: 12-13, 1988.
- 32) Graham K, Koren G: Maternal cocaine use and risk of sudden infant death *J Pediatr* 115: 333, 1989.
- 33) Koren G: Toxic effects of atenolol consumed during breast feeding. *J Pediatr* 115: 336-337, 1989.
- 34) Koren G: Book Review "Pace of Mind During Pregnancy", *Amer J Dis Child* 143: 904, 1989.
- 35) Koren G: Concentrations of beta blocking drugs in human milk. *J Pediatr* 16: 156, 1990.
- 36) Koren G: Antibiotics and the premature neonate. *Ped Trauma & Acute Care* 3: 16, 1990.
- 37) Koren G, Randor S, Martin S, Danneman D: Maternal ginseng use associated with neonatal androgenization, *JAMA* 264: 2866, 1990.
- 38) Koren G: Clinical Pharmacology of EMLA. In: EMLA; A breakthrough in topical anesthesia. *Toronto, MES. 1990.*
- 39) Koren G: Uses of EMLA in pediatrics. In: EMLA: A breakthrough in topical anesthesia. *Toronto, MES. 1990.*
- 40) Koren G, Randor S, Martin S, Danneman D: Maternal ginseng use associated with neonatal androgenization, *JAMA* 264: 2866, 1990.
- 41) Koren G: Pharmacokinetics of mercaptopurine in children with acute lymphocytic leukemia. *N Engl J Med* 323: 1566, 1990.
- 42) Olivieri N, Koren G, Freedman MH, Roifman C: Rarity of systemic lupus erythematosus after oral iron chelator L<sub>4</sub>, *Lancet* 337: 924, 1991.
- 43) Koren G: Drinking and pregnancy. *Can Med Assoc J* 145: 1552, 1991.

- 44) Koren G: Maternal use of ginseng and neonatal androgenization. *JAMA* 265: 1828, 1991.
- 45) O'Brien J, Conover B, Frias J, Koren G, Quinn D, Robert E, Rosenwasser S: Formation of the organization of teratology information services (OTIS). *Reprod Toxicol* 5: 463, 1991.
- 46) Koren G: Lithium and pregnancy. *Lancet* 339: 869, 1992.
- 47) Koren G, Eliopoulos C: Getting the facts straight. *Can Med Assoc J* 147: 988, 1992.
- 48) Koren G: Validity of AAPCC data base. *J Clin Toxicol* 32: 101-102, 1994.
- 49) Koren G: Neurodevelopment after *in utero* exposure to phenytoin and carbamazepine. *JAMA* 272: 850-851, 1994.
- 50) Pastuszak AL, Koren G: Varicella infection in pregnancy. *N Engl J Med* 331: 482, 1994.
- 51) Koren G: Hair nicotine and cotinine in women and newborn infants. *JAMA* 271: 1904-1905, 1994.
- 52) Liao M, Ito S, Koren G: Silicone in breastmilk. *JAMA* 272: 769, 1994.
- 53) Ito S, Koren G: Antidepressants and breastfeeding. *Am J Psychiatr* 154: 1174, 1997.
- 54) Bailly B, Einarson A, Koren G: Alert over sound-alike drugs. *Can Med Assoc J* 157: 16-18, 1997.
- 55) Taddio A, Koren G: Lidocaine-Prilocaine cream over pain. *N Engl J Med* 337: 568-570, 1997.
- 56) Bailey B, Einarson A, Koren G: Cases of mistaken identity. *Can J Hosp Pharm* 50: 53-54, 1997.

#### **MEDICAL BOOKS**

- 1) Koren G, Prober C, Gold R: Antimicrobial therapy in infants and children. *Marcel Dekker Inc., New York*. 1987.
- 2) Koren G: Maternal - Fetal Toxicology; Clinician's Guide. *Marcel Dekker Inc., New York* 1990.
- 3) Koren G, MacLeod SM: The International Network of Pediatric Pharmacology Training Programs. *International Union of Pharmacology*, 1991.
- 4) Koren G: Textbook of Ethics in Pediatric Research. *Krieger, Florida*, 1993.

- 5) Koren G: Retinoids; The Risk Benefit Ratio. *Marcel Dekker, NY, 1993.*
- 6) Koren G: Maternal-Fetal Toxicology; A Clinician's Guide. *Second Edition, Marcel Dekker, New York, 1994.*
- 7) Koren G: The Parents' Guide to Poisons In The Home. *Stoddard Ltd., Toronto, 1994.*
- 8) Ito S, Koren G: Fetal Drug Therapy. *Clinics in Perinatology, WB Saunders, Philadelphia 1994.*
- 9) Koren G: Eutectic Mixture of Local Anesthetics; A breakthrough in skin anesthesia. *Marcel Dekker NY, 1994.*
- 10) Koren G: Folic acid and the prevention of neural tube defects. *The Motherisk Program, 1994.*
- 11) Koren G, Lishner M, Farine D (ed): Cancer in pregnancy; maternal and fetal risks. *Cambridge University Press UK, 1997.*
- 12) Koren G, Bailey B (ed): Pediatric Clinics of North America: New Frontiers in Pediatric Drug Therapy. *Saunders, NY, 1997.*
- 13) Koren G: The Children of Neverland. *The Kid In Us Publications, Toronto, 1997.*
- 14) Koren G, Diav-Citrin O: Paediatric Pharmacology: Towards evidence-based drug therapy. *Bailliere's Clinical Paediatrics, 1998.*
- 15) Koren G, Bishai R: NVP- State of the Art 2000. *Motherisk Program, 2000.*
- 16) Koren G: Maternal-Fetal Toxicology; A Clinician's Guide. *Third Edition, Marcel Dekker, New York, 2001.*
- 17) Steiner M, Koren G: Handbook of Female Psychopharmacology. *Martin Dunitz, London UK, 2003.*
- 18) Koren G, Nulman I: Motherisk Handbook for the Diagnosis of FASD. *Motherisk Program, 2003.*
- 19) Koren G: Everyday Risk during pregnancy and lactation. *Robert Rose, Toronto, 2005.*
- 20) Koren G, Lishner G, Santiago S: Cancer in pregnancy. *Second Edition, Motherisk Program, 2005.*

#### ABSTRACTS

- 1) Koren G, Frand M, Barzilay Z: Dexamethasone in laryngotracheitis. *Isr J Med Sci 18:214, 1980.*



- 2) Koren G, Barzilay Z, Modan M: Errors in computing drug dosages – an interdivisional study. *Isr J Med Sci* 18:548:1982.
- 3) Koren G, Brand N, Dani S, Halkin H: Determination of optimal phenytoin dosage in children by graphic analysis of Michaelis-Menten Kinetics. *Isr J Med Sci* 18:547, 1982.
- 4) Koren G, Shachar E, Rotem Y: Antipyretic efficiency of aspirin suppositories in children. *Isr J Med Sci* 18:544, 1982.
- 5) Koren G, Brand N, Dani S, Halkin H: A comparative study on bioavailability of locally produced phenytoin vs American. *Isr J Med Sci* 18:544, 1982.
- 6) Koren G, Brand N, Dani S, Halkin H: Correlation between phenytoin levels and antiepileptic effect in children. *Isr J Med Sci* 18:546, 1982.
- 7) Koren G, Boichis C, Keren G: Effects of tea on absorption of pharmacological doses of an oral iron preparation. *Isr J Med Sci* 18:547, 1982.
- 8) Koren G, Shahar E, Barzilay Z, Brand N, Dani S, Halkin H: Single dose intravenous phenytoin in the management and prevention of acute seizures in children. *Isr J Med Sci* 18:1070, 1982.
- 9) Sirota L, Koren G, Aladjem M: Accumulation of gentamicin in rats pretreated with digoxin. *Isr J Med Sci* 18:1074, 1982.
- 10) Aladjem J, Koren G, Aladjem M: Maturation of renal transport of gentamicin in the rat. *Isr J Med Sci* 18:1073, 1982.
- 11) Koren G, Halkin H, Shachar E, Barzilay Z, Brand N, Dani S: Disposition of intravenous phenytoin in children. *Clin Pharm Ther* 33:245, 1983.
- 12) Koren G, Halkin H, Shachar E, Barzilay Z, Brand N, MacLeod S: Phenytoin CSF levels in children. *Clin Pharm Ther* 33:245, 1983.
- 13) Koren G, Soldin S, MacLeod S: Digoxin verapamil interaction: *In vitro* studies in rat tissue. *Clin Pharm Ther* 33:208, 1983.
- 14) Koren G, Frand M, Barzilay Z, MacLeod SM: Corticosteroids in laryngotracheitis versus spasmodic croup in children. *Pediatr Res* 17:225A, 1983.
- 15) Koren G, Zarfin Y, Perlman M, MacLeod SM: Influence of indomethacin on digoxin pharmacokinetics in preterm infants. *Pediatr Res* 17:150A, 1983.
- 16) Koren G, Brand N, Dani S, Halkin H, MacLeod SM: The influence of impaired bioavailability on the Michaelis-Menten kinetics in children. *Neurology* 33[Suppl 2]:148, 1983.
- 17) Koren G, Shachar E, Barzilay Z, Brand N, Dani S, Halkin H: Intravenous phenytoin in children. *Pediatr Res* 17:150A, 1983.

- 18) Koren G, Soldin S, MacLeod SM: Interaction of digoxin with commonly coadministered drugs - Two different renal mechanisms. *Clin Res.* 31:249A, 1983.
- 19) Koren G, Soldin S, MacLeod SM: Digoxin amiodarone interaction. *In vivo* and *in vitro* studies in rat. Canadian Federation of Biological Societies. *Proceedings*, 26:57, 1983.
- 20) Koren G, Zarfin Y, Perlman M, MacLeod SM: Influence of indomethacin on digoxin pharmacokinetics in preterm infants. *II World Conference on Clinical Pharmacology and Therapeutics*. 32, 1983.
- 21) Hesslein PS, Costigan DC, Koren G, Holland FJ, MacLeod SM, Rowe RD: Oral amiodarone therapy in childhood-early experience. *Canadian Cardiovascular Society, Proceedings of the Annual Meeting, Toronto, October p 47, 1983.*
- 22) Koren G, Crean P, Goresky G, Klein J, MacLeod S: Improved pediatric fentanyl-dosing based on pharmacokinetics during cardiac surgery, *Clin Invest Med* 6:2, p 34, 1983.
- 23) Koren G, Soldin S, MacLeod SM: Interaction of digoxin with co-administered drugs: Two different renal mechanisms. *Clin Invest Med* 6:2, p 34, 1983.
- 24) Crean P, Goresky G, Koren G, Klein J, MacLeod SM, Roy L: Fentanyl pharmacokinetics in children with congenital heart disease. *Anesthesiology* 59:A448, 1983.
- 25) Hesslein PS, Costigan DC, Koren G, Holland FJ, MacLeod SM, Rowe RD: Oral amiodarone therapy in childhood: Early experience. *Pediatr Cardiol* 4:313, 1984.
- 26) Koren G, Crean P, Goresky G, Klein J, Villamater J, MacLeod SM: Irreversible binding of fentanyl to the cardiopulmonary bypass. *Anesth Analg* 63:236, 1984.
- 27) Koren G, Hesslein P, MacLeod SM: Kinetics of amiodarone associated digoxin toxicity in children. *Clin Pharmacol Ther* 35:252, 1984.
- 28) Crean P, Koren G, Goresky G, Klein J, Villamater J, MacLeod SM: Sequestration of fentanyl by the cardiopulmonary bypass. *Clin Pharmacol Ther* 35:232, 1984.
- 29) Shear H, Koren G, MacLeod SM: The role of the skin in the distribution of digoxin and in the digoxin-quinidine interaction. *J Invest Dermatol* 82:423, 1984.
- 30) Koren G, Weizman Z, Forstner G, Durie P: Plasma benzoyl-tyrosyl-PABA test in evaluating exocrine pancreatic function in CF: A pharmacokinetic approach. *Pediatr Res* 18:203A, 1984.
- 31) Koren G, Goresky G, Crean P, Klein J, MacLeod S: Unexpected abnormalities of fentanyl disposition in children undergoing cardiac surgery. *Pediatr Res* 18:154A, 1984.
- 32) Koren G, MacLeod S: Characteristics of digoxin interaction with quinidine, verapamil and amiodarone: *in vivo* and *in vitro* studies. *Pediatr Res* 18:154A, 1984.

- 33) Koren G, MacLeod S: Failure to achieve therapeutic ASA concentrations in children with Kawasaki disease. *Pediatr Res* 18:154A, 1984.
- 34) Shear NH, Koren G, MacLeod SM: The role of the skin in the distribution of digoxin and in the digoxin-quinidine interaction. *Clin Res* 34:615A, 1984.
- 35) Zarfin Y, Koren G, Maresky D, Perlman M, MacLeod SM: Indomethacin aminoglycoside interaction in preterm infants. *Clin Invest Med* 7:49, 1984.
- 36) Greenwald M, Koren G, Lavi S, MacLeod S, Gelfand E: Two methods for individualizing intrathecal drug therapy. *Clin Invest Med* 7:50, 1984.
- 37) Koren G, Leeder S, Harding E, MacLeod SM: Improved gentamicin dosing based on pharmacokinetics in preterm infants. *Clin Invest Med* 7:33, 1984.
- 38) Koren G, Soldin S, MacLeod SM: Optimization of a therapeutic drug monitoring (TDM) program. *Annals RCPSC*, 17:301, 1984.
- 39) Shear NH, MacLeod SM, Koren G: Cutaneous digoxin binding: An *in vitro* model for study of drug interaction. *Proceedings of the 9th International Congress of Pharmacology, London 1984. Abstract No. 87.*
- 40) Shear NH, St-Pierre MV, Koren G, Spielberg SP: Theophylline metabolism by keratinocytes *in vitro*. *Proceedings of the 6th International Symposium on Microsomes and Drug Oxidations, Brighton, England, P. 95, 1984.*
- 41) Koren G, Farine D, Maresky D, Heyes J, Soldin S, Taylor J, MacLeod SM: Significance of endogenous digoxin-like substance (EDLS) in newborns and mothers. *Clin Invest Med* 7(2) 35, 1984.
- 42) Koren G, Harding E, Rajchgot P, MacLeod S: Improved intravenous delivery of antibiotics for the newborn. *Clin Invest Med* 7(2) 36, 1984.
- 43) Collins C, Koren G, Crean P, Klein J, Roy WL, MacLeod SM: The correlation between fentanyl pharmacokinetics and pharmacodynamics in preterm infants during PDA ligation. *Anesthesiology A:422, 1984.*
- 44) Koren G, Crean P, Goresky G, Klein J, MacLeod SM: Fentanyl anesthesia for cardiac surgery in children: a) Fentanyl-oxygen vs. Fentanyl N2O; b) Relationship between drug concentrations and pharmacodynamics. *Anesthesiology A:444, 1984.*
- 45) Farine D, Koren G, MacLeod SM, Taylor J: Significance of the endogenous digoxin like substance in neonates and mothers. *Proceedings of ACOG district 5, 31 Annual Meeting, Toronto, Oct. 24, 1984.*
- 46) Farine D, Milligan J, Koren G, MacLeod SM, Taylor J: Characteristics of EDLS in neonates and their mothers. *Proceedings of the 8th Annual Ontario and Quebec Prenatal Investigators Meeting, Kingston, Ontario, Nov. 24, 1984.*

- 47) Soldin SJ, Papanastasiou-Diamandi A, Lingwood C, Heyes J, Koren G: Measurement of digoxin and digoxin-like factors: Problems and Pitfalls. *Eastern Analytical Symposium, New York, November, 1984.*
- 48) Koren G, Farine D, Maresky D, Taylor J, Heyes J, Soldin S, MacLeod SM: Endogenous digoxin like substance (EDLS) in newborns and mothers: Pharmacokinetic and Pharmacodynamic Implications. *Clin Pharmacol Ther* 37:205, 1985.
- 49) Koren G, Zarfin Y, Maresky D, Spiro T, MacLeod SM: Pharmacokinetics of intravenous clindamycin in newborn infants. *Clin Pharmacol Ther* 37:205, 1985.
- 50) MacLeod SM, Koren G, Chin T, Correia J, Tesoro A: Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. *Clin Pharmacol Ther* 37:209, 1985.
- 51) Koren G, Sloan J: The pharmacokinetics of N2O in children: A new approach to study inhaled anesthetics. *Proceedings of the American Academy of Pediatrics, Section of Anesthesiology, Spring Meeting, P 12, 1985.*
- 52) Koren G, Parker R, Spielberg SP, MacLeod SM: Interpretation of putatively toxic digoxin serum concentrations in children. *Ped Res* 19:175A, 1985.
- 53) Koren G, Soldin S, MacLeod SM: Endogenous digoxin-like substance(s) in newborn infants. *Ped Res* 19:175A, 1985.
- 54) Koren G, Rose V, Lavi S, Rowe R: Probable efficacy of high dose salicylate in reducing coronary involvement in Kawasaki disease. *Ped Res* 19:240A, 1985.
- 55) Koren G, Barker C, Bohn D, Kent G, Biggar D: The influence of hypothermia on the pharmacokinetics of gentamicin and theophylline in piglets. *Crit Care Med* 13:347, 1985.
- 56) Koren G, Barzilay Z: Ten-fold errors in computation of drug doses in children - a neglected iatrogenic disease. *Vet Hum Toxicol Aug. 1985.*
- 57) Koren G, Butt W, Chinyanga H, Soldin S, Pape K: Morphine-induced seizures in newborn infants. *Vet Hum Toxicol Aug. 1985.*
- 58) Koren G, Butt W, Mayer J, Pape K, MacLeod S: Paraldehyde pharmacokinetics and seizure control in newborn infants. *Clin Invest Med* 8:A57, 1985.
- 59) Koren G, James A, Perlman M: Assessment of GFR in the newborn using routine gentamicin pharmacokinetics. *Clin Invest Med* 8:A58, 1985.
- 60) Koren G, MacLeod S, Silverman M: Digoxin transport in dog kidney. *Clin Invest Med* 8:A152, 1985.

- 61) Greenwald M, Koren G: Decreased theophylline clearance in association with acute viral infection in children. *Clin Invest Med* 8:A183, 1985.
- 62) Strunin L, Sale JP, Goresky GV, Koren G: Pharmacokinetics of alfentanil in young children. *J Eur Acad Anesth*, Sept. 1985.
- 63) Koren G, Goresky G, Strunin L, Sale JP: Alfentanil-a pharmacokinetically predictable narcotic analgesic in children. *Clin Pharmacol Ther* 39:203, 1986.
- 64) Koren G, MacLeod SM, Silverman M: Digoxin interaction with quinidine and verapamil at the brush border of the dog kidney. *Clin Pharmacol Ther* 39:203, 1986.
- 65) James A, Koren G, Perlman SM: A simple method for determination of GFR with gentamicin. *Clin Pharmacol Ther* 39:200, 1986.
- 66) Whalen CC, Soldin SJ, Sulh H, Koren G, Greenberg M: Pharmacokinetic determinants of 6-MP, myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia. *AACC-CSCC*, 1986.
- 67) Koren G, MacLeod S, Silverman M: Application of novel in vivo and in vitro methods to study renal digoxin handling. *Clin Res* 45:200, 1986.
- 68) O'Calaghan AC, Koren G, Sloan JAJ: Effects of age and cardiac shunts on the rate of uptake of nitrous oxide in children. *Br J Anaesth* 58:1332P, 1986.
- 69) Koren G, Baker C, Klein J, Kent G, Bohn D, Biggar D, MacLeod SM: The effect of hypothermia on pharmacokinetics and response to drugs - animal and human studies. *Pediatr Res* 20:205A, 1986.
- 70) Koren G, MacLeod SM, Silverman M: Application of novel in vivo and in vitro methods to the study of renal digoxin handling. *Pediatr Res* 20:205A, 1986.
- 71) Koren G, Sulh H, Whalen C, Soldin S, Zipursky A, Greenberg M: Pharmacokinetic determinants of 6-mercaptopurine (6MP) myelotoxicity and therapeutic failures in children with acute lymphoblastic leukemia (ALL). *Pediatr Res* 20:205A, 1986.
- 72) Schaffer FM, Koren G, Duffy C, Cameron B, Silverman E, Stein L, Suria D, MacLeod SM, Gelfand EW, Laxer RM: Acute changes in bioavailability and clearance rate of ASA in Kawasaki disease. *Pediatr Res* 20:209A, 1986.
- 73) Koren G, Barzilay Z, Goldstein D: Tenfold errors in computation of drug doses in children - a neglected hiatrogenic disease. *Pedatar Res* 20:258A, 1986.
- 74) Ballin A, Koren G, Kohelet D, Bryan C, Zipursky A: Acute reduction in platelet counts in newborn infants induced by mechanical ventilation. *Pediatr Res* 20:387A, 1986.
- 75) Sale JP, Goresky GV, Koren G, Strunin L: Pharmacokinetics of alfentanil in children. *Anesth Analg* 65:5129, 1986.

- 76) Kirpalani H, Schmidt B, Koren G, Santos R, England S, Bryan AC: Pharmacokinetics and pulmonary function following a test dose of IV salbutamol in ventilated infants with BPD.
- 77) Kohelet D, Perlman M, Kirpalani H, Koren G, Bryan AC: Reduction in incidence of iatrogenic lung disease with early initiation of high frequency oscillation (HFO) for persistent pulmonary hypertension (PPNH).
- 78) Koren G, MacLeod S, Silverman M: Application of novel in vivo and in vitro methods to the study of renal digoxin handling. Proceedings of The III World Conference on Clinical Pharmacology and Therapeutics. *Stockholm, Abstract 1034, July 1986.*
- 79) Koren G, Sulh H, Whalen C, Soldin S, Zipursky A, Greenberg M: Pharmacokinetic determinants of 6-MP myelotoxicity and therapeutic failures in children with acute lymphoblastic leukemia. Proceedings of the III World Conference on Clinical Pharmacology and Therapeutics. *Stockholm, Abstract 852, July 1986.*
- 80) Long D, Koren G, James A: How many blood samples are required for accurate determination of pharmacokinetics in newborn infants? *Clin Invest Med 9:A129, 1986.*
- 81) James A, Koren G, Milliken J, Soldin S, Prober CG: Vancomycin pharmacokinetics and dose recommendations for preterm infants. *Clin Invest Med 9:A89, 1986.*
- 82) Koren G, Klein J, MacLeod SM, Silverman M: Digoxin handling by the renal tubular cell. *Clin Invest Med 9:A16, 1986.*
- 83) Koren G, Klein J, MacLeod S, Silverman M: Cellular mechanisms of digoxin transport and toxic interactions in the kidney. *Vet Hum Toxicol 28:497-498, 1986.*
- 84) Koren G, Klein J, MacLeod S, Silverman M: Digoxin handling by the renal tubular cell. *Clin Res 34:867A, 1986.*
- 85) Koren G, Kirpalani H, Schmidt B, Santos R, Kwang TY, Soldin S, England S, Bryan CA: Pharmacokinetics and respiratory pharmacodynamics of IV salbutamol in neonates with BPD. *Pediatr Res 21:236A, 1987.*
- 86) Koren B, Peters M, Jakubovic D, Zipursky A: The effect of physicians' compliance on relapse rate in ALL in children. *Pediatr Res 21:236A, 1987.*
- 87) Long D, Koren G, James AG: Ethical considerations in pharmacokinetic studies in neonates. *Pediatr Res 21:238A, 1987.*
- 88) Koren G, Litwack J: Ethics of drug studies in neonates. How many samples should be permitted for pharmacokinetic analysis? *Pediatr Res 21:284A, 1987.*
- 89) Ballin A, Brown EJ, Koren G, Zipursky A: Vitamin C induced erythrocyte damage in premature infants: human and animal studies. *Pediatr Res 21:406A, 1987.*

- 90) Kohelet D, Perlman M, Kirpalani H, Koren G: Reduced incidence of BPD with early initiation of HFO for persistent pulmonary hypertension of the newborn. *Pediatr Res* 21:456A, 1987.
- 91) Koren G, Vaisman N, Goldstein DA, Yok-Kwang T, Soldin S, Pencharz P: Pharmacokinetics and pharmacodynamics of inhaled salbutamol in patients with CF. *Pediatr Res* 21:503A, 1987.
- 92) Koren G, Klein J, Dayan R, MacLeod SM, Silverman M: Simultaneous inhibition of renal tubular and biliary transport of digoxin. *Clin Invest Med* 10: B57, 1987.
- 93) Long DR, Roberts EA, Brill-Edwards M, Quaggin S, Correia J, Koren G, MacLeod SM: The effect of oral contraceptive Ortho 777 on theophylline clearance in non smoking women aged 18 - 22. *Clin Invest Med* 10: B59, 1987.
- 94) Koren G, Feldman Y, Bologa-Campeanu M: Motherisk, a new approach to drug/chemical induced teratogenicity. *Clin Invest Med* 10: B56, 1987.
- 95) Koren G, Klein J: Enhancement of digoxin clearance by mannitol diuresis: In Vivo and In Vitro studies and their clinical implications. *Vet Hum Toxicol* 29:484, 1987.
- 96) Koren G, Bologa-Campeanu M, Rieder M, McGuigan M: Drugs and chemicals most commonly concerning pregnant women: The Motherisk experience. *Vet Hum Toxicol* 29:469, 1987.
- 97) Dupuis LL, Laxer RM, Koren G, Soldin S, Shore A, Silverman ED: Methotrexate - NSAID's drug interaction in children with juvenile arthritis. *Arthr Rheumat* 31:1988.
- 98) Koren G, Klein J, Giesbrecht E, Soldin SJ: The effect of mannitol on digoxin handling; *in vivo* and *in vitro* studies in the dog. *Clin Pharmacol Ther* 43:155, 1988.
- 99) Koren G, Long D, Klein J: The effects of prematurity and hyperkalemia on membrane  $\text{Na}^+\text{K}^+\text{ATPase}$ . *Ped Res* 23:259A, 1988.
- 100) Koren G, Klein J, Giesbrecht E, Soldin S, MacLeod SM, Silverman M: The effects of quinidine on the renal tubular and biliary transport of digoxin. *Ped Res* 23:259A, 1988.
- 101) Koren G, Feldman Y, Mattice D, Shear N, Pellegrini E, MacLeod SM: Determinants of recall and recall bias in studies of drug exposure in pregnancy. *Ped Res* 23:268A, 1988.
- 102) Halperin DS, Koren G, Wyss M: Topical anesthesia for venipuncture in children. *Ped Res* 23:320A, 1988.
- 103) Koren G, Lau A, Klein J, Golas C, Bologa-Campeanu M, Soldin S, Prober C, MacLeod SM: Pharmacokinetics, dose recommendations and safety of amphotericin B in infants and children. *Proceedings of the 1st meeting of the European Society for Developmental Pharmacology, Abst. No. 10, 1988.*

- 104) Koren G, Barker C, Bohn D, Kent G, McGuigan M, Biggar D: The effect of hypothermia on the pharmacokinetics of ethanol in piglets. *Vet Hum Toxicol* 30:356, 1988.
- 105) Bentur Y, Koren G, McGuigan M, Spielberg S: An unusual skin exposure to copper; clinical and pharmacokinetic evaluation. *Vet Hum Toxicol* 30:361, 1988.
- 106) Bentur Y, Koren G, Klein J, Tesoro A, Leeder S: Pharmacokinetics and nephrotoxicity of deferoxamine. *Vet Hum Toxicol* 30:371, 1988.
- 107) Graham K, Dimitrakoudis D, Pellegrini E, Koren G: Outcome of pregnancy following first trimester exposure to cocaine. *Vet Hum Toxicol* 30:376, 1988.
- 108) Koren G, Bologa Campeanu M, Long D, Feldman Y, Henderson K, Shear N: The perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. *Teratology* 37:472, 1988.
- 109) Koren G, Lau A, Klein J, Bologa-Campeanu M, Soldin S, Prober C, MacLeod SM: Pharmacokinetics, dose recommendations and safety of amphotericin B in infants and children. *Clin Invest Med* 11:C171, 1988.
- 110) Koren G, Bologa-Campeanu M, Pellegrini EM, Long D, Feldman Y, Henderson K, Shear N: The perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. *Clin Invest Med* 11:C20, 1988.
- 111) Bentur Y, Koren G, Klein J, Tesoro A, Leeder S: Preliminary studies into the mechanisms of desferal neuro- and nephrotoxicity. *Clin Invest Med* 11:C20, 1988.
- 112) Dorian P, Koren G, Klein J, Sborowska Sluis D, Ogilvie RI: Cyclosporine decreases digoxin clearance. *Clin Invest Med* 11:D73, 1988.
- 113) Bentur Y, Koren G, Tesoro A, Freedman M: Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children vs those exhibiting severe neurotoxicity. *Clin Pharmacol Ther* 45: 134, 1989.
- 114) Bentur Y, Koren G, Tesoro A, Freedman M: Relationship between neurotoxicity and pharmacokinetics of deferoxamine in children with thalassemia major. *Ped Res* 25: 64A. 1989.
- 115) Koren G, Langevin AM, Olivieri N, Giesbrecht E, Zipursky A, Greenberg M. Diurnal variation in 6-mp pharmacokinetics and myelotoxicity in children with leukemia. *Ped Res* 25: 69A.1989.
- 116) Olivieri NF, Koren G, Freedman MH, St Louis P, Panicucci R, McLelland RA: Randomized, cross over comparison of iron excretion between desferoxamine (DFO) and the new oral chelator 1,2 Dimethyl -3- hydroxypyrid -4- one (Pediater Res L.). 25: 71A, 1989.



- 117) Graham K, Koren G, Klein J, Schneiderman J: Detecting maternal exposure to cocaine by hair analysis. *Ped Res* 25: 764, 1989.
- 118) Koren G, Pastuzak A: Ethical boundaries of medical research in infants and children in the eighties: analysis of studies rejected by the review board of a large pediatric hospital. *Ped Res* 133A, 1989.
- 119) Koren G, Olivieri NF, Freedman M, St Louis P, Panicucci R, McLelland RA: Randomized, cross over comparison of iron excretion between desferoxamine (DFO) and the new oral chelator 1, 2 Dimethyl -3- hydroxypyrid -4- one (L<sub>1</sub>). *Eur J Clin Pharmacol* 36: A43, 1989.
- 120) Klein J, Koren G, Bentur Y, Chung D, Moselhy G: The effect of organic anions and cations on the renal tubular transport of cisplatin. *Eur J Clin Pharmacol* 36: A76, 1989.
- 121) Pop R.D., Hummel D, Koren G, Spino M, Roifman C: Individual dose tailoring of IgG replacement for patients with hypogammaglobinemia. *Clin Invest Med* 12: B16, 1989.
- 122) Levy M, Koren G, Egerseg P, Strong A, Tesoro A, Spino M, Bannantyne R, Fear D, Pornic D: Pharmacokinetic analysis of cloxacillin loss in children undergoing major surgery with massive bleeding. *Clin Invest Med* 12: B16, 1989.
- 123) Duffy C, Levy M, Pollock P, Budd E, Caulfield L, Koren G: Home based palliative care: a feasibility study. *Clin Invest Med* 12: B17, 1989.
- 124) Duffy C, Levy M, Pollock P, Budd E, Koren G: Home based palliative care: a cost saving manoeuvre. *Clin Invest Med* 12: B17, 1989.
- 125) Duffy K, Levy M, Pollock P, Koren G: Home based palliative care: Parental satisfaction with an existing program. *Clin Invest Med* 12: B17, 1989.
- 126) Graham K, Koren G, Klein J, Schneiderman J: Detecting maternal exposure to cocaine by hair analysis. *Clin Invest Med* 12: B13, 1989.
- 127) Koren G, Langevin AM, Olivieri N, Giesbrecht A, Zipursky A, Greenberg M: Diurnal variation in 6-MP pharmacokinetics and myelotoxicity in children with leukemia. *Clin Invest Med* 12: B13, 1989.
- 128) Koren G, Olivieri N, Freedman M, St. Louis P, Panicucci R, McClelland R: Randomized, cross over comparison of iron excretion between deferoxamine and L<sub>1</sub>: *Clin Invest Med* 12: B14, 1989.
- 129) Zalstein E, Koren G, Gow R, Freedom RM, Finley JP, Virmani S, Rosenberg HC: Efficacy and safety of propafenone in children. *Clin Invest Med* 12: (5) C73, 1989.
- 130) Freedman MH, Bentur Y, Koren G: Biological and toxic properties of deferoxamine. The 10th congress of the International Society of Haematology. Jerusalem, Israel, September 1989.

- 131) Bentur Y, Stone J, Zalstein E, Soldin S, Koren G: The effect of endogenous digoxin like substances on the interpretation of excessive digoxin concentrations in children. *Ped Res* 27: 57A, 1990.
- 132) Derewlany LO, Leeder JS, Kumar R, Radde I, Knie B, Koren G: The transport of digoxin across the perfused human placental lobule. *Ped Res* 27: 58A, 1990.
- 133) Koren G, Ferrazini G, Langevin AM, Sulh H, Kapelushnik J, Giesbrecht E, Soldin S, Greenberg M: Variability in 6-MP exposure: A prognostic factor in low and standard risk acute lymphocytic leukemia in children. *Ped Res* 27: 61A, 1990.
- 134) Graham K, Klein J, Koren G: Determinants affecting accumulation of cocaine in maternal and neonatal guinea pig hair. *Ped Res* 27: 68A, 1990.
- 135) Graham K, Koren G, Feigenbaum A, Weksberg R, Einaron T, Goldberg S, Ashby S: Pregnancy outcome and infant development following gestational cocaine use by social cocaine users in Toronto, Canada. *Clin Invest Med* 13: B14, 1990.
- 136) Bologa M, Klein J, Tang B, Koren G: Pregnancy induced changes in drug metabolism in epileptics. *Clin Invest Med* 13: B14, 1990.
- 137) Klein J, Koren G, Bentur Y, Chung D, Moselhy C: The effect of organic anions and cations on the renal tubular transport of cisplatin. *Clin Invest Med* 13: B14, 1990.
- 138) Levy M, Koren G, Dupuis L, Read SE: Vancomycin induced Red Man syndrome in children. *Clin Invest Med* 13: B15, 1990.
- 139) Bentur Y, Stone J, Zalstein E, Soldin S, Koren G: Falsely high digoxin concentrations in children: the role of endogenous digoxin like substances. *Clin Invest Med* 13: B16, 1990.
- 140) Ito S, Harper P, Koren G: Transport mechanisms of digoxin and ouabain by a renal tubular cell line (LLC-PK1). *Clin Invest Med* 13: B17, 1990.
- 141) Weitzman S, Klein J, Koren G: Pharmacokinetics of carboplatinum in an anephric child with recurrent Wilms' tumor. *Proceedings of ASCO volume 10, page 116, March 1991.*
- 142) Robieux I, Dorian P, Klein J, Cheung D, Ogilvie R, Koren G: The effect of cardiac transplantation and cyclosporine therapy on digoxin pharmacokinetics. *Clin Pharmacol Ther* 49: 140-143, 1991.
- 143) Klein J, Chung D, Hermann C, Matsui D, St. Louis P, Olivieri N, Koren G: Pharmacokinetics and iron excretion of the new oral iron chelator L<sub>1</sub> in thalassemic children. *Clin Pharmacol Ther* 49: 162, 1991.
- 144) Koren G, Olivieri N, Hermann C, Matsui D: Use of the medication event monitor system in evaluation of a new therapy; assessment of children's compliance, *Clin Pharmacol Ther* 49: 163, 1991.

- 145) Robieux I, Koren G: Measuring pain and analgesia in infants. *Clin Pharmacol Ther* 49: 163, 1991.
- 146) Ito S, Harper P, Koren G: Digoxin transport by monolayer renal tubular cells (LLC-PK1). *Clin Pharmacol Ther* 49: 170, 1991.
- 147) Shore RW, Geary D, Koren G, Weitzman S, Greenberg M: Iphosphomide related nephrotoxicity in children, *Proceedings of ASCO, volume 10, March 1991*.
- 148) Ito S, Harper P, Koren G: Digoxin transport by renal tubular cells (LLC-PK1). *Ped Res* 29: 60 A, 1991.
- 149) Koren G, Forman R, Graham K, Schneiderman J, Klein J: Hair test: Biological markers for gestational exposure to cigarette smoking and cocaine. *Ped Res* 29: 61A, 1991.
- 150) Koren G, Matsui D, Hermann C, Chung D, Klein J, Grunau V, DuPuis L, Olivieri N: Correlation between pharmacokinetics and iron excretion pharmacodynamics of the new oral chelator L4. *Ped Res* 29: 61A, 1991.
- 151) Koren G, Olivieri N, Hermann C, Matsui D: Use of the medication event monitor system in evaluation of a new therapy: Assessment of children's compliance. *Ped Res* 29: 61A, 1991.
- 152) Robieux I, Koren G: Measuring pain and analgesia in infants. *Ped Res* 29: 61A, 1991.
- 153) Koren G, Bologna M, Klein J, Tang B: Pregnancy-induced changes in drug metabolism in epileptics. *Ped Res* 29: 70A, 1991.
- 154) Robieux I, Kellner JD, Coppes M, Shaw D, Brown L, Olivieri NF, Koren G, Zipursky A: Continuous intravenous infusion of morphine for painful sickle cell crises. *Ped Res* 29: 61A, 1991.
- 155) Gallie BL, Koren G, Thorner PS, Verjee Z, Haddad E, Giesbrecht E, Greenberg ML, Ling V, Koren HSL: Reversal of multi-drug resistance (MDR) in retinoblastoma by cyclosporine A. *9th International society of Genetic Eye Disease*.
- 156) Chan HSL, Thorner PS, Weitzman S, Solh H, Koren G, Thiessen J, Haddad G, Giesbrecht E, Verjee Z, Greenberg ML, Gallie BL, Ling V: Cyclosporine A for reversal of multi-drug resistance in childhood malignancies. *Proceedings of Amer Assoc Cancer Research* 33: 2854.
- 157) Olivieri NF, Koren G, Freedman MH, St. Louis P, Panicucci R, McClelland RA. Effective iron chelation with the oral agent 1,2-dimethyl-3-hydroxypyrid-4-one (L1). *Clin Res* 37: 385A, 1989.
- 158) McGee A, Liu P, Benson L, Koren G, Olivieri N. Cardiac disease free survival in thalassemia major patients receiving deferoxamine: *An update of the Toronto Cohort. Blood* 74 (7): Suppl 1, 311A, 1989.

- 159) Olivieri NF, Koren G, Hermann C, Klein J, Chung D, Bentur Y, McClelland R, St. Louis P, Templeton D. Iron chelation with L<sub>1</sub>: Iron balance and dose response studies. *Blood* 74 (7): (Suppl 1) 51A, 1989.
- 160) Olivieri NF, Koren G, Klein J, Freedman MH, Hermann C, Matsui D, Chung D, Templeton DA: Oral Iron Chelation with 1,2-Dimethyl-3-Hydroxypyrid-4-One (L<sub>1</sub>) in Thalassemia Major (TM): Pharmacokinetics, Safety, and Iron Excretion, *Blood* 76 (10) Suppl 1, 72A. 1990.
- 161) Olivieri NF, Koren G, Matsui D, Templeton D. Oral iron chelation with L<sub>1</sub> in thalassemia major: a comparison with the efficacy of subcutaneous deferoxamine over one year of therapy. In Press, *Blood*, 1991.
- 162) Olivieri NF, Koren G, Matsui D, Blendis L, Cameron R, McClelland RA, Templeton D. Normalization of serum ferritin concentration and demonstrated reduction of tissue iron stores with the use of L<sub>1</sub>. In Press, *Blood*, 1991.
- 163) Matsui D, Klein J, Koren G, Olivieri N: Relationship between pharmacokinetics and pharmacodynamics of L<sub>1</sub> in Thalassemia major patients. *Clin Invest Med* 14: 17A, 1991.
- 164) Ito S, Harper PA, Koren G: Transepithelial transport of digoxin by renal tubular cells. *Clin Invest Med* 14: 18A, 1991.
- 165) Neuman MG, Yang S, Randor S, Koren G, Roberts EA: Protective effect of silymarin on the hepatocellular toxicity of acetaminophen in human cell line in vitro. *Clin Invest Med* 14: 20A, 1991.
- 166) Forman R, Koren G, Graham K, Schneiderman J, Klein J: Hair test: Biological markers for gestational exposure to cigarette smoking and cocaine. *Clin Invest Med* 14: 20A, 1991.
- 167) Morrison C, Rieder MJ, Natale R, Koren G: Comparison between utilization patterns of referred and non referred teratogen information services in Ontario. *Clin Invest Med* 14: 20A, 1991.
- 168) DeLamoy IAM, Hol, Koren G, Silverman M: Cyclosporin inhibition of the renal transport of digoxin: in vivo studies in the dog, *Clin Invest Med* 14: 129A, 1991.
- 169) Ito S, Harper PA, Koren G: Energy-dependent secretory transport of digoxin by renal tubular cells (LLC-PK1). *Clin Pharmacol Ther* 51: 137, 1992.
- 170) Matsui D, Olivieri N, Koren G, Templeton D, Liu P: Use of the new oral iron chelator L<sub>1</sub> in thalassemia patients. *Clin Pharmacol Ther* 51: 144, 1992.
- 171) Forman R, Klein J, Graham K, Schneiderman J, Koren G: Hair test: Biological markers for gestational exposure to cigarette smoking and cocaine. *Clin Pharmacol Ther* 51: 155, 1992.

- 172) Ondrusek N, Abranovitch R, Koren G: Children's ability to volunteer for non therapeutic research. *Ped Res* 31: 26A, 1992.
- 173) Ito S, Harper PA, Koren G, Silverman M: Mechanism of digoxin secretion by renal tubular cells. *Ped Res* 31: 61A, 1992.
- 174) Simone C, Derewlany LO, Koren G: Acetylcholinesterase activity in the human placenta: Implications for fetal cocaine exposure. *Ped Res* 31: 66A, 1992.
- 175) Jacobson SJ, Jones KL, Johnson K, Ceolin L, Kaus P, Sahn D, Donnenfeld A, Rieder M, Santelli R, Pastuszak A, Koren G: A prospective multicenter study of pregnancy outcome following lithium exposure during the first trimester of pregnancy. *Ped Res* 31: 69A, 1992.
- 176) Dagan O, Margalit D, Barak I, Koren G: Is there a need for lumbar puncture in simple febrile convulsion - A prospective study. *Ped Res* 31: 212A, 1992.
- 177) Johnson D, Schuh S, Koren G, Jaffe D: The acute treatment of croup with aerosolized dexamethasone. *Ped Res* 31: 123A, 1992.
- 178) Peled N, Dagan O, Babyn P, Silver M, Barker J, Hellman J, Koren G: Neonatal gastric outlet obstruction induced by prostaglandin therapy. *Ped Res* 31: 237A, 1992.
- 179) Simone C, Derewlany L, Knie B, Koren G: Can the human placenta biotransform cocaine? *Clin Invest Med* 15: A19, 1992.
- 180) Ito S, Koren G: Exposures of pregnant health care workers to ribavirin through inhalation of contaminated air. *Clin Invest Med* 15: A20, 1992.
- 181) Ito S, Blajchman A, Schtury N, Stephenson M, Eliopoulos C, Koren G: Prospective followup of adverse reactions in breastfed infants exposed to maternal medications. *Clin Invest Med* 15: A21, 1992.
- 182) Taddio A, Robieux I, Nulman I, Koren G, Reid E: Efficacy of lidocaine-prilocaine cream on pain from SC and IM injection. *Clin Invest Med* 15: A21, 1992.
- 183) Matsui D, Olivieri N, Koren G, Templeton D, Liu P: Use of the new oral iron chelator L4 in thalassemia patients. *Clin Invest Med* 15: A21, 1992.
- 184) Scolnik D, Nulman I, Rovet J, Koren G: A prospective, controlled study of developmental outcome following in utero exposure to phenytoin and carbamazepine monotherapy. *Clin Invest Med* 15: A21, 1992.
- 185) Forman R, Graham K, Greenwald M, Schneiderman J, Klein J, Koren G: Detection of gestational cocaine exposure in Toronto using hair analysis. *Clin Invest Med* 15: A21, 1992.

- 186) Shilalukey K, Koren G, Robieux I, Spino M, Greenwald M: Are current pediatric dose recommendations for intravenous theophylline appropriate? *Clin Invest Med* 15: A21, 1992.
- 187) Dagan O, Bohn D, Gruenwald C, Barker G, Koren G: Evaluation of the effect of ECMO on drug levels. *Clin Invest Med* 15: A22, 1992.
- 188) Pennie RA, Koren G, Crevoisier C: Steady state pharmacokinetics of mefloquine in long term travellers. *Clin Invest Med* 15: A74, 1992.
- 189) Dagan O, Peled N, Kroen G, Barker G: Neonatal gastric obstruction induced by prostaglandins. *Clin Invest Med* 15: A118, 1992.
- 190) Pastuszek A, Koren G, Rieder M: Utilization of the isotretinoin pregnancy prevention program; compliance with contraception guidelines. *Clin Invest Med* 15: A119, 1992.
- 191) Dupuis LL, Koren G, Silverman ED, Laxer R: Influence of food on the bioavailability of oral methotrexate. *Amer College of Rheumatology*, 1992, *Abstr* 133, 1992.
- 192) Berkovitch M, Laxer RM, Matsui D, Frizler MJ, Hedden D, Pilavkzic D, Koren G, Klein J, Templeton D, Pritzker KPH, Olivieri N: Analysis of adverse rheumatological effects of iron chelators. *Blood* 78: 70, 1992.
- 193) Olivieri N, Matsui D, Berkovitch M, Templeton DM, McClelland RA, Wanless I, Blendis L, Liu PP, Koren G: Superior effectiveness of L<sub>1</sub> vs desferal in beta thalassemia. *Blood* 78: 344a, 1992.
- 194) Neuman MG, Koren G, Tiribelli C: Epomediol prevents the *in vitro* ethanol-induced cytotoxicity on the human hepatocyte Hep G2 cell line. *J. Hepatology, EASL, Supplement*, 1, 16, T 147, S105, 1992.
- 195) Neuman MG, Koren G, Tiribelli C: Epomediol reduces *in vitro* ethanol-induced cytotoxicity on human hepatocytes Hep G2 cell line. *J. Basic & Clinical Physiology & Pharmacology, Supplement*, Vol. 3, P 145, 288, 1992.
- 196) Neuman MG, Koren G, Katz A, Tiribelli C: Epomediol reduces *in vitro*, ethanol-induced hepatocytotoxicity, on Hep G2 cell line. *THE FASEB J. Abs.* 4863, A842, 1993.
- 197) Neuman MG, Koren G, Pencharz P, Katz A, Tiribelli C: Ethanol cytotoxicity is reversed by epomediol in Hep G2 cells. *Clinical Biochemistry*, Vol. 26, 2, Abs. 8, 125, 1993.
- 198) Neuman MG, Koren G, Katz A, Tiribelli C: Epomediol protective effect on ethanol cytotoxicity *in vitro* human hepatocytes Hep G2 cell line. *Therapeutic Drug Monitoring*, Vol. 15, 2, Abs. 20, 163, 1993.
- 199) Neuman MG, Koren G, Katz A, Tiribelli C: Epomediol reduces *in vitro* ethanol-induced hepatocytotoxicity on HEP G2 cell line. *Alcohol Metabolism* (4858-4863), 1993.

- 200) Sandler A, Baxter A, Katz J, Samson B, Roger S, Hull K, Friedlander M, Koren G: Postoperative analgesia with transdermal fentanyl: analgesic, respiratory and pharmacokinetic effects. *Can Anaesth Assoc J (In Press)*.
- 201) Neuman ME, Pencharz PB, Koren G, Katz A, Tiribelli C: Ethanol increases apolipoproteins A and B in Hep G2 cell line: Effect of epomediol. *J Hepatol 16: S105, 1992*.
- 202) Rovet J, Scolnik D, Nulman I, Altmann D, Koren G: Does maternal epilepsy increase the risk of adverse neurodevelopmental outcome in children. *4th Florida Conference on Child Health Psychology, Gainesville, FL, April 22, 1993*.
- 203) Ito S, Woodland C, Harper P, Koren G: Verapamil-digoxin interaction in renal tubular cells (LLC-PK1). *Ped Res 33: 65A, 1993*.
- 204) Simone C, Derewlany L, Oskamp M, Koren G: Placental metabolism and transplacental pharmacokinetics of cocaine: Perfusion studies with the human placental cotyledon. *Ped Res 33: 69A, 1993*.
- 205) Nulman I, Scolnik D, Rovet J, Gladstone D, Czuchta D, Gardner A, Gladstone R, Ashby P, Weksberg R, Einarson T, Koren G: Pregnancy outcome and neurodevelopment of children exposed in utero to antiepileptics: Prospective, blinded assessment of phenytoin and carbamazepine monotherapy. *Ped Res 33: 73A, 1993*.
- 206) Berkovitch M, Laxer RM, Matsui D, Fritzler MJ, Hedden D, Piloykzic D, Koren G, Klein J, Templeton DM, Pritzker PH, Olivieri NF: Analysis of adverse rheumatologic effects of iron chelators in patients with homozygous beta thalassemia. *Ped Res 33: 136A, 1993*.
- 207) Olivieri NF, Matsui D, Berkovitch M, Templeton D, McClelland R, Wanless I, Blendis L, Liu P, Koren G: Superior effectiveness of L<sub>1</sub> vs deferoxamine in patients with beta thalassemia: The impact of patient compliance during two year therapy. *Ped Res 33: 144A, 1993*.
- 208) Pastuszak AL, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihm S, Donnenfeld A, McCormack M, Leen-Mitchell M, Woodland C, Hom A, Gardner A, Koren G: A prospective, multicentre study of pregnancy outcome following first trimester exposure to fluoxetine (Prozac). *Clin Invest Med 16: B15, 1993*.
- 209) Taddio A, Ito S, Einarson T, Leeder JS, Koren G: Effect of patient counselling on the incidence of clinical events reported to the Motherisk Program. *Clin Invest Med 16: B20, 1993*.
- 210) Ito S, Woodland C, Harper P, Koren G: The mechanism of the verapamil-digoxin interaction *in vitro*. *Clin Invest Med 16: B21, 1993*.
- 211) Simone C, Derewlany L, Oskamp M, Knie B, Koren G: Transfer of cocaine and benzoylecgonine by the perfused human placenta. *Clin Invest Med 16: B22, 1993*.

- 212) Eliopoulos C, Klein J, Phan MK, Knie B, Greenwald M, Chitayat D, Koren G: Hair analysis- a biological marker for fetal exposure to gestational smoking. *Clin Invest Med* 16: B22, 1993.
- 213) Fassos F, Koren G, Klein J, Fernandes D, Matsui D, Olivieri N: Correlation between pharmacokinetics and iron excretion pharmacodynamics of  $L_1$  in homozygous  $\beta$ -thalassemia patients. *Clin Invest Med* 16: B22, 1993.
- 214) Stobie S, Tyberg J, Matsui D, Fernandes D, Klein J, Olivieri N, Koren G: Comparison of the pharmacokinetics of  $L_1$  in healthy volunteers with and without co-administration of ferrous sulfate and in thalassemia patients. *Clin Invest Med* 16: B22, 1993.
- 215) Joshi P, Koren G, King S, Klein J, McLeod K: Pharmacokinetic study of acyclovir in immunocompromised children. *Clin Invest Med* 16: B23, 1993.
- 216) Matsui D, Olivieri N, Berkovitch M, Templeton D, Wanless I, Blendis L, Liu P, Koren G: Effective iron chelation using oral iron chelator  $L_1$ . *Clin Pharmacol Ther* 53: 145, 1993.
- 217) Klein J, Phan MK, Knie B, Greenwald M, Chitayat D, Koren G: Hair analysis-a biological marker for fetal exposure to gestational smoking. *Clin Pharmacol Ther* 53: 149, 1993.
- 218) Ito S, Koren G: Maternal medications and breastfeeding behavior. *Clin Pharmacol Ther* 53: 150, 1993.
- 219) Ito S, Woodland C, Harper P, Koren G: The mechanism of the verapamil-digoxin interaction *in vitro*. *Clin Invest Med* 16: B22, 1993.
- 220) Joshi P, Koren G, King S, Klein J, McLeod K: Pharmacokinetic study of acyclovir in immunocompromised children. *Clin Invest Med* 16: B22, 1993.
- 221) Simone C, Derewlany L, Oskamp M, Knie B, Koren G: Transfer of cocaine and benzoylecgonine by the perfused human placenta. *Clin Invest Med* 16: B23, 1993.
- 222) Eliopoulos C, Klein J, Phan MK, Knie B, Greenwald M: Hair analysis: A biological marker for fetal exposure to gestational smoking. *Clin Invest Med* 16: B23, 1993.
- 223) Stobie S, Tyberg J, Matsui D, Fernandes D, Klein J, Olivieri N, Koren G: Comparison of the pharmacokinetics of 1,2-Dimethyl-3-hydroxypyrid-4-one ( $L_1$ ) in healthy volunteers with and without co-administration of ferrous sulfate and in thalassemia patients. *Clin Invest Med* 16: B23, 1993.
- 223) Fassos F, Koren G, Klein J, Fernandes D, Matsui D, Olivieri NF: Correlation between pharmacokinetics and iron excretion pharmacodynamics of 1,2-dimethyl-3-hydroxypyrid-4-one ( $L_1$ ). In homozygous  $\beta$ -thalassemia (HBT) patients (PTS). *Clin Invest Med* 16: B24, 1993.



- 224) Johnson D, Simone C, Derewlany LO, Oskamp M, Koren G: Transplacental pharmacokinetics of N-acetyl-L-cysteine in the perfused human placental cotyledon. *Vet Hum Toxicol* 35 (4): 365, 1993.
- 225) Jacobson S, Kopecky EA, Joshi P, Martin M, Koren G: A retrospective review of a paediatric palliative care program. *Clin Invest Med* 17: A23, 1994.
- 226) Magee LA, Conover B, Schick B, Sage S, Cook L, Raman Williams L, Koren G: Exposure to calcium channel blockers in human pregnancy. A prospective, controlled, multicentre cohort study. *Teratology* 49: 372, 1994.
- 227) Pastuszak AL, Klein J, Koren G: Detection of retinoic acid in the placenta up to 1 month after therapy. *Teratology* 49: 375, 1994.
- 228) Magee LA, Taddio A, Downar E, Sermer M, Boulton BC, Cameron D, Rosengarten M, Waxman M, Allen LC, Koren G: Pregnancy outcome following gestational exposure to amiodarone. *Teratology* 49: 398, 1994.
- 229) Pastuszak AL, Levy M, Shick B, Zuber C, Feldkamp M, Gladstone J, BarLevy F, Jackson E, Mechino W, Koren G: Pregnancy outcome following maternal varicella infection in the first 20 weeks of gestation. A controlled multicentre study. *Teratology* 49: 399, 1994.
- 230) Eliopoulos C, Klein J, Phan MK, Knie B, Greenwald M, Chitayat D, Koren G: Nicotine and cotinine concentrations in maternal and neonatal hair following cigarette smoke exposure during pregnancy. *Ped Res* 35: 83A, 1994.
- 231) Schwartz H, Johnson D, Forman R, Klein J, Jacobson S, Greenwald M, Koren G: Assessment of *in utero* exposure to cocaine. *Ped Res* 35: 88A, 1994.
- 232) Taddio A, Gazarian M, Klein J, Kent G, Koren G: Metabolism of prilocaine to orthotoluidine in newborn piglets. *Ped Res* 35: 89A, 1994.
- 233) Berkovitch M, Pastuszak AL, Gazarian M, Lewis M, Koren G: Safety of quinolones in pregnancy. *Ped Res* 35: 91A, 1994.
- 234) Pastuszak AL, Levy M, Sick B, Zuber C, Feldkamp M, Gladstone J, BarLevy F, Jackson E, Meschino W, Koren G: Pregnancy outcome following maternal varicella. *Ped Res* 35: 92A, 1994.
- 235) Taddio A, Ito S, Koren G: Excretion of fluoxetine and its metabolite in human breast milk. *Ped Res* 35: 149A, 1994.
- 236) Berkovitch M, Brittenham GM, Koren G, Olivieri NH: Need for early, low dose chelation therapy in young children with transfused thalassemia. *Ped Res* 35: 157A, 1994.

- 237) Berkovitch M, Meydan N, Donsky J, Collins AF, Sher G, Matsui D, Koren G, Hackman R, Roifman C, Olivieri NF: Detailed investigation of immune function in thalassemia patients receiving L<sub>1</sub>. *35: 158A, 1994.*
- 238) Berkovitch M, Olivieri NF, Brittenham GM, Koren G: Reduction in hepatic iron stores with L<sub>1</sub>. *Ped Res 35: 158A, 1994.*
- 239) Joshi P, Koren G, King S, Klein J, McLeod K: Pharmacokinetic study of acyclovir in immunocompromised children. *Ped Res 35: 183A, 1994.*
- 240) Ondrusek N, Abramovitch R, Azcue M, Pencharz P, Koren G: Children's assent to clinical research. *Proceedings of Can Bioethics Soc 1994.*
- 241) Davies HD, King SM, Doyle J, Matlow A, Koren G, Hamilton R, Portwine C: Randomized, blinded controlled pilot study of rapid amphotericin B infusions in children. *ICCAC, 1994.*
- 242) Matsui D, Berkovitch M, Olivieri NF, Koren G: Reduction in hepatic iron stores with L<sub>1</sub>. *Clin Pharmacol Ther 55: 175, 1994.*
- 243) Gazarian M, Klein J, Kent G, Koren G: Systemic exposure to prilocaine and lidocaine after penile absorption of EMLA cream. *Clin Pharmacol Ther 55: 176, 1994.*
- 244) Ito S, Moretti M, Leu M, Koren G: Initiation and duration of breastfeeding in women receiving antiepileptics. *Clin Pharmacol Ther 55: 177, 1994.*
- 245) Klein J, Eliopoulos C, Chitayat D, Zelazo P, Koren G: Hair analysis: a biological marker for fetal exposure to substances of abuse. *Clin Pharmacol Ther 55: 178, 1994.*
- 246) Nulman I, Rovet J, Altmann D, Bradley C, Einarson T, Koren G: Neurodevelopment of adopted children exposed in utero to cocaine. *Can Med Assoc J 151: (11), 1994.*
- 247) Otton SV, Droll K, Klein J, Koren G, Chaudhari S, Sellers EM: Lower frequency of the drug metabolizing cytochrome P450 2D6 deficiency phenotype in a cocaine dependent population. In: NIDA Research Monograph. Problems of drug dependence College Inc. *1994.*
- 249) Fassos FF, Berkovitch M, Daneman N, Koren L, Cameron R, Klein J, Falcitelli C, St. Louis P, Koren G: The oral iron chelator deferiprone prevents mortality following acute iron intoxication in rats. *J Clin Toxicol 33: 498, 1995.*
- 250) Theis JW, Koren G: Camphorated oil - still endangering the lives of Canadian children. *Clin Invest Med 18: A38, 1995.*
- 251) Blowey DL, Moncica I, Scolnik D, Arbus GS, Hebert D, Balfe JW, Koren G: Felodipine compliance, blood pressure control and pharmacokinetics in hypertensive children. *Clin Invest Med 18: A51, 1995.*

- 252) Berkovitch M, Matsui D, Sher G, Hdzialic G, Olivieri N, Koren G: Pharmacokinetics of arginine butyrate in hemoglobinopathy patients. *Eur J Pharmacol (In Press)*.
- 253) Agro K, Devlin J, Makarchian N, Trepanier E, Einarson T, Koren G: Moderate alcohol consumption and perinatal risks. *Proceedings of Can Pharmacopidemiology Forum, Montreal, 1995*.
- 254) Theis J, Chur M, Koren G: The mechanism underlying anaphylactoid reactions to high dose cyclosporine infusions in children. *Clin Pharmacol Ther* 59: 144; 1996.
- 255) Diav Citrin O, Atanackovic G, Olivieri N, Koren G: Pharmacokinetic/dynamic of decreased long-term effectiveness of deferiprone. *Clin Pharmacol Ther* 59: 150, 1996.
- 256) Woodland C, Ito S, Koren G: The contribution of propafenone metabolites to the digoxin-propafenone interaction in MDCK renal tubular cells. *Clin Pharmacol Ther* 59: 155: 1996.
- 257) Nulman I, Rovet J, Stewart D, Kulin NA, Koren G: Neurodevelopment of children exposed to fluoxetine in utero: A prospective longitudinal study. *Clin Pharmacol Ther* 59: 159: 1996.
- 258) Nulman I, Klein J, Berkovitch M, Lester RS, Shear N, Koren G: Pharmacokinetics of isotretinoin and its 4-oxo metabolite at steady state. *Clin Pharmacol Ther*, 59: 200; 1996.
- 259) Chattergoon DS, Verjee Z, Johnson D, Ito S, Koren G: Carbamazepine interference with tricyclic antidepressant assays. *Clin Pharmacol Ther* 59: 214, 1996.
- 260) Loebstein R, Zahid N, Diav-Citrin O, Atanackovic G, Utrecht J, Koren G: Deferiprone-induced agranulocytosis: A possible mechanism. *Clin Pharmacol Ther* 61: 139, 1997.
- 261) Theis JGW, Chan HSL, Greenberg ML, Malkin D, Karaskov V, Moncica I, Koren G, Doyle J: Toxicity assessment in children receiving cancer chemotherapy with cyclosporine. *Clin Pharmacol Ther* 61: 145, 1997.
- 262) Diav-Citrin O, Atanackovic G, Loebstein R, Koren G: Investigation of variability in response to deferiprone. *Clin Pharmacol Ther* 61: 146, 1997.
- 263) Bayley B, Lee A, Addis A, Lau M, Koren G: Cisapride use during pregnancy. *61: 169, 1997*.
- 264) Escobar MR, Woodland C, Ito S, Koren G: Cisplatin interaction with organic cation uptake by opossum kidney. *Clin Pharmacol Ther* 61: 216, 1997.
- 265) Klein J, Bailey B, McMartin KI, Morris P, Koren G: Transplacental kinetics of cocaine and benzoylecgonine in plasma and hair of Rhesus monkeys. *Clin Pharmacol Ther* 61: 222, 1997.

- 266) Kopecky EA, Simone C, Derewlany LO, Knie B, Koren G: Naloxone does not alter the transfer of morphine across the human term placenta perfused *in vitro*. *Clin Invest Med* 19: 510, 1996.
- 267) Taddio A, Oskamp M, Ito S, Bryan H, Farine D, Ryan D, Koren G: Is nifedipine used during labor and breastfeeding safe for the neonate? *Clin Invest Med* 19: 511, 1996.
- 268) Klein J, McMartin KI, Morris P, Koren G: Incorporation of cocaine into maternal and fetal hair following chronic cocaine exposure throughout pregnancy. *Clin Invest Med* 19: 511, 1996.
- 269) McMartin KI, Klein J, Platt MS, Koren G: The effect of tobacco smoking on nicotine and cotinine levels in lung tissue of SIDS and non SIDS cases. *Clin Invest Med* 19: 511, 1996.
- 270) Woodland C, Ito S, Koren G: Inhibition of the renal tubular transport of digoxin and vinblastine by mifepristone (R4 486). *Clin Invest Med* 19: 511, 1996.
- 271) Chattergoon DS, McGuigan M, Koren G, Kwang P, Ito S: Multiorgan dysfunction in two children following lamotrigine and valproic acid. *Clin Invest Med* 19: 512, 1996.
- 272) Khattak S, Moghtader GK, McMartin K, Barrera M, Kennedy D, Koren G: Pregnancy outcome following gestational exposure to organic solvents. *Clin Pharmacol Ther* 63: 137, 1998.
- 273) Lalkin A, Loebstein R, Addis A, Koren G: Safety of omeprazole in pregnancy. *Clin Pharmacol Ther* 63: 154, 1998.
- 274) Khattak S, Rogan JW, Blowey D, Arbus GS, Koren G: The effectiveness of amlodipine in pediatric hypertension. *Clin Pharmacol Ther* 63: 159, 1998.
- 275) Loebstein R, Addis A, Ho E, Donnenfeld A, Koren G: Pregnancy outcome following exposure to fluoroquinolones. *Clin Pharmacol Ther* 63: 180, 1998.
- 276) Diav-Citrin O, Atanackovic G, Koren G: Correlation between initial hepatic iron concentration and response to deferiprone. *Clin Pharmacol Ther* 63: 192, 1998.
- 277) Ito S, Weitzman S, Klein J, Greenberg M, Lau R, Atanackovic G, Koren G: Lack of cisplatin-ranitidine interactions in children. *Clin Pharmacol Ther* 63: 193, 1998.
- 278) Addis A, Loebstein R, Koren G, Einarson TR: Meta-analysis of the clinical effectiveness of oral deferiprone. *Clin Pharmacol Ther* 63: 224, 1998.
- 279) Escobar MR, Ito S, Koren G: Organic ion uptake alters cisplatin induced renal cell apoptosis and necrosis. *Clin Pharmacol Ther* 63: 235, 1998.
- 280) Woodland C, Ito S, Klein J, Camille G, Wainer I, Koren G: First evidence of renal biotransformation of ifosfamide to nephrotoxic metabolites. *Clin Pharmacol Ther* 63: 236, 1998.

- 281) Ito S, Woodland C, Sarkad B, Walker SE, Koren G: Modeling of P-glycoprotein mediated renal tubular transport of digoxin and vinblastine. *Clin Pharmacol Ther* 63: 237, 1998.
- 282) Diav Citrin O, Park L, Pastuszak A, Beigne L, Hunnisett L, Friesen MH, Jacobson S, Kasapirovic S, Chang D, Einarson TR, Koren G: Pregnancy outcome following maternal exposure to corticosteroid. *Teratology* 57: 188, 1998.
- 283) Einarson A, Schick B, Addis A, Mazzone T, Koren G: A prospective controlled multicentre study of clarithromycin in pregnancy. *Teratology* 57: 188, 1998.
- 284) Fouladi M, Koren G, Greenberg ML, Klein J, Gammon J, Baruchel S: Safety and monitoring guidelines of amifostine in the pediatric population. *Clin Invest Med* 58: 1998.
- 285) Phillips E, Einarson A, Mawii F, D'Alimonte D, Shick B, Addis A, Mazzone T, Matsui D, Koren G: A prospective controlled multicentre study of clarithromycin in pregnancy. *Clin Invest Med* 59: 1998.
- 286) Kopecky E, Ryan ML, Barret J, Ryan G, Koren G, Amankwah K: Fetal response to maternally administered morphine sulfate. *Clin Invest Med* 59: 1998.
- 287) Pastrakuljic A, Derewlany LO, Simone C, Knie B, Koren G: Inhibition of amino acid transport by cocaine and nicotine in the human placenta perfused *in vitro*. *Clin Invest Med* 510: 1998.
- 288) McMartin KI, Koren G: A proactive approach for the evaluation of fetal safety of chemical industries. *Clin Invest Med* 511: 1998.
- 289) Mazzotta P, Magee LA, Taddio A, Koren G: Risk determinants for legal abortions among Canadian and American women suffering from nausea and vomiting of pregnancy. *Clin Invest Med* 511: 1998.
- 290) Woodland C, Blowey DL, Ito S, Camille G, Wainer J, Klein J, Koren G: Ifosfamide is biotransformed to toxic metabolites by human kidney. *Clin Invest Med* 511: 1998.
- 291) Inocencion G, Loebstein R, Lalkin A, Geist R, D'Alimonte D, Petric M, Koren G: Randomized trial of varicella immune globulin in pregnant women. *Clin Invest Med* 514: 1998.
- 292) Lee A, Ito S, Moretti M, Callentes A, Chang D, Koren G: The safety of PTU during breastfeeding. *Clin Invest Med* 514: 1998.
- 293) Moretti M, Spiczynski Y, Hashemi G, Koren G, Ito S: Prospective follow-up of infants exposed to 5-ASA through maternal milk. *Clin Invest Med* 516: 1998.
- 294) Guo F, Tesoro A, Koren G, Spino M: *In vitro* and *in vivo* studies of novel second generation oral iron chelators. *Clin Invest Med* 518: 1998.

- 295) Forman R, Koren G, Shear NH: Erythema multiforme stevens-Johnson in a pediatric population. *Clin invest Med S28: 1998.*
- 296) Bishai R, Freedman MH, Koren G: Amethocaine vs Lidocaine-Prilocaine local anaesthetic ointments for procedural pain in children. *Clin Pharmacol Ther 65: 138, 1999.*
- 297) Nulman I, Wolpin J, Theis J, Stewart D, Koren G: Perinatal outcome following gestational exposure to antidepressants: Separating the effects of depression, pharmacotherapy and other confounders. *Clin Pharmacol Ther 65: 138, 1999.*
- 298) Nulman I, Rovet J, Greenbaum R, Loebstein M, Wolpin J, Pace Asiack P, Koren G: The effects of intrauterine cocaine exposure on neurodevelopment of adopted children: The Toronto adoption study. *Clin Pharm Ther 65: 138, 1999.*
- 299) Moretti ME, Sharma A, Bar Oz B, Koren G, Ito S: Fluoxetine and its effects on the nursing infant: A prospective cohort study. *Clin Pharmacol Ther 65: 141, 1999.*
- 300) Inocencion G, Loebstein R, Lalkin A, Geist R, D'Alimonte D, Petric M, Woloski B, Koren G: Randomized trial of VZIG to prevent or modify the course of VZV infection in pregnancy. *Clin Pharmacol Ther 65: 199, 1999.*
- 301) Mazzotta P, Magee LA, Koren G: The perception of teratogenic risk by women with NVP. *Clin Pharmacol Ther 65: 200, 1999.*
- 302) Lobaugh NJ, Karaskov V, Rombough V, Rovet J, Levichek Z, Laslo D, Citrin O, Koren G, Haslam RH: Piracetam does not enhance cognitive abilities in moderate to high functioning 7-13 yr old children with Down's syndrome. *Ped Res 16A, April 1999.*
- 303) Nulman I, Kennedy D, Rovet J, Wolpin J, Wasson C, Loebstein M, Gladstone J, Levy M, Freed S, Pace-Asciack P, Koren G: Neurodevelopment of children exposed *in utero* to maternal binge alcohol consumption: A prospective controlled study. *Teratology 69: 37, 1999.*
- 304) Einarson A, Mastroiacovo P, Aron J, Ornoy A, Addis A, Ritvanen A, Koren G: A prospective controlled multicentre study of loperamide in pregnancy. *Teratology 59: 377, 1999.*
- 305) Einarson A, Lyskiewicz D, Koren G: The safety of dextromethorphan in pregnancy: A prospective controlled study. *Teratology 59: 377, 1999.*
- 306) Okotore B, Einarson A, Chambers CD, Mastroiacovo P, Addis A, Schuler L, Koren G: Pregnancy outcome following gestational exposure to venlafaxine: A multivariate prospective controlled study. *Teratology 59: 377, 1999.*
- 307) Bar-Oz B, Ma J, Tsoe S, Hackman R, Zamin M, Einarson TR, Koren G: The effects of cyclosporine therapy on pregnancy outcome in organ transplanted women: A meta-analytical review. *Teratology 59: 440, 1999.*

### PRESENTATIONS

- 1) June 1979, Tel-Aviv: The annual meeting of the Israeli Society of Clinical Pediatrics: Dexamethasone in laryngotracheitis.
- 2) June 1981, Tel-Aviv: The annual meeting of the Israeli Society of Clinical Pediatrics: Errors in computing drug dosage - an interdivisional study.
- 3) June 1981, Tel-Aviv: The annual meeting of the Israeli Society of Clinical Pediatrics: Determination of optimal phenytoin dosage in children by graphic analysis of Michaelis Menten Kinetics.
- 4) June 1982, Tel-Aviv: The annual meeting of the Israeli Society of Clinical Pediatrics: Intravenous phenytoin in children.
- 5) June 1982, Tel-Aviv: The annual meeting of the Israeli Society of Clinical Pediatrics: Maturation of renal transport of gentamicin in the rat. *Isr J Med Sci.*
- 6) October 1982, Toronto: International Symposium on Developmental Pharmacology: Interaction of digoxin with verapamil, indomethacin and other coadministered drugs. A comparative study in rat tissue.
- 7) February 1983, Toronto: Pediatric Update: Controversies in the treatment of croup.
- 8) March 1983, San Diego: The annual meeting of the American Society for Clinical Pharmacology and Therapeutics: Intravenous phenytoin in children.
- 9) March 1983, San Diego: The annual meeting of the American Society for Clinical Pharmacology and Therapeutics: CSF phenytoin in children.
- 10) March 1983, San Diego: The annual meeting of the American Society for Clinical Pharmacology and Therapeutics: Digoxin-verapamil interactions: in vitro studies in rat tissues.
- 11) April 1983, San Diego: The annual meeting of the American Academy of Neurology: The influence of impaired bioavailability on the Michaelis Menten kinetics of phenytoin in children.
- 12) May 1983, Washington, DC: The annual meeting of the American Society for Pediatric Research: Steroids in the treatment of laryngotracheitis vs. spasmodic croup in children.
- 13) May 1983, Washington, DC: The annual meeting of the American Society for Pediatric Research: The influence of indomethacin on digoxin pharmacokinetics in preterm infants.
- 14) June 1983, Ottawa: The annual meeting of the Canadian Federation of Biological Societies: Digoxin Amiodarone interaction. *In vivo* and *in vitro* studies in rat.

- 15) August 1983, Washington, DC: The second international meeting on Clinical Pharmacology and Therapeutics: Digoxin indomethacin interaction in preterm infants.
- 16) September 1983, Calgary: The annual meeting of the Canadian Society of Clinical Investigation: The interaction of digoxin with coadministered drugs.
- 17) October 1983, Toronto: Workshop: "Digoxin: Research Issues for the Eighties". a) Interactions of digoxin with coadministered drugs. b) Postmortem redistribution of digoxin.
- 18) March 1984, Reno, Nevada: Irreversible binding of fentanyl by the cardiopulmonary bypass. The annual meeting of the International Meeting of Anesthesiology Research.
- 19) March 1984, Atlanta, Georgia: Kinetics of amiodarone associated digoxin toxicity in children. Plenary Session, American Society of Clinical Pharmacology Annual Meeting.
- 20) May 1984, San Francisco: Unexpected abnormalities of fentanyl disposition in children undergoing cardiac surgery. American Society of Pediatric Research, Annual Meeting.
- 21) May 1984, San Francisco: Characteristics of digoxin interaction with quinidine, verapamil and amiodarone: *in vivo* and *in vitro* studies. American Society of Pediatric Research, Annual Meeting.
- 22) June 1984, Toronto: Improved gentamicin dosing based on pharmacokinetics in preterm infants. Plenary Session. The Canadian Pediatric Society.
- 23) September 1984, Montreal: The Canadian Society of Clinical Investigation Annual Meeting: Significance of Endogenous Digoxin-like Substance in Neonates and Mothers.
- 24) September 1984, Montreal: The Canadian Society of Clinical Investigation: Improved Intravenous Delivery of Antibiotics in the Newborn.
- 25) September 1984, Montreal: The Royal College of Physicians and Surgeons of Canada, Annual Meeting: Optimization of TDM System.
- 26) October 1984, New Orleans: The Annual Meeting of The American Society of Anesthesiologists. Fentanyl Anesthesia for Cardiac Surgery in Children: a) Fentanyl Oxygen vs. Fentanyl N<sub>2</sub>O, b) Relationships between Drug Concentrations and Pharmacodynamics.
- 27) March 1985, San Antonio: The 86th Meeting of the American Society of Clinical Pharmacology & Therapeutics: The pharmacokinetics of clindamycin in newborn infants.
- 28) March 1985, San Antonio: The 86th Meeting of the American society of Clinical Pharmacology & Therapeutics: Endogenous digoxin-like substance in infants & mothers: pharmacokinetic and pharmacodynamic implications.



- 29) May 1985, Washington DC: The Society of Pediatric Research Annual Meeting: Endogenous digoxin like substance in infants and mothers.
- 30) May 1985, Washington DC: The Society of Pediatric Research Annual Meeting: Probable efficacy of salicylates in reducing coronary involvement in Kawasaki disease.
- 31) May 1985, Chicago: The Society of Critical Care Medicine Annual Meeting: The influence of hypothermia on the pharmacokinetics of gentamicin and theophylline in piglets.
- 32) August 1985, Kansas City: The American Academy of Clinical Toxicology annual meeting. Morphine-induced seizures in newborn infants.
- 33) August 1985, Kansas City: The American Academy of Clinical Toxicology. Ten-fold errors in calculation of drug doses in children; a neglected iatrogenic disease.
- 34) September 1985, Vancouver: The Canadian Society of Clinical Investigation annual meeting: Digoxin uptake by the dog kidney.
- 35) September 1985, Vancouver: The Canadian Society of Clinical Investigation annual meeting: Paraldehyde pharmacokinetics and seizure control in newborn infants.
- 36) March 1986, Washington DC: The American Society of Clinical Pharmacology and Therapeutics annual meeting: Interaction of digoxin with quinidine and verapamil in the brush border of the dog kidney.
- 37) March 1986, Washington DC: The American Society of Clinical Pharmacology and Therapeutics annual meeting: Alfentanil - a pharmacokinetically predictable drug in children.
- 38) April 1986, St. Louis Missouri: FASEB annual meeting: Application of novel *in vivo* and *in vitro* methods to study renal digoxin handling.
- 39) May 1986, Washington DC: Annual meeting of SPR: Application of novel *in vivo* and *in vitro* methods to the study of renal digoxin handling.
- 40) May 1986, Washington DC: Annual meeting of SPR: Pharmacokinetic determinants of 6MP myelotoxicity and therapeutic failures in children with ALL.
- 41) May 1986, Washington DC: Annual meeting of SPR: Ten fold errors in computation of drug doses in children - a neglected iatrogenic disease.
- 42) May 1986, Kingston, Ont.: The Annual meeting of the Genetic Counselors of Ontario: Motherisk - a new approach to antenatal counselling of drug and chemical exposure.
- 43) May 1986, St. Catherine's, Ont.: In: "Future Directions in Planning and Implementing Programs for the Prevention of Developmental Handicaps. Organized by The Western NY Task Force on Prevention of Mental Retardation and the Ontario Association for the Mentally Retarded. "Chemical and Physical Hazards and the Fetus."

- 44) July 1986, Stockholm, Sweden: The III World Conference on Clinical Pharmacology: Application of novel in vivo and in vitro methods to the study of renal digoxin handling.
- 45) July 1986, Stockholm, Sweden: The III World Conference on Clinical Pharmacology: Pharmacokinetic determinants of 6MP myelotoxicity and therapeutic failures in children with ALL.
- 46) September 1986, Toronto: The annual meeting of the Canadian Society of Clinical Investigation: Digoxin handling by the renal tubular cell.
- 47) September 1986, Toronto: The annual meeting of the Canadian Society of Clinical Investigation: Vancomycin pharmacokinetics and dose recommendations for preterm infants.
- 48) September 1986, Santa Fe: The annual meeting of the American Academy of Toxicology: Motherisk - a new approach to drug/chemical exposure in pregnancy.
- 49) September 1986, Santa Fe: The annual meeting of the American Academy of Toxicology: Cellular mechanisms of digoxin transport and toxic interactions in the kidney.
- 50) October 1986, New York: The Eastern Section of APCR: Digoxin handling by the renal tubular cell.
- 51) October 1986, Toronto: Research with children: ethics and implementation. International Meeting "The Responsibility of the Investigator".
- 52) November 1986, Toronto: 2nd Annual Perinatal Day. Drug effects on the fetus.
- 53) November 1986, Buffalo NY: Third annual conference for prevention of mental retardation and developmental disabilities. "Teratogenic cause of developmental disabilities".
- 54) January 1987, Children's Hospital of Winnipeg, Manitoba: The Ian Goldberg Lectureship in Pediatrics.
- 55) February 1987, Children's Hospital of Ottawa: "Motherisk - A New Approach to Drug/Chemical Teratogenicity".
- 56) March 1987, Orlando, Florida: Annual Meeting of the American Society of Clinical Pharmacology (Plenary session): Physician compliance as a risk factor in acute lymphoblastic leukemia.
- 57) April 1987, Cincinnati, Ohio: 20th anniversary of the Poison Control Center, "A New Approach to Drug/Chemical Teratogenicity".
- 58) April 1987, Cleveland, Ohio: Rainbow's Babies and Children's Hospital: Glaxo lectureship.

- 59) April 1987, Anaheim, Society of Pediatric Research: Pharmacokinetics and respiratory pharmacodynamics of IV salbutamol in neonates with BPD.
- 60) June 1987, Hamilton, Ontario: Canadian Society of Laboratory Technicians: A New Approach to Chemical Exposure in Pregnancy.
- 61) September 1987, Winnipeg, Manitoba: Annual Meeting of the Canadian Society for Clinical Investigation: Simultaneous inhibitors of renal tubular and biliary transport of digoxin.
- 62) September 1987, Winnipeg, Manitoba: Annual Meeting of the Canadian Society for Clinical Investigation: Motherisk-A new approach to drug/chemical induced teratogenicity.
- 63) October 1987, Smolenice, Czechoslovakia: Perinatal Pharmacology Meeting: Ethics of drug studies in infants.
- 64) March 1988, Toronto, Ontario: Annual Meeting of The Clinical Research Society of Toronto: Pharmacological determinants of survival in childhood leukemia.
- 65) April 1988, Les Diableret, Switzerland: European Society of Developmental Pharmacology: Pharmacokinetics, dose recommendations and safety of amphotericin B in infants and children.
- 66) April 1988, Boston, MA: Teratogen Information Services Workshop: Perception of teratogenic risk by pregnant women exposed to drugs and chemicals in pregnancy.
- 67) May 1988, Washington DC: Annual Meeting of SPR: The effects of quinidine on the renal tubular and biliary transport of digoxin.
- 68) June 1988, Toronto, Ontario: American College of Physicians - Complications of Pregnancy Workshop: Prescribing in pregnancy.
- 69) September 1988, Baltimore MD: Annual meeting of the American Academy of Clinical Toxicology: The Effect of Hypothermia on the Disposition of Ethanol in Piglets.
- 70) September 1988, Ottawa: The Annual Meeting of the Canadian Society of Clinical Investigation: Pharmacokinetics and Safety of Amphotericin B in children.
- 71) November 1988, Tokyo Japan: 3rd International Conference of Kawasaki Disease: Salicylates in Kawasaki Disease.
- 72) January 1989, London Ontario: MRC Queen Elizabeth II Visiting Professor. Western University, London.
- 73) January 1989, Miller's Children Hospital, Long Beach California: The effects of drugs in pregnancy.

- 74) March 1989, Nashville Tennessee: The annual meeting of the American Society of Clinical Pharmacology & Therapeutics: Perinatal Toxicology (Symposium).
- 75) March 1989, London UK: IUPHAR Pediatric Pharmacology Network meeting.
- 76) April 1989, Charlottesville Virginia: The Bird song Annual conference: Therapeutic drug monitoring in children.
- 77) May 1989, Washington DC: The annual meeting of the Society for Pediatric Research: Diurnal variation of 6MP pharmacokinetics and myelotoxicity in children.
- 78) July 1989, Manneheim, Germany: The World Conference in Clinical Pharmacology: Randomized, cross over comparison of iron excretion between desferoxamine and the new oral chelator L<sub>4</sub>.
- 79) July 1989, Paris: The 19th World Conference in Pediatrics; Symposium: 3rd generation cephalosporin use in neonates.
- 80) September 1989, Edmonton; Alberta: The Canadian Society of Clin. Pharmacology annual meeting: Randomized, crossover comparison of iron excretion between deferoxamine and L<sub>4</sub>.
- 81) September 1989, Edmonton Alberta: Diurnal variation in 6-MP pharmacokinetics and myelotoxicity in children with leukemia.
- 82) October 1989; Atlanta Georgia: Annual meeting of the American Academy of Toxicology. Fetal outcome following carbon monoxide poisoning in pregnancy.
- 83) October 1989: Long Beach California: Workshop on ribavirin: Safety of ribavirin in pregnancy.
- 84) November 1989: New Brunswick, New Jersey, Department of Pediatrics: New frontiers in pediatric pharmacology.
- 85) February 1990: Salt Lake City: 3rd international conference of teratogen information services: Lithium in pregnancy.
- 86) March 1990: San Francisco Ca.: Annual meeting of the American Society of Clinical Pharmacology, Symposium: EMLA a novel.
- 87) May 1990: Los Angeles: The Society of Pediatric Research: Variability of 6-MP exposure.
- 88) May 1990: Tremezzo, Italy: The European Society of Developmental Pharmacology: Ethics of Research in Pediatrics.
- 89) June 1990: Strbske Pleco, Slovakia: Adverse drug effects in Pediatrics: ADR in pregnancy.

- 90) September 1990: Tucson AZ: American Academy of Clinical Toxicology symposium "Maternal-Fetal Toxicology".
- 91) October 1990: Barcelona Spain: TDM meeting: TDM in pregnancy.
- 92) October 1990: Barcelona, Spain: TDM meeting: Hair testing for gestational cocaine exposure.
- 93) October 1990: Barcelona Spain: TDM meeting: Cardiac glycosides.
- 94) November 1990: FDA, Washington DC: Pharmacokinetic determinants of survival in childhood leukemia.
- 95) November 1990: Ottawa: Symposium "Risk estimation of pharmaceuticals". Risk estimation in pregnancy.
- 96) December 1990: Ashkelon Israeli: Israeli Society of Clin. Pediatrics Annual Meeting: Novel approaches in pediatric pharmacology.
- 97) February 1990: Ottawa: Health Protection Branch: Drug therapy in children.
- 98) March 1991, San Antonio Texas: Annual meeting, Amer Soc. Clin. Pharmacol symposium: Measuring cocaine in neonatal hair.
- 99) April 1991: Chicago IL: Annual meeting, Teratology Information Services. Quality Assurance in TIS.
- 100) May 1991: New Orleans: Annual meeting of the Society for Pediatric Research: Pregnancy-induced changes in drug metabolism in epileptics.
- 101) May 1991: New Orleans: Annual meeting of The Society for Pediatric Research. Use of Medication Even Monitor System.
- 102) June 1991: Ramat Gan Israel: International Society of Chronobiology. "Diurnal variation of methotrexate pharmacokinetics".
- 103) September 1991: Quebec City: Royal College annual meeting: The use of EMLA in pediatric pain.
- 104) October 1991: Toronto: Annual meeting of the American Academy of Clinical Toxicology: Risk evaluation of drugs in pregnancy.
- 105) October 1991: Tours, France: 46th meeting of the French Association of Pharmacologists: Ethics of drug studies in pediatrics.
- 106) November 1991: Vancouver BC: Dept. of Genetics, U.B.C. Cocaine in pregnancy.

- 107) November 1991: BC Children's Hospital Vancouver: The use of EMLA in pediatric pain.
- 108) November 1991: Victoria General Hospital, Victoria BC: The use of EMLA in pediatric pain.
- 109) November 1991: Calgary: Children's Hospital of Alberta, Dept. of Anesthesia: The use of EMLA in pediatric pain.
- 110) November 1991: Calgary: Children's Hospital of Alberta, Dept. of Pediatrics: New approaches to pediatric pain.
- 111) November 1991: Edmonton: University of Alberta Hospital, Dept. of Dermatology: EMLA for hiatrogenic pain.
- 112) November 1991: Ottawa General Hospital: Dept. of Anesthesia, EMLA for pediatric pain.
- 113) November 1991: Children's Hospital of Western Ontario, London: Dept. of Pediatrics: EMLA for pediatric pain.
- 114) November 1991: Children's Hospital of Columbus Ohio: The 1991 Wheeler's Professorship: Medication errors in children.
- 115) February 1992: Child Health 2000, Vancouver: Fetal exposure to drugs and chemicals.
- 116) February 1992: Child Health 2000, Vancouver: Environmental risks to the fetus.
- 117) April 1992: The Organization of Teratology Information Services, SanDiego: Reproductive risks of ribavirin.
- 118) May 1992: European Society of Developmental Pharmacology, Borgholm, Sweden: Hair test: Biological markers for gestational exposure to cigarette smoking and cocaine.
- 119) May 1992: New York Academy of Sciences, San Diego: Nutrition in Pregnancy workshop: Perception of teratogenic risk.
- 120) June 1992: The Teratology Society, Boca Raton, Fla: Perception of teratogenic risk.
- 121) June 1992: The Teratology Soceity, Boca Raton Fla: Research in reproductive toxicology.
- 122) August 1992: The International Pediatric Nephrology Association, Jerusalem Israel: Novel approaches to study kidney-drug interactions.
- 123) July 1992: Canadian Therapeutic Update 1992, Niagara on the Lake: The use of EMLA.
- 124) August 1992: International Society for Pediatric Pharmacology, Jerusalem: Novel Ways to Study Kidney-Drug Interations During Development.

- 125) September 1992: International workshop in pediatric pharmacology, Smolenice, Slovakia: (1) Maternal Fetal Toxicology, (2) "Awakening".
- 126) September 1992: The Can. Society of Clin Pharmacology, Ottawa, Ontario: The effect of ECMO on drug disposition in children.
- 127) September 1992: The Can Pediatric Society, Ottawa, Ontario: Drug of abuse in pregnancy.
- 128) October 1992: The Amer College of Rheumatology, Atlanta, Georgia: The role of the placenta in drug transfer.
- 129) November 1992: Montreal's Children Hospital: Biological markers of intrauterine exposure to cocaine and cigarette smoke.
- 130) November 1992: Mead Johnson Perinatology Training Program; Marco Island, Fla: (1) Bias against the null hypothesis. (2) Biological markers of intrauterine exposure to cocaine.
- 131) December 1992: Ottawa, Ontario: National Council on Bioethics in Human Research; Workshop on the Ethics of Research Involving Children. (1) The perspective of research ethics boards. (2) Current procedures for protection of children in research.
- 132) January 1993: Palm Beach Fla: Pro Coin International: Round Table on New Approaches to Local Anesthesia: The Use of EMLA in Pediatrics.
- 133) March 1993: Honolulu, Hawaii, American Society of Clinical Pharmacology annual meeting: Perinatal exposure to NSIDS (*Presentation in Symposium*).
- 134) March 1993: Chicago, IL: American Academy of Pediatrics: Medication errors in children.
- 135) April 1993: Vancouver, BC: Annual drug therapy medications in pregnancy; pain therapy in children.
- 136) May 1993: Washington, DC: Society for Pediatric Research: Nephrotoxicity of Ifosphamide and cisplatin (Presented in symposium).
- 137) May 1993: Indianapolis, In. Poison control center annual day: Poisoning in pregnancy.
- 138) June 1993: Saskatoon and Regina: Saskatchewan Institute on Prevention of Handicaps: Role of folic acid in preventing neural tube defects.
- 139) December 1993: Halifax, NS: Health Canada Workshop on FAS: Fetal Alcohol Syndrome. The Motherisk Approach.

- 140) February 1994: New York, NY: The American Medical Association: Tobacco, Public Health and Public Policy: Measurement of nicotine and cotinine in maternal and neonatal hair.
- 141) February 1994: Toronto: DIA workshop: A Team Approach to Drug Safety Research: Drugs in Pregnancy and Lactation.
- 142) March 1994: New Orleans, Louisiana: The American Society for Clinical Pharmacology. Workshop: Drug therapy during pregnancy and lactation.
- 143) April 1994: Boston MA: Massachusettes General Hospital's annual course on human teratogens: \*(1) Perception of teratogenic risk; (2) Clinical consultations; (3) Reproductive toxicology of antiviral drugs.
- 144) May 1994: Montreal, Quebec: McGill's University Therapeutic Update: Drug therapy in pregnancy.
- 145) May 1994: York, UK: The European Society for Developmental Pharmacology: Fetal exposure to drugs and chemicals.
- 146) June 1994: Genova, Italy: 2nd Workshop on Hair Analysis for Drugs: Fetal exposure to drugs and chemicals.
- 147) July 1994: Niagara-on-the-Lake, Ont.: Annual Therapeutic Update. Can Society for Clinical Pharmacology: Perinatal toxicology.
- 148) September 1994: Toronto, Ont.: The Royal College of Physicians & Surgeons of Canada Workshop: Drug exposure during pregnancy.
- 149) September 1994: Rochester, NY: Grand Round of OBGYN: The Motherisk Program.
- 150) October 1994: Montreal, Quebec: St. Justine Grand Rounds: Biological markers of intrauterine exposure to drugs.
- 151) October 1994: Orlando, Fla.: CF annual meeting: Renal drug handling in CF.
- 152) November 1994: Taipei, Taiwan: 1) Drug abuse in pregnancy.  
2) Interpretation of postmortem drug concentrations.  
In: The 5th World Congress of The World Federation of Associations of Clinical Toxicology Centers & Poison Control Centers.
- 153) November 1994: Calgary, Alberta: Grand Round of Children's Hospital: Frontiers in pediatric drug therapy.
- 154) November 1994: Long Beach, Cal.: Grand Round in Miller Children's Hospital: The Bear Theatre.
- 155) December 1994: Toronto, Ont.: Alcohol, The Fetus & Pregnancy, In: Health Effects of Moderate Alcohol Consumption.



- 156) February 1995: Toronto, Ont.: Drug Information Association: Safety of Drugs in Pregnancy.
- 157) February 1995: Ottawa, Ont.: Grand Round, Dept. of Obstetric/Gynecology: Safety of Drugs in Pregnancy.
- 158) April 1995: Toronto, Ont.: The First Motherisk International Course: Human Teratogens; Drugs of abuse in pregnancy.
- 159) May 1995: Quebec City: Annual Meeting, Canadian College of Family Physicians: Drugs in pregnancy.
- 160) May 1995: Vancouver: Child Health 2000: Environmental risks in pregnancy.
- 161) June 1995: Vancouver: The Can Soc for Neuro psycho pharmacology: Biological markers for intrauterine drug exposure.
- 162) September 1995: Montreal, Quebec: Annual Meeting: Royal College: Novel methods to measure kidney drug interactions.
- 163) September 1995: Rochester, NY: Annual North American Toxicology Meeting: Treating the mother-protecting the unborn.
- 164) November 1995: Istanbul Turkey: International Herpes Management Forum: Varicella in Pregnancy.
- 165) November 1995: Jerusalem, Hadassa Mt. Corpus: Drugs in pregnancy and lactation.
- 166) December 1995: Braselton, Georgia: Safety and Toxicity of Nicotine. Nicotine and cigarette smoke in pregnancy.
- 167) January 1996: Palm Spring, Cal.: Biological markers of fetal exposure to drugs. Annual Sudden Infant Death Syndrome meeting, Shriner Institute.
- 168) February 1996: Toronto: Bias against the null hypothesis in reproductive toxicology. Annual Drug Information Association Meeting of the Toronto Drug Safety Research Group.
- 169) March 1996: San Diego, Cal.: "Treating the Mother-Protecting the Unborn". The annual meeting, American Society of Clinical Pharmacology and Therapeutics.
- 170) May 1996: Quebec City: Drugs in pregnancy - an update. Annual meeting. The Canadian College of Family Physicians.
- 171) May 1996: Pecs Hungary: New frontiers in pediatric pharmacology. 5th Congress of the European Society for Developmental Pharmacology.
- 172) July 1996: Niagara-on-the-Lake: New frontiers in pediatric drug therapy.

- 173) October 1996: Toronto, Ont.: Risks of prenatal exposure to drugs, "Addiction in Pregnancy" Conference. The Infant Mental Health Project.
- 174) November 1996: Toronto, Ont.: Update on drugs in pregnancy. Ontario Association of Family Physicians.
- 175) June 1996: San Diego, Cal.: "Drugs in pregnancy; industry academia collaboration". 32nd meeting of the Drug Information Association.
- 176) July 1996: Chicago, Ill: Therapeutic drug monitoring in neonates. Amer Academy of Clin. Chemistry.
- 177) November 1996: Toronto, Ont.: Ontario Association of Family Physicians: Drugs in Pregnancy.
- 178) December 1996: Toronto, Ont.: 2nd Provincial Conference on Fetal Alcohol Syndrome and Effects: Motherisk approach.
- 179) December 1996: Montreal, Queb.: Toxicology Society of Canada: Drugs in pregnancy.
- 180) January 1997: Tel Aviv, Israel: Association of Clinical Biochemistry: Therapeutic Drug Monitoring.
- 181) January 1997: Department of Medicine, Tel Aviv University, Kefar Saba Hospital: Drugs in Pregnancy.
- 182) March 1997: San Diego, Cal.: American Society for Clinical Pharmacology & Therapeutics: "Bias against the null hypothesis in maternal fetal toxicology".
- 183) April 1997: Hamilton, Ont: The Canadian Pharmacoepidemiology Forum. Bias against negative results.
- 184) May 1997: Indianapolis, Global Health Convention: Antidepressants in Pregnancy.
- 185) May 1997: Washington, DC: The Society for Pediatric Research. EMLA for circumcision pain.
- 186) June 1997: Halifax, NS: The Society of Obstetrics & Gynecology of Canada: Drugs in pregnancy.
- 187) June 1997: Vancouver, BC: Child Health 2000: Environmental toxins in pregnancy.
- 188) September 1997: Washington, DC: The New York Academy of Sciences: Cocaine effects in pregnancy.
- 189) November 1997: Cleveland, OH: The Cleveland Hospitals. Antidepressant drugs in pregnancy.

- 190) October 1997: Rio de Janeiro: The Neuropsychopharmacology Society of Brazil. Antidepressants in pregnancy.
- 191) November 1997: Vancouver, BC: The International Society of TDM: Biological markers of intrauterine exposure to drugs.
- 192) January 1998: Toronto, Ont.: The Air Children Breathe. Pollution Probe.
- 193) February 1998: Regina, Sask: The POGO annual meeting for physicians & nurses: The Children of Neverland.
- 194) March 1998: Whistler, BC: The International Conference of Emergency Medicine: Drugs in pregnancy.
- 195) March 1998: Sault Ste. Marie, Ont.: Effects of Alcohol in Pregnancy.
- 196) April 1998: Nice, France: Pain in the neonate consensus meeting: Topical Analgesia.
- 197) April 1998: Budapest, Hungary: Hungarian Association of Psychiatry: Antidepressants in Pregnancy.
- 198) June 1998: Boston, Mass: Drug Information Association: Drugs in Pregnancy.
- 199) September 1998: Copenhagen, Denmark: European Society of Psychiatry. Antidepressants in Pregnancy.
- 200) October 1998: Toronto, Ont.: International Conference on Hair-Drug testing: Testing drugs in neonates.
- 201) October 1998: San Francisco, CA: American Academy of Pediatrics: Drugs in breastfeeding.
- 202) October 1998: Vancouver, BC: University of BC OBG-Family Practice Annual Day: Drugs in Pregnancy.
- 203) October 1998: Toronto, Ont.: First International Conference on NVP.
- 204) November 1998: Quebec City: Annual meeting of Society of Clinical Chemistry of Quebec: Biological markers of drug exposure in the neonate.
- 205) November 1998: Halifax, NS: Shoppers Drug Mart Pharmacists: Folic acid in pregnancy.
- 206) November 1998: Calgary, Alberta: Shoppers Drug Mart Pharmacists: Folic acid in pregnancy.
- 207) February 1999: Tel Aviv, Israel: Sheba Medical Center: New frontiers in pediatric pharmacology.

- 208) February 1999: Banff, Alberta: Canadian College of Family Physicians: Treatment of NVP.
- 209) March 1999: Maui, Hawaii: North American Association of Psychosocial Obstetrics: Antidepressant drugs in pregnancy.
- 210) March 1999: Moncton, NB: Moncton General Hospital Neonatal Unit: Illicit drug exposure in pregnancy.
- 211) March 1999: Vancouver, BC: Westminster General Hospital: Fetal Alcohol Syndrome.
- 212) March 1999: Prince George, BC: Prince George General Hospital: Fetal Alcohol Syndrome.
- 213) April 1999: Halifax, NS: Dalhousie University. The Peter E. Dressel Memorial Lectureship in Pharmacology.
- 214) April 1999: Boston: Harvard University: Annual course in teratology: (1) organic solvents in pregnancy, (2) epidemiological considerations.
- 215) May 1999: Calgary, Alberta: Fetal Alcohol Syndrome Convention: The Motherisk alcohol line.
- 216) August 1999: Baden, Austria: International consensus group for pain in the neonate.
- 217) September 1999: Montreal, QC: Royal College meeting: Perception of teratogenic risk by women.
- 218) September 1999: Toronto: American Society for Reproductive Medicine. Exposure to antidepressants in pregnancy.
- 219) October 1999: Detroit, Michigan: NIH planning meeting on Nausea and Vomiting of pregnancy.
- 220) March 2000: Cleveland, Ohio: Rainbow & Babies Hospital: Biological markers of intrauterine exposure to drugs.
- 221) March 2000: Los Angeles, California: American Society of Clinical Pharmacology and Therapeutics Meeting. Issues with drug compliance.
- 222) March 2000: Los Angeles, California: American Society for Clinical Pharmacology: Renal tubular mechanisms of drug handling.
- 223) April 2000: London, Ontario: Children's Hospital: Do neonates remember neonatal pain?
- 224) April 2000: London, Ontario (UWO): Renal handling of drugs: opening the black box.

- 225) May 2000: Detroit, Michigan: Children's Hospital Residents Round: Tenfold errors in drug doses.
- 226) June 2000: Boca Raton, Fla: Teratology Society. Herbal products in pregnancy.
- 227) July 2000: Detroit, Michigan: Children's Hospital Grand Rounds: Drugs in pregnancy: Treating the mother, protecting the unborn.
- 228) September 2000: Washington, DC: International Nausea and Vomiting in Pregnancy: US vs Canadian experience.
- 229) September 2000: Washington, DC: NIH Meeting on Nausea and Vomiting in Pregnancy.
- 230) September 2000: Washington, DC: FDA Pregnancy Labeling Committee: Motherisk approach to counseling.
- 231) October 2000: Kelowna, BC: BC College of Family Physicians: Drugs in pregnancy-an update.
- 232) November 2000: Toronto, Ontario: Medical Information Group of the Rx/R&D: Drugs in pregnancy update.
- 233) November 2000: Toronto, Ontario: Innovus Workshop on drug trials in children: Interaction with the American Centers.
- 234) November 2000: Long Island NY: Northshore Hospital (Dr. A. Hershlag): Drugs in Pregnancy.
- 235) December 2000: Washington, DC: NIH/FDA Conference: Clinical Pharmacology in Pregnancy: The interface of Clinical Pharmacology and Fetal Safety.
- 236) January 2001: Dalhousie University, Halifax, NS: IWK Grand Rounds: Do children remember circumcision pain?
- 237) February 2001: Ottawa, Ont.: CIHR: Network of Canadian Pediatric Pharmacology.
- 238) February 2001: Mont. Tremblant, Quebec: Canadian Rheumatology Association: Drugs in Pregnancy.
- 239) February 2001: Toronto: Drug Information Association: The Mother-Net.
- 240) March 2001: Berlin: 1<sup>st</sup> World Congress of Women's Mental Health: Antidepressant Drugs in Pregnancy.
- 241) April 2001: Bethesda, MD: NIH: Adverse Drug Reactions in Children. Renal handling of drugs.
- 242) April 2001: Ottawa, Ont.: Ethical Framework of Drug Trials in Children. Canadian Ped Society Bal Fetal Drug Therapy.

- 243) April 2001: Ottawa, Ont.: Ethical Framework of Drug Trials in Children. Canadian Ped Society. Pediatric Subpopulations: Case presentation and discussion.
- 244) April 2001: Baltimore, MD: Society for Pediatric Research: Ethical dilemmas in children: Voluntariness of children.
- 245) April 2001: Dept. of Medicine, Dalhousie University, Halifax NS: Treating the Mother-Protecting the Unborn.
- 246) May 2001: Gander, Newfoundland: First provincial meeting on FAS: Prevention and diagnosis of FAS.
- 247) May 2001: Gander, Newfoundland: First provincial meeting on FAS: The Motherisk Program.
- 248) May 2001: Calgary, Alberta: Faculty of Medicine Biological markers of intrauterine exposure to drugs.
- 249) June 2001: Quebec City: Creating a CME for Drugs in Pregnancy (Chairperson).
- 250) June 2001: Washington, DC: American Society for Clinical Pharmacology & Therapeutics: Pediatric Pharmacology, Medication Misadventures.
- 251) August 2002: Toronto, Ont.: Arthritis consumer experts: Chloroquine in pregnancy.
- 252) August 2001: Toronto, Ont.: CIHR Institute of Genetics: Clinical Genetics Research Workshop: Common pitfalls in clinical studies.
- 253) September 2002: Washington, DC: International association of therapeutic drug monitoring and clinical toxicology: Biomarkers of drug exposure during pregnancy.
- 254) September 2001: Toronto, Ont.: 2<sup>nd</sup> Annual Fetal Alcohol Syndrome Annual Day, Motherisk Program. Overview of critical issues.
- 255) September 2001: Paris, France: 3<sup>rd</sup> Society of Research in Nicotine and Tobacco. Nicotine replacement therapy in pregnancy.
- 256) October 2001: Kamloops, BC: BC Reproductive Care Program: Better Beginnings – Motherisk prevention and diagnosis of FAS.
- 257) October 2001: Kamloops, BC: Drug exposure during pregnancy and lactation.
- 258) October 2001: Minnett, Ont.: The Ontario Coalition of CPAC and CPNP Projects: Fetal Alcohol Syndrome: Diagnosis and Prevention.
- 259) November 2001: Limassol, Cyprus: The European Society for Dev. Pharmacology: Drugs in pregnancy: The real, unreal and surreal.

- 260) December 2001: Petach Tikva, Israel: Schneider National Children's Hospital: State of the art of Pediatric Drug Therapy.
- 261) January 2002: Houston, TX: OTID research meeting: Ethics of drug research in pregnancy.
- 262) February 2002: Long Island, NY: Northshore Hospital (Dr. A. Hershtag): Drugs in Pregnancy.
- 263) April 2002: Toronto, ON: Pediatric Update, The Hospital for Sick Children. 1) Drugs in pregnancy-suffer the children. 2) Critical appraisal of scientific papers.
- 264) April 2002: Rockville, MD: FDA/CDER: Perception of teratogenic risk. Visiting Professor.
- 265) April 2002: Bethesda, MD: NIH: Workshop on chemicals and drugs in breastmilk. Counseling nursing mothers taking medication.
- 266) April 2002: Kelowna B.C.: Society for rural physicians of Canada. Diagnosing FASD.
- 267) May 2002: Peterborough, Ont: Department of Health: Chemical exposure in pregnancy.
- 268) June 2002: Toronto, Ont: Canadian Pediatric Society 3<sup>rd</sup> Annual Meeting. Drug exposure in pregnancy.
- 269) June 2002: San Francisco, CA: Fetal-Alcohol-Canadian Expertise, 2<sup>nd</sup> Annual Meeting. Chair and presenter of Motherisk Experience.
- 270) September 2002: Muskoka, Ont: CAPC Annual Meeting: Diagnosing FASD.
- 271) September 2002: Vancouver B.C.: Fetal Alcohol Day: Diagnosing FASD.
- 272) September 2002: Vancouver B.C.: Drugs in pregnancy. Workshop for physicians.
- 273) October 2002: Liege, Belgium: European Society for Developmental Pharmacology: Global Consortium of Pediatric Pharmacology.
- 274) October 2002: Essen, Germany: Society for Prevention of Tobacco Induced Disease, 1<sup>st</sup> Meeting. 1) NRT in pregnancy. 2) Bupropion in pregnancy.
- 275) October 2002: Ottawa, Ont: The Ottawa Hospital, Department of OB/GYN: Drugs in pregnancy.
- 276) November 2002: Tel Aviv, Israel: The Unborn Child-Scientific Discovery, Medical and Ethical Issues", "Drugs in Pregnancy".
- 277) January 2003: Houston, TX: OTIS Research meeting: Acutane in pregnancy.

- 278) March 2003: Washington, DC: American Society for Clinical Pharmacology & Therapeutics: International symposium: Issues of drugs in pregnancy.
- 279) Ontario Meeting on FASD: The Motherisk Approach.
- 280) May 2003: Tel Aviv, Israel: "Art therapy for children". The Israeli Society for Developmental Pediatrics. The Bear Theatre.
- 281) May 2003: Zerifin, Israel: Pediatric Grand Rounds Systemic exposure to morphine and sickle cell crisis.
- 282) May 2003: Owen Sound, ON: FASD diagnostic training.
- 283) June 2003: Fort Lauderdale, CA: FACE meeting: Fetal Alcohol Canadian Expertise.
- 284) June 2003: Philadelphia: Teratology – OTIS meeting: Accutane in pregnancy.
- 285) June 2003: Sioux Lookout: FASD diagnostic training.
- 286) August 2003: Ottawa, ON: Health Canada diagnostic task force on FASD.
- 287) September 2003: Rome, Italy: International Association of Pediatric Laboratory Medicine: Biomarkers of drug exposure in pregnancy.
- 288) September 2003: Ottawa, ON: 25<sup>th</sup> Anniversary of Canadian Society for Clinical Pharmacology. Symposium: The future of Clinical Pharmacology in Canada.
- 289) October 2003: Winnipeg: International Society for Tobacco Induced Disease 2<sup>nd</sup> Congress "Smoking in Pregnancy".
- 290) November 2003: Toronto, ON: Ontario College of Family Physicians: Drugs in Pregnancy.
- 291) November 2003: Ottawa, ON: First Canadian Drug Information Association Meeting: Drugs in Pregnancy.
- 292) November 2003: Winnipeg: The Northwest Convention of FAS: Meconium Analysis for FAS.
- 293) November 2003: Toronto, ON: Motherisk Update: Accutane in Pregnancy.
- 294) November 2003: Toronto, ON: Motherisk Update: Diagnosis of FAS.
- 295) December 2003: Toronto, ON: Street Women and FAS Convention. The Children of Neverland.
- 296) January 2004: Salt Lake City:
- 297) January 2004: Toronto, ON: FASD Workshop First Nations.



- 298) February 2004: Ottawa, ON: Diclectin Dosing
- 299) March 2004: Hamilton, ON: CAS (Children's Aid Society): Measuring drugs in neonates.
- 300) March 2004: Miami, FL: ASCPT (American Society for Clinical Pharmacology & Therapeutics) Congress.
- 301) March 2004: Rockville, MD: NICHD SEP Review Study Session.
- 302) April 2004: Prague : ENTIS Talk
- 303) April 2004: Providence, RI: Grand Rounds (Obstetric Medicine – Brown's University).
- 304) May 2004: London, ON: Royal Victoria Hospital: Drugs in Pregnancy.
- 305) May 2004: London, ON: Rounds at London-Med University Hospital.
- 306) May 2004: North Bay, ON: FASD Workshop.
- 307) May 2004: London, ON: Drug Therapy Day (Talk in smoking cessation in pregnancy and panel for Pediatrics).
- 308) June 2004: Winnipeg, MB: Therapeutic Congress. Pain management in children.
- 309) June 2004: Vancouver, BC: Teratology Society: Treating the Mother-Protecting the Unborn.
- 310) November 2004: Toronto: POGO: Chemotherapy for neonatal cancer.
- 311) November 2004: Beer Sheba Israel: Israeli Society for Clin. Pediatrics: Pharmacology of Pain in Children.
- 312) November 2004: Montreal: Quebec Association of Rheumatologists: Treating rheumatologic conditions in pregnancy.
- 313) November 2004: Yellowknife: Yellowknife Public Health Unit: Diagnosis of FASD.
- 314) November 2004: Yellowknife: Yellowknife General Hospital Grand Rounds: Drug therapy in pregnancy.
- 315) December 2004: Montreal, Quebec: CIHR Workshop in Toxicology: Perception of teratogenic risk by women.
- 316) December 2004: Montreal, Quebec: CIHR Workshop in Toxicology: Drug exposure during pregnancy.
- 317) June 2004: Vancouver, BC: Fetal Alcohol Canadian Expertise: Chairing the meeting.

- 318) September 2004: Saskatoon: Fetal Alcohol Canadian Expertise 5<sup>th</sup> round table: Toward behavioral phenotype of FAS.
- 319) September 2004: Regina, SK: FACE Meeting: Diagnosing FASD.
- 320) June 2004: Essen, Germany: European Society for Developmental Pharmacology: Health economical implications of pediatric pharmacology.
- 321) May 2004: Prague: European Society for Teratology Information Services – Nato Symposium. Cancer chemotherapy in pregnancy.
- 322) May 2004: Prague: European Society of Teratology Information Services – Nato Symposium. Perception of teratogenic risk.
- 323) April 2004: Rhode Island: Brown's University. Visiting professorship: Drug therapy during pregnancy.
- 324) May 2004: London, ON: Victorial Hospital, Grand Rounds: Drugs in pregnancy.
- 325) May 2004: London, ON: St. Joseph's Hospital, Grand Rounds: Drugs in pregnancy.
- 326) June 2004: London, ON: London, ON Health Science Centre: Drugs in pregnancy.
- 327) October 2004: London, ON: Children's Hospital of Western Ontario Grand Rounds: Opioid for pain in children.
- 328) January 2005: Scotsdale, AZ: OTIS Research Meeting: Health Economy of TIS.
- 329) January-March 2005: (3 sessions): Toronto, ON: Children's Aid Society: Diagnosis of FASD.
- 330) April 2005: Vancouver, BC: Canadian Therapeutic Forum: The status of Pediatric Pharmacology.
- 331) April 2005: Vancouver, BC: Women's Hospital, Dept. of OBGYN Grand Rounds: Fetal Alcohol Spectrum Disorder.
- 332) April 2005: Louisville, KY: International Association of Therapeutic Drug Monitoring & Clinical Toxicology meeting. Round Table: Therapeutic drug monitoring in breastfeeding.
- 333) June 2005: Santa Barbara, CA: Fetal Alcohol Canadian Expertise meeting.
- 334) June 2005: Santa Barbara, CA: FAS Study Group: Digital measurement of morphometry in diagnosing FASD.
- 335) June 2005: St. Petersburg, FL: OTIS – Teratology meeting. Symposium: Reproductive Toxicology of Organic Solvents: The knowledge, the gap.

- 336) June 2005: Hamilton, ON: Catholic Children's Aid. Neonatal hair and meconium for drugs and alcohol.
- 337) February 2005: Washington, DC: OPRU Meeting, NICHD.
- 338) February 2005: Barcelona, Spain: Drugs in pregnancy; - Fetal Alcohol Syndrome biological markers. University of Barcelona, DiMar Hospital.
- 339) February 2005: Barcelona, Spain: Novartis: Global Epidemiology. Drugs in pregnancy.
- 340) March 2005: Ottawa: Health Canada: FASD Diagnosis.
- 341) April, 2005: Washington, DC: OPRU meeting, NICHD.
- 342) April 2005: Vancouver, BC: Paediatric Clinical Pharmacology Challenges and Opportunities Symposium.
- 343) June 2005: St. Petersburg, FL: OTIS Annual Meeting: Organic solvents in pregnancy.
- 344) June 2005: Vancouver, BC: Teratology Society Annual Meeting.
- 345) July 2005: Montreal, QC: NIH-CIHR. Summer Institute of Obstetric Pharmacology, Course Coordinator.
- 346) September 2005: Edmonton, AB: Edmonton Health Region Pharmacists: Drugs in Pregnancy.
- 347) September 2005: Montreal, Quebec: 36<sup>th</sup> Annual Meeting: International Society of pharmaneuroendocrinology: Biological markers of intrauterine drug exposure.
- 348) October 2005: Newfoundland: Canadian Association of Pediatric Health Centers. Fetal Alcohol Spectrum Disorder.
- 349) October 2005: Ottawa: IHDCYH Strategic Plan Review, CIHR.

#### **EDUCATIONAL FILE**

##### **A. Regular Teaching:**

- 1) 2nd year medicine - Pharmacology. Developmental Pharmacology & Toxicology; drug interactions, New Frontiers; (Since 1989).
- 2) 3rd year medicine - Clinical Pharmacology. Drug Compliance; (Since 1988).
- 3) Department of Pharmacology - Graduate course in Clinical Pharmacology (PCL 1004), course developer and coordinator (Since 1989).

- 4) 3rd year medicine - Pediatrics; Teaching pediatric skills, (Since 1986).
- 5) 4th year medicine - Pediatrics; Teaching pediatric clerks as Ward Chief, (Since 1986).
- 6) 4th Pharmacy - Clinical Pharmacy; Clinical Teratology, (Since 1986).
- 7) Graduate Pharmacy: Therapeutic Drug Monitoring Digoxin, (Since 1986).
- 8) PCL 473 - Interdisciplinary Toxicology (since 1993).

**B. Supervision of Graduate Students:**

1. ***Department of Pharmacology:*** (Year of graduation)
  - Karen Graham (graduated 1990) - Cocaine in the fetus (U of T open).
  - Dr. Monica Bologa (1990) - Drug metabolism in pregnancy (MOH).
  - Rachel Forman (1992) - Fetal exposure to cocaine (U of T open).
  - Lydia Derwelany (1992) - Placental drug transfer.
  - Dr. Kathleen Shilalukey (1993) - Theophylline in children (WHO).
  - Shannon Stobie (1993) -  $L_1$  Kinetics.
  - Carmine Simone (1993); presently PhD student. - Placental cocaine transference (MRC).
  - Donna Zemlickis (1993) - Cancer in pregnancy.
  - Cindy Woodland (1999) - Renal handling of drugs (CF foundation).
  - Dr. Richard Haynes (1993) - Kinetics in children.
  - Anne Pastuszak (1994) - Retinoids in pregnancy (U of T open & Cannought).
  - Chrisoula Eliopoulos (1994) - Hair accumulation of nicotine (MRC).
  - Dr. Elena Pope (1995) -  $L_1$  kinetics (MRC-Industry).
  - John Rogan (1997) - Amlodipine in children (Pfizer).
  - Myla Moretti (1996) - Drugs in breastmilk.
  - Kristen McMartin (1996); presently PhD student. - (U of T open).
  - Paulo Mazzotta (1997) - Pharmacology of morning sickness (Industry Duchesnay).
  - Natalie Kulin (1997) - Depression in pregnancy.
  - Dr. Aleksandra Pastrakuljic (2003) - RestraCom.
  - Amy Chan (1997) (with S. Ito) - Drugs in breast milk (Motherisk fund).
  - Katarina Aleksa (present) - Renal drug handling (MRC).
  - Amy French (2003) - *In utero* malignancy and drug/nutrient exposure.
  - Natasha Pinto (2004) - Ontogeny of P-gp in the kidney.
  - Brian Chan (2003) - Bupropion in pregnancy.
  - Daphne Chan (2003) - FAEE and FAS.
  - Jennifer Kraemer (2005) - Placental P-gp.
  - Kate McKenna (2004) - Antipsychotics in pregnancy.
  - Eric Ahn (present) - Pregvit in pregnancy.
  - Patricia Nguyen (present) - Pregvit in pregnancy.
  - Sanjog Kalra (present) - Cortisol and depression
  - Christelle Gedeon (present) - Placental perfusion of glyburide.
  - Brittany Sauve (present) - Corticosteroids in pregnancy.
  - Diana Stempak (present) - Antiangiogenic therapy for pediatric tumors.
  - Rebecca Hancock (present) - Neonatal \_\_\_\_?

2. *School of Pharmacy:*

Anna Taddio (1997) - Pain in the neonate (U of T open & other).  
 Arnold Seto (1992) (with T. Einarson) - H<sub>1</sub> blockers in pregnancy.  
 Edith St. Pierre (1995) - Daunorubicin in children (Motherisk fund).  
 Franka Grilli (2000) - Detection of cocaine in hair (part time student).  
 Colleen Duncan (2000) - Motherisk counseling process (part time student).  
 Ernest Kopecky (1999) - Transplacental morphine (Industry).  
 Marry Chu (1996) - Cyclosporine adverse effects (Motherisk).  
 Marjie Hard (1998-2003) - Etiology of FAS (NSERC).  
 Matthew Wong (1998-2000) - HIE in pregnancy.  
 Samar Shuhaibar (2000-2002) - Anesthetics in pregnancy.  
 Lori Bonari (2003) - Depression in pregnancy.  
 Lisa O'Brien (2001-2004) - Ametop for pain in neonates.  
 Charlene Ho (2002-2004) - Analgesia in neonates.  
 Anna Sivolejesova (present) - Drugs in pregnancy.  
 Moumita Sarkar (present) - Alcohol in pregnancy.  
 Ingrid Goh (present) - Fetal alcohol spectrum disorder.

3. *Institute of Medical Sciences:*

Nancy Ondrusek (1994) - Ethics of drug research in children (part time).  
 Frank Fassos (1997) - L<sub>1</sub> kinetics & dynamics (MRC-Industry).  
 Anne Pastuszak (present) - Evidence in maternal fetal toxicology.  
 Brenda Stade (present) - Economic burden of FAS (RestraCom).  
 Dr. Mariam Fouladi (2002) - Amifostine kinetics.  
 Leslie Born (2004) - Dysphoria in women (MRC).  
 Dionne Laslo (present) - Organic solvents in pregnancy.  
 Dr. Bikul Das (present) - Oncopharmacology.  
 Phillip Blanchette (2005) - Smoking in pregnancy.  
 Lisa O'Brien (present) - Depression in pregnancy.

4. *University of Western Ontario (Physiology-Pharmacology)*

Nancy Chen - Developmental nephrotoxicity.

C. **Supervision of Postdoctoral Fellows:**

Dr. David Long (UK) - (until 1986) - Maternal-fetal toxicology.  
 Dr. Jacob Feldman (Israel) - (1987) - Maternal-fetal toxicology.  
 Dr. Christine Hermann (USA) - (1990) - L<sub>1</sub> trials (MRC).  
 Dr. Monica Bologa (Canada) - (1992) - Maternal-fetal toxicology (MOH).  
 Dr. Yedidia Bentur (Israel) - (1990) - Pediatric toxicology (MOH).  
 Dr. David Johnson (USA) - (1991) - Pediatric pharmacology (MOH).  
 Dr. Isabelle Robieux (France) - (1992) - Pediatric pharmacology (French MRC).  
 Dr. Elliahu Zalstein (Israel) - (1989) - Pediatric Pharmacology-cardiology (MOH).  
 Dr. Maurice Levy (Canada) - (1990) - Pediatric pharmacology (MOH).  
 Dr. Gianmario Ferrazinni (Switzerland) - (1990) - 6-MP kinetic-dynamic (Swiss grant).  
 Dr. Shinya Ito (Japan) - (1995) - Membran-transport (RestraCom/MRC).  
 Dr. Irena Nulman (Israel) - present - FAS research (Motherisk).  
 Dr. Prashant Joshi (Canada) - (1994) - Pediatric pharmacology (MOH).  
 Dr. Doreen Matsui (Canada) - (1993) - L<sub>1</sub> trials (MOH).

- Dr. Jeff Tyberg (Canada) - (1993) - Clinical Toxicology (MOH).  
 Dr. Lyla Warif (Canada) - (1993) - Maternal-fetal toxicology (Motherisk).  
 Dr. Laura Magee (Canada) - (1994) - Maternal-fetal toxicology (MOH).  
 Dr. Izhar Qamar (US) - (1994) - Pediatric Pharmacology (MOH).  
 Dr. Robert Lau (Canada) - (1994) - Pediatric pharmacology (MOH).  
 Dr. Pascale Burtin (France) - (1994) - Pediatric pharmacology (French MRC).  
 Dr. Douglas Blowey (US) - (1996) - Renal handling of drugs (Kansas City grant).  
 Dr. Abhya Gupta (Canada) - (1997) - Pediatric pharmacology (MOH, Can Soc Clin Pharm)  
 Dr. Dhurbasa Chattergoon (Trinidad) - (1996) - Pediatric Pharmacology (MOH).  
 Dr. Elena Pope (Romania) - (1996) - L<sub>1</sub> trials (MRC-industry).  
 Dr. Ileana Moncica (Romania) - (1995) - Pediatric hypertension (Pfizer).  
 Dr. Jochem Theis (Germany) - (1996) - Pediatric pharmacology (German MRC).  
 Dr. Shlomit BenDavid (Israel) - (1995) - Maternal-fetal toxicology (Motherisk).  
 Dr. Jennifer Knight (Jamaica) - (1994) - Nicotine in children (MOH).  
 Dr. Candice Rowe (Canada) - (1996) - Pediatric pharmacology (MOH).  
 Dr. Sohail Khattak (Canada) - (1998) - Organic solvents in pregnancy (MOH).  
 Dr. Anil Hinaria (India-Canada) - (1996) - Pediatric pharmacology (Motherisk).  
 Dr. Madlen Gazarian (Australia) - (1996) - Rheumatology-pharmacology.  
 Dr. Ronen Loebstein (Israel) - (1998) - L<sub>1</sub> trials (MRC-industry).  
 Dr. Debbie Kennedy (Australia) - (1997) - Maternal-fetal pharmacology (Motherisk).  
 Dr. Benoit Bailey (Canada) - (1997) - Pediatric pharmacology - (MOH).  
 Dr. Arie Lalkin (Israel) - (1998) - Clinical toxicology (Motherisk).  
 Dr. Orna Diav-Citrin (Israel) - (1998) - L<sub>1</sub> trials (MRC-industry).  
 Dr. Svetlana Emilianova (Canada) - (2000) - Maternal-fetal toxicology (Motherisk).  
 Dr. Vladimir Karaskov (Canada) - (1998) - Pediatric pharmacology (Sanzoz).  
 Dr. Savithiri Rathnapalan (Seylon, Canada) - (1997) - Pediatric pharmacology (MOH).  
 Dr. Raafat Bishai (Egypt, Canada) - (1999) - Nausea & vomiting of pregnancy (Duchesnay).  
 Dr. Reza Moienafshari (Iran) - (1999) - Pediatric pharmacology (Motherisk).  
 Dr. Benny Bar Oz (Israel) - (1999) - Neonatal pharmacology (RestraCom).  
 Dr. Richard Hackman (Syria) - (2000) - Nicotine patch in pregnancy (Motherisk).  
 Dr. Sunita Vohra (Canada) - (1999) - Drug trial methodology (MOH).  
 Dr. Tommy Ho (Canada) - present - Pediatric-pharmacology (Can Soc. Clin. Pharmacol).  
 Dr. Gil Klinger (Israel) - (2000) - Maternal-fetal toxicology (RestraCom).  
 Dr. Gordana Atanackovic (Yugoslavia) - (2000) - Nausea and vomiting in pregnancy (Duchesnay).  
 Dr. Zina Levichek (Russia) - 2002 - Perinatal Pharmacology (Motherisk).  
 Dr. Meena Pole (India) - 2001 - Maternal-fetal toxicology (Motherisk).  
 Dr. Massoud Rezvani (Iran) - Present - Pediatric Pharmacology.  
 Dr. Dick Oepke (Netherlands) - (2000) - Nausea and vomiting in pregnancy (Duchesnay).  
 Dr. Chris Parshuram (Australia) - 2003 - Pediatric pharmacology (HSC).  
 Dr. Adriana Costei (Romania) - 2003 - HIV in pregnancy (Motherisk).  
 Dr. Alexander Liaschko (Russia) - 2001.  
 Dr. Eran Kozar (Israel) - 2002 - Pediatric pharmacology (Motherisk).  
 Dr. Yaron Yagev (Israel) - 2001 - Occupational exposures in pregnancy.  
 Dr. Lillian Sung (Canada) - 2004 - (with Dr. Brian Feldman): N of 1 studies in children.

Dr. Naomi Halachmi (Israel) – 2003 – Ontogeny of renal drug metabolism.  
Dr. Rada Boskovic (Bosnia) – present – Drugs in pregnancy.  
Dr. Raanan Cohen-Kerem (Israel) – 2004 – Drugs in pregnancy.  
Dr. Sergei Gargaun (Russia) – 2004 – Drugs in pregnancy.  
Dr. Ibrahim Fayez (Egypt) – 2004 – Clinical Pharmacology.  
Dr. Marina Avner (Israel) – 2005 – Developmental Pharmacology.  
Dr. Charlse Pivko (Switzerland) – 2004 – Pharmaco-economics.  
Dr. Yaron Finkelstein (Israel) – present – Restracom.  
Dr. Tali Finkelstein (Israel) – present  
Dr. Alejandro A. Nava-Ocampo (Mexico) – 2004 – Maternal-fetal pharmacology.  
Dr. Han Yeol Jung (Korea) – 2004 – Maternal-fetal pharmacology.  
Dr. Tali Schechter (Israel) – present – Pediatric oncopharmacology.  
Dr. Alon Shrim (Israel) – present – Maternal-fetal pharmacology.  
Dr. Facundo Garcia-Bourssien (Argentina) – present – Developmental pharmacology.  
Dr. Alaa Ali (Egypt) – 2005 – Perinatal pharmacology.

D. Supervision of The Undergraduate Project Course in Pharmacology/Toxicology (PCL 472, PCL 47V) :

Ten students each academic year (since 1986).

E. The Arts and Science of Clinical Medicine II. 1986-96

F. The MSc Program in Genetic Counselling: Concepts in Clinical Genetics (MMG 12264): Pharmacogenetics. 1999 –

G. “Membrane Transport” graduate course: (JFK 1122H). 1994 -

H. “Clinical Toxicology” graduate course (JNP 1016S). 1999 -

I. Graduate Seminars in toxicology (JNP1016S). 2003 -

J. Pharmaeepidemiology (PHM 1118). 1999 -

I. International:

1. The International Network of Training Programs in Pediatric Pharmacology. Founder and coordinator (see under Books, No. 3).

2. Training program in Clinical Toxicology: Coordinator of the Toronto program (one of 15 approved by The American Academy of Clinical Toxicology), (until 1996).

3. Director: University of Toronto Program in Clinical Pharmacology.

EDUCATIONAL INNOVATIONS:

1) Created and continuously improves the U of T course in Clin. Pharmacology (PCL 1004).

2) Created the program "Awakening" to teach Clin Pharmacology (published in Clin, Pharmacol Ther).

- 3) Created the International Network of Pediatric Pharmacology Training Program (published as a book).
- 4) Created Motherisk Update for CME of family physicians (published monthly in Can. Family Physician).
- 5) Created Motherisk Website ([www.motherisk.org](http://www.motherisk.org)) as CME for OBGYN (with support of SOGC).
- 6) Created a course in critical appraisal of drug studies in children (every Thursday at 10:00 a.m.).
- 7) Created a program to identify and improve tenfold medication errors by pediatric residents.
- 8) Created the International Diploma in Pediatric Pharmacology.

#### **CHILDREN'S BOOKS**

- 1) G. Koren: "*Shubi Dubi Tales*". Sifriyat Poalim Pub. Comp. Tel-Aviv, 1979.
- 2) G. Koren: "*Journey to Noteland*". Or-tav Pub. Comp. Tel-Aviv, 1980.
- 3) G. Koren: "*Touti is Ill*". Sifriyat Poalim Pub. Comp. Tel-Aviv, 1981.
- 4) G. Koren: "*Israeli Children Street Songs*". Dalia Peled Pub. Comp. Tel-Aviv, 1982.
- 5) G. Koren: "*Pediatric Ward*". Dalia Peled Pub. Comp. Tel-Aviv, 1982.
- 6) G. Koren: "*Pictures Telling Stories*". A series of 16 books. Yavne Pub. Comp. Tel-Aviv, 1982.
- 7) G. Koren: "*Books To Those We Love*". First 4 books out of 8. Yavne Pub. Comp. Tel-Aviv, 1982.
- 8) G. Koren: "*Pitzimouse I*". Or-tav Pub. Comp. Tel Aviv, 1985.
- 9) G. Koren: "*Pitzimouse II*". Or-tav Pub. Comp. Tel Aviv, 1987.
- 10) G. Koren: "*Get Well Soon*". Kidfest Ltd., New York, 1988.
- 11) G. Koren: "*Shoobi Doobi Bear*". Kidfest Ltd., New York, 1988.
- 12) G. Koren: "*Pitzimouse III*". Or-tav Pub. Comp. Tel Aviv, 1988.
- 13) G. Koren: "*Books To Those We Love*". Books 5-8 out of 8. Yavne Ltd., Tel Aviv, Israel 1990.
- 14) G. Koren: "*Pitzimouse IV*". Or-tav Pub. Comp. Tel Aviv, 1991.



- 15) G. Koren: *"The Time Turtle"*. Tarbuton Ltd, Tel Aviv, Israel, 1992.
- 16) G. Koren: *"Tails-A Fairy Tale on Furry Tails"*, The Kid In Us Publications, Toronto, 1992.
- 17) G. Koren: *"A Medical Encyclopedia for Children"*. Yavne Ltd, Tel Aviv, Israel, 1992.

## MUSIC

GK created over 50 musical albums, for both adults and children, in Israel. The album "Tails" was released in Toronto in 1993.

## CHILDREN'S PLAYS


- 1) "Shubi Dubi Tales": Orot Ltd., Tel Aviv 1978-80.
- 2) "Zalman" - Israeli Children's Street Songs": TEDI productions, Tel Aviv 1980-83.
- 3) "The Journey to Noteland": University of California, Children's Theatre Dept. 1986-87.
- 4) "Tails": The Bear Theatre, The Hospital for Sick Children, Toronto 1992 - (also performed in Miller's Children Hospital of Long Beach California and in Shneider National Children Center in Petah Tiqua, Israel).

**APPENDIX 2**  
**(Gervais Declaration)**

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1460.

Date of Signature

and Deposit: 10/12/06



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Duchesnay Inc.  
Serial No.: 10/611,803  
Filed: July 1, 2003  
Title: PHARMACEUTICAL DOSAGE FORM BEARING PREGNANCY-FRIENDLY  
INDICIA  
Examiner: Hawes, Pili Asabi

---

DECLARATION UNDER 37 CFR 1.132

---

Dear Sir:

I, Eric Gervais, of the City of Laval, Canada, being duly sworn, **MAKE OATH AND SAY AS FOLLOWS:**

1. This Declaration sets forth my opinion relating to this matter and the basis for my opinion.
1. **EXPERIENCE AND QUALIFICATIONS**
2. I have been the Executive Vice-President of Duchesnay Inc. since 1994.
3. Created before 1870 to distribute over-the-counter and prescription medications to Quebec pharmacies, Duchesnay Inc. underwent a change of orientation around 1991, becoming the first pharmaceutical company to dedicate itself exclusively to the pregnant women and their newborn, to ensure that expecting women who require pharmacological treatments for pre-existing or pregnancy-related diseases have

access to proper counselling and to medications that are proven safe for them and for their newborns. Since then, Duchesnay has been evolving as a research-based pharmaceutical company with the vision to improve women's quality of life of women during pregnancy and lactation while reducing the number of birth defects and impacts on their newborns.

4. Thus, I have more than 12 years of experience in leading a company dedicated to pregnant women's health, as well as in associated research and development.
5. I am also an inventor in several patents and patent applications in the name of Duchesnay Inc.
6. I am one of the inventors of United States Patent Application 10/611,803.

II. DICLECTIN®

7. Diclectin® comprises doxylamine succinate and pyridoxine hydrochloride as active ingredients. In Canada, it is the only anti-nauseant and anti-vomiting medication specifically indicated, prescribed and labelled for the management of NVP (nausea and vomiting of pregnancy) at any stage of pregnancy. It is sold in the form of unit bottles comprising 100 tablets each.
8. Diclectin® was first launched on the Canadian market in 1975.
9. Throughout the recent years, the percentage of yearly increase of sales of unit bottles of Diclectin® was generally decreasing from year to year in Canada as a whole, as per the table below. Such tendency was not expected to change.

1998-1999	1999-2000	2000-2001	2001-2002
18%	11.7%	9.4%	8.6%

10. It is to be noted that, since Diclectin® is the only available prescription medicament for NVP in Canada, Duchesnay is the only company in this particular field. Thus an

increase in the sales of unit bottles of Diclectin® is directly linked to an increased number of pregnant women buying these bottles.

11. A Diclectin® with a graphical indicia of a pregnant woman applied on each tablet was launched in the Canadian market around the end of November 2002. The application of the indicia constituted the only change to the medicament. Absolutely no specific marketing was associated with this change.
12. Very surprisingly, we, at Duchesnay, observed that the sales of unit bottles of Diclectin® in 2003 for Canada increased by 14.8% with regard to those of 2002, which constituted an exceptionally high increase, as compared to the increases observed over the preceding years.
13. That increase was the average of significant individual increases in all territories of Canada (British Columbia, Alberta, Saskatchewan+Manitoba, Ontario, Quebec, Atlantic provinces), whether or not medical representatives were circulating therethrough.
14. For example, there were at that time four medical representatives in Ontario, where the sales increase observed between 2002 and 2003 was of 17.73%, and there was absolutely no medical representative in Saskatchewan+Manitoba, where the sales increase observed between 2002 and 2003 was of 17.8%.
15. By contrast, no increase in the natality rate was observed in Canada in 2002-2003, to which the increased number of sales could have been attributed.
16. Thus, in my opinion, nothing else than the application of a graphical representation of a pregnant woman on each tablet of Diclectin® has caused this surprising increase in sales.
17. Since Diclectin® is prescribed by physician, the increase in sales is most probably due to greater amounts of prescription refills.

VI. CONCLUSION

## 18. In my opinion:

18.1 The exceptional increase of sales of Diclectin® unit bottles observed in 2003 constituted an unexpected commercial success for the medicament.

18.2 The commercial success of Diclectin® observed in 2003 is solely due to the application of pregnancy-friendly indicia on each Diclectin® tablet at the end of 2002.

19. I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the above-identified application or any patent issuing thereon.

Respectfully submitted,

11/02/2006  
Date

  
Eric Gervais